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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 67 Revision 2 
(FGE.67Rev2): Consideration of 28 furan-substituted compounds evaluated 
by JECFA at the 55th, 65th and 69th meetings (JECFA, 2001, 2006a, 
2009b)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of the European Food 
Safety Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The substances were evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The present 
consideration concerns a group of 28 furan-substituted compounds evaluated by the JECFA. This revision of 
FGE.67 is due to new data on toxicity for 3-(-methyl-2-furyl) butanal [FL-no: 13.058] providing an appropriate 
NOAEL for the evaluation of candidate substance [FL-no: 13.058]. The Panel concluded that 11 substances [FL-
nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190] do not give 
rise to safety concerns at the levels of dietary intake, estimated on the basis of the MSDI approach. However, 
based on mTAMDI calculations, for these eleven candidate substances, except [FL-no: 13.058], more reliable 
intake data are required for a re-evaluation. Besides the safety assessment of these flavouring substances, the 
specifications for the materials of commerce have also been considered, which for all candidate substances are 
adequate.  For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 
13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] a concern for genotoxicity was raised and 
therefore these were not evaluated using the Procedure. The Panel noted further that for 7 of these 17 substances 
[FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.069 and 13.083], use levels have not yet been submitted. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the implications for human health of chemically defined flavouring substances used in or on foodstuffs 
in the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The present revision of FGE.67, FGE.67Rev2, which has been made due to new toxicity data provided 
for 3-(5-methyl-2-furyl) butanal, deals with 28 substances. Twenty-seven of these were previously 
considered by the JECFA in a group of 40 furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers (JECFA, 2009a). 
One of these 40 substances [FL-no: 13.192] appeared to be a synonym of substance [FL-no: 13.178] 
which has already been evaluated in FGE.13Rev2. Therefore this substance [FL-no: 13.192] will not 
be further considered in this FGE and should be removed from the Register. Another substance [FL-
no: 13.176] will be evaluated in FGE.99 rather than in FGE.67, because of better structural similarity 
with candidate substances in FGE.99. Furthermore, one candidate substance [FL-no: 13.031] from 
FGE.66Rev1 has been included in this revision of FGE.67, because this substance has better structural 
similarity to a candidate flavouring substance [FL-no: 13.074] in FGE.67 than to the other candidate 
flavouring substances in FGE.66Rev1. 
Thirteen of the 40 substances considered by JECFA are α,β-unsaturated carbonyls, which have been 
evaluated by EFSA in FGE.19 context with respect to a concern for a possible genotoxic potential. 
This concern for genotoxicity could not be alleviated for six substances [FL-nos: 13.034, 13.043, 
13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 subgroup 4.6. These six substances 
were therefore not further considered in this FGE. 
For five substances the Flavourings Industry has announced that they do no longer support their use as 
flavouring substances in Europe [former FL-nos: 13.029, 13.030, 13.092, 13.107 and 13.191], these 
substances have been withdrawn from the safety evaluation in the present FGE.  
The 28 candidate substances considered in this FGE [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 
13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 13.069, 13.070, 13.074, 
13.083, 13.101, 13.103, 13.105, 13.106, 13.116, 13.123, 13.138, 13.148, 13.163 and 13.190] have 
been allocated to various subgroups, based on their chemical structures. These substances are 
structurally related to the group of 27 furfuryl and furan derivatives evaluated by EFSA in 
FGE.13Rev2. Part of the substances is also structurally related to a group of 33 sulphur-substituted 
furan derivatives used as flavouring agents, evaluated by EFSA in FGE.65Rev1 and another part is 
structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1. 
The Panel agrees with the JECFA for 17 of the substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 
13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 
13.163] that these substances cannot be evaluated through the Procedure, based on concerns with 
respect to genotoxicity.  
On the basis of the new data on toxicity for 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] an 
appropriate NOAEL of 5.9mg/kg bw per day was derived, supporting the evaluation of this candidate 
substance.  
In line with the approaches taken in previous FGEs (FGE.13Rev2, FGE.65Rev1 and FGE.66Rev1), 
the Panel considers that 11 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 
13.047, 13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure. It was concluded 
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for all 11 substances, that they would be of no safety concern at their estimated intake levels based on 
the MSDI approach. 
In order to determine whether the conclusion for the evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity are available for all 28 substances. Thus, for the 11 
furane derivatives evaluated through the Procedure [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 
13.031, 13.047, 13.058, 13.074, 13.116 and 13.190], the Panel considered that the materials of 
commerce would not present a safety concern at their estimated levels of intake based on the MSDI 
approach. 
The mTAMDI could be calculated for 4 of the 11 substances that were evaluated through the 
Procedure. For three substances [FL-nos: 13.031, 13.047 and 13.074] the mTAMDI exceeds the 
threshold for the corresponding structural class and therefore more reliable exposure data are required. 
For seven substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190], use levels 
are needed in order to calculate the mTAMDIs and identify those flavouring substances that need 
more refined exposure assessment to finalise the evaluation. On the basis of such additional data these 
flavouring substances should be reconsidered along the steps of the Procedure. Then, additional 
toxicological data might become necessary.  
For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 
13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] additional toxicity / genotoxicity 
data are required. The Panel noted further that for 7 of these 17 substances [FL-nos: 13.045, 13.052, 
13.054, 13.059, 13.061, 13.069 and 13.083], use levels have not yet been submitted. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings in food is regulated under Regulation (EC) No 1334/2008 of the European 
Parliament and Council of 16 December 20084 on flavourings and certain food ingredients with 
flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an 
evaluation and approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012.5 The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.6 
On 6 July 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (CEF) adopted an opinion on FGE.67, Revision 1 (FGE.67Rev1): consideration of 40 furan-
substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, 
sulfides, disulfides and ethers evaluated by JECFA at the 65th meeting and re-evaluated at the 69th 
meeting.7 
In its opinion the Panel stated that: “No NOAEL could be identified to support the evaluation of 
substance [FL-no: 13.058] at step B4. Therefore for this substance no conclusion as to its safety when 
used as a chemically defined flavouring substance can be reached". 
As a consequence, the Panel concluded that for this substance additional toxicity data were 
required. 
Subsequently, the substance was included in the Union List with a Footnote 4. 
On 23 January 2014, the applicant submitted additional relevant data on 3-(5-methyl-2-furyl)butanal 
[FL-no: 13.058] from FGE.67. 
3-(5-Methyl-2-furyl) butanal is a stand-alone substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this new 
information and, depending on the outcome, proceed to the full evaluation of this flavouring substance 
in accordance with Commission Regulation (EC) N° 1565/2000. 
SUPPORTING DOCUMENTS 
Submission by the European Flavour Association  
INTERPRETATION OF THE TERMS OF REFERENCE 
The present scientific opinion FGE.67Rev2 covers the safety assessment of the following flavouring 
substance: 3-(5-methyl-2-furyl) butanal [FL-no: 13.058]. 
                                                     
4
  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5
  Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-161. 
6
  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
7 
 FGE.67rev1; EFSA Journal 2011; 9(10):2315. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), hereafter named the “EFSA Procedure”. This 
Procedure is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been 
derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered “how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006b). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 µg/Person per day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 µg/person per day as part of the evaluation procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”) (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
The first revision of FGE.67, FGE.67Rev1 included the consideration of eight additional substances.  
Seven of the eight additional substances [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 
13.163] were α,β-unsaturated ketones originally allocated to FGE.19 subgroup 4.5 (FGE.221) (EFSA, 
2008b). This structural characteristic is a known alert for genotoxicity, which may preclude the 
evaluation of substances through the Procedure. EFSA concluded in November 2008 that the α,β-
unsaturated structure in conjugation with an aromatic ring system, which is present in these seven 
substances, is comparable to acetophenone, i.e. no longer considered a structural alert for genotoxicity 
(EFSA Panel, 2011). These seven substances are shown in Table 1, Subgroup VI-B. 
The eighth substance, 2-benzofurancarboxaldehyde [FL-no: 13.031], was also an α,β-unsaturated 
aldehyde originally allocated to FGE.19 subgroup 4.3 (FGE.219) (EFSA, 2008b). Also for this 
substance the α,β-unsaturated structure was in conjugation with an aromatic ring system which is 
comparable to the situation for benzaldehyde for which no genotoxic concern is present (EFSA Panel, 
2008c). Accordingly, this substance can also be evaluated using the Procedure. Although the substance 
originally was allocated by the JECFA to the group of furfuryl alcohol derivatives covered in 
FGE.66Rev1, the Panel considered that the substance belongs to the benzofurans in group V-B of the 
present FGE.67 (see Table 1). 
Finally, the sub-grouping of two ketones [FL-nos: 13.045 and 13.138] was changed from subgroup III 
to subgroup VI-B, and the evaluation of these two ketones was revised due to a concern for 
genotoxicity. 
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FGE Opinion adopted Link No. of substances 
FGE.67 26 November 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1404.htm 25 
FGE.67Rev1 06 July 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2315.htm 33 
FGE.67Rev2 07 May 2015 http://www.efsa.europa.eu/en/efsajournal/pub/4115.htm 28 
 
The present revision of FGE.67 (FGE.67Rev2) is due to submission of additional information, 
requested in FGE.67 and FGE.67Rev1, namely a 90-day dietary toxicity study for 3-(5-methyl-2-
furyl) butanal [FL-no: 13.058] (IOFI, 2013). A search in the open literature did not reveal any 
pertinent new information. 
Furthermore, requested data on specifications have been submitted for three substances [FL-nos: 
13.031, 13.045 and 13.047] (EFFA, 2014). 
Finally, the industry has informed the Commission that five substances [FL-nos: 13.029, 13.030, 
13.092, 13.107 and 13.191], are no longer supported for use in the EU as flavouring substances. These 
five substances will no longer be considered in this FGE (DG SANCO, 2012).8 Accordingly 
FGE.67Rev2 deals with 28 flavouring substances.  
For three substances [FL-nos: 13.052, 13.061 and 13.123] the Panel is aware that requested 
information has not been submitted before the deadline as indicated in Regulation EC 872/2012. The 
EU Commission has communicated (DG SANTE, 2015) that these three substances are now in the 
process leading to deletion from the Union List. However, since these substances have not been 
formally withdrawn, and are still mentioned in the Union list, they are maintained in the current 
revision of the FGE. 
2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
The JECFA has evaluated a group of 40 diverse furan derivatives, first at their 65th meeting (JECFA, 
2006a) where a request for additional data was expressed. The furan group was on the agenda again at 
the 69th JECFA meeting (JECFA, 2009b) where additional data had been provided. 
2.1.1. JECFA Status 
The JECFA expressed at its 69th meeting (JECFA, 2009a):“At its 65th meeting (JECFA, 2006a), the 
JECFA reviewed a group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, 
carboxylic acids and related esters, sulfides, disulfides and ethers. The JECFA at that meeting took 
note of the extensive evidence for the genotoxicity of several members of this group of flavouring 
agents related to furan, including the clastogenicity of 2-furyl methyl ketone (JECFA-no: 1503) (2-
acetylfuran, [FL-no: 13.054]) in mouse bone marrow. This substance accounts for 87 – 96 % of total 
exposure to this group of flavouring agents. Noting also that furan is carcinogenic and is known to 
undergo epoxidation and ring opening to form a reactive 2-ene-1,4-dicarbonyl intermediate, the 
JECFA at its sixty-fifth meeting expressed concern that the observed genotoxicity might be due to 
formation of a reactive metabolite. Few data on genotoxicity in vivo were available, and specific 
assays to address potential carcinogenicity in vivo were lacking. The JECFA at its sixty-fifth meeting 
therefore concluded that the Procedure for the Safety Evaluation of Flavouring Agents could not be 
applied to this group because of the above concerns. It was also concluded that studies of metabolism 
and in vivo assays for deoxyribonucleic acid (DNA) reactivity, mutagenicity and carcinogenic 
                                                     
8
 Commission Implementing Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 
1334/2008 of the European Parliament and of the Council as regards removal from the Union list of certain flavouring 
substances. Official Journal of the European Communities 14.3.2014, L 74, 58-60. 
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potential of members of this group with representative structures would assist in resolving the 
concerns (JECFA, 2006a). 
Additional studies of genotoxicity in vitro and in vivo with 2-furyl methyl ketone [FL-no: 13.054] 
were available to the Committee (the JECFA) at its present meeting (Durward, 2007a; Durward, 
2007b; Sujatha, 2007). The Committee (JECFA, 2009b) included the new studies in its re-evaluation 
of the group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic 
acids and related esters, sulfides, disulfides and ethers.”  
“The new data on 2-furyl methyl ketone (JECFA-no: 1503) (2-acetylfuran, [FL-no: 13.054]) available 
to the Committee at its present meeting were a study on UDS in cultured hepatocytes in vitro, a study 
on UDS in rat liver in vivo/in vitro and a test for SCEs in mouse bone marrow in vivo. 2-Furyl methyl 
ketone did not induce UDS either in vitro or in vivo/in vitro. However, it did induce SCEs, confirming 
the concern for clastogenicity as expressed by the Committee at its previous meeting. The Committee 
at its present meeting therefore considered that the new data available did not resolve the concerns 
expressed previously”. 
“The Committee concluded that the Procedure for the Safety Evaluation of Flavouring Agents could 
not be applied to this group because of the unresolved toxicological concerns. Studies that would assist 
in the safety evaluation include investigations of the influence of the nature and position of ring 
substitution on metabolism and on covalent binding to macromolecules. Depending on the findings, 
additional studies might include assays related to the mutagenic and carcinogenic potential of 
representative members of this group”. 
At its 55th meeting (JECFA, 2001) the JECFA has evaluated the substance 2-benzofuran 
carboxaldehyde [FL-no: 13.031] via the Procedure for the evaluation of flavouring substances. The 
JECFA conclude that the substance was of no safety concern. 
2.1.2. EFSA Considerations 
The group of furan derivatives evaluated by the JECFA is a very diverse group of 40 flavouring 
substances which can be subdivided into six major subgroups with further subdivision of subgroup V 
and VI, as depicted in the Table 1: . The substance [FL-no: 13.031], also included in Table 1:  was 
evaluated by the JECFA at the 55th meeting (JECFA, 2001) in the group of furfuryl derivatives 
evaluated by EFSA in FGE.66Rev1, but as [FL-no: 13.031] has structural similarity to [FL-no: 
13.074] considered in FGE.67, it has been included in FGE.67. 
The structures of these 41 substances are given in Table 1. 
Table 1:  Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th 
and 69th meetings  
Sub-
group 
FL-no 
JECFA-no 
EU Register name Structural 
formula 
Supporting substances, 
represented in FGEs and 
subgroups 
I 13.116 
1523 
2,5-Dimethyl-3-
thioacetoxyfuran 
O
S
O
 
FGE.65Rev1 (Thioesters) 
I 13.190 
1525 
3-((2-Methyl3-furyl)thio)-2-
butanone 
O
S
O
 
FGE.13Rev2,  
Subgroup IIa (Sulphides) 
I 13.191(a) 
1526 
o-Ethyl S-(2-
furylmethyl)thiocarbonate O S O
O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
I 13.192(b) 
1524 
Furfuryl 2-methyl-3-
furyldisulfide 
O
S
S
O
 
FGE.13Rev2  
Subgroup IIc (Disulphides) 
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Table 1:  Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th 
and 69th meetings  
Sub-
group 
FL-no 
JECFA-no 
EU Register name Structural 
formula 
Supporting substances, 
represented in FGEs and 
subgroups 
II 13.006 
1517 
Phenethyl 2-furoate 
O
O
O
 
FGE.13Rev2 
Subgroup Ia (Related to 
furfuryl alcohol) 
III 13.021 
1516 
Isopentyl 4-(2-
furan)butyrate 
O O
O
FGE.13Rev2  
Subgroup Ia 
III 13.022 
1513 
Ethyl 3(2-furyl)propionate 
O
O
O
 
FGE.13Rev2  
Subgroup Ia 
III 13.023 
1515 
Isopentyl 3-(2-
furan)propionate O O
O FGE.13Rev2  
Subgroup Ia 
III 13.024 
1514 
Isobutyl 3-(2-
furyl)propionate 
O
O
O
 
FGE.13Rev2  
Subgroup Ia 
III 13.047 
1518 
Propyl 3-(2-furyl)acrylate 
O
O
O
 
FGE.13Rev2  
Subgroup Ia 
III 13.058 
1500 
3-(5-Methyl-2-furyl) butanal O
O
 
FGE.13Rev2  
Subgroup Ia 
IV 13.029(a) 
1488 
2,5-Dimethylfuran O
 
FGE.13Rev2  
Subgroup Ic (Alkyl-
substituted furans) 
IV 13.030(a) 
1487 
2-Methylfuran O
 
FGE.13Rev2  
Subgroup Ic 
IV 13.059 
1491 
2-Pentylfuran O
 
FGE.13Rev2  
Subgroup Ic 
IV 13.069 
1492 
2-Heptylfuran O
 
FGE.13Rev2  
Subgroup Ic 
IV 13.092(a) 
1489 
2-Ethylfuran O
 
FGE.13Rev2  
Subgroup Ic 
IV 13.103 
1490 
2-Butylfuran O
 
FGE.13Rev2  
Subgroup Ic 
IV 13.106 
1493 
2-Decylfuran O FGE.13Rev2  
Subgroup Ic 
IV 13.148 
1494 
3-Methyl-2(3-methylbut-2-
enyl)furan 
O
 
FGE.13Rev2  
Subgroup Ic 
V-A 13.052(c) 
1520 
Furfuryl methyl ether O O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
V-A 13.061(c) 
1522 
Difurfuryl ether 
O
O
O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
V-A 13.123(c) 
1521 
Ethyl furfuryl ether O O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
V-B 13.031 
751 
2-
Benzofurancarboxaldehyde 
OO
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
V-B 13.074 
1495 
2,3-Dimethylbenzofuran 
O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
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Table 1:  Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th 
and 69th meetings  
Sub-
group 
FL-no 
JECFA-no 
EU Register name Structural 
formula 
Supporting substances, 
represented in FGEs and 
subgroups 
V-C 13.107(a) 
1496 
2,4-Difurfurylfuran OO
O
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1 
VI-A 13.034(d) 
1497 
3-(2-Furyl)acrylaldehyde O O
 
Not yet considered due to 
genotoxicity concern. 
VI-A 13.043(d) 
1501 
Furfurylidene-2-butanal O O
 
Not yet considered due to 
genotoxicity concern. 
VI-A 13.044(d) 
1511 
4-(2-Furyl)but-3-en-2-one 
O
O
 
Not yet considered due to 
genotoxicity concern. 
VI-A 13.046(d) 
1498 
3-(2-Furyl)-2-methylprop-2-
enal O
O
 
Not yet considered due to 
genotoxicity concern. 
VI-A 13.137(d) 
1502 
3-(2-Furyl)-2-phenylprop-2-
enal 
O
O
 
Not yet considered due to 
genotoxicity concern. 
VI-A 13.150(d) 
1499 
3-(5-Methyl-2-furyl)prop-2-
enal 
O
O
 
Not yet considered due to 
genotoxicity concern. 
VI-B 13.045 
1508 
1-(2-Furyl)-propan-2-one O
O
 
FGE.13Rev2  
Subgroup Ib (Alkoyl-
substituted furans) 
VI-B 13.054 
1503 
2-Acetylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.066 
1506 
3-Acetyl-2,5-dimethylfuran O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.070 
1512 
2-Hexanoylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.083 
1504 
2-Acetyl-5-methylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.101 
1505 
2-Acetyl-3,5-dimethylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.105 
1507 
2-Butyrylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.138 
1510 
1-(2-Furyl)butan-3-one 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-B 13.163 
1509 
2-Pentanoylfuran 
O
O
 
FGE.13Rev2  
Subgroup Ib 
VI-C 13.176 
1519 
Furaneyl butyrate O
O O
O
 
None in FGE.13Rev2, 
FGE.65Rev1 or 
FGE.66Rev1; Supporting 
substances in FGE.99. 
(a): Substances no longer supported by the Industry for use as flavouring substances in the EU. 
(b): [FL-no: 13.192] is a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. 
(c): The Panel is aware that requested information for subgroup V-A has not been submitted before the deadline as indicated 
in Regulation EC 872/2012. The EU Commission has communicated that substances [FL-nos: 13.052, 13.061 and 
13.123] are now in the process leading to deletion from the Union List (DG SANTE, 2015). 
(d): Currently under evaluation for genotoxicity concern in FGE.222. 
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Group I 
This subgroup comprises four substances. These substances [FL-nos: 13.116, 13.190, 13.191 and 
13.192] are structurally related to 14 sulphur-substituted furan derivatives evaluated by EFSA in 
FGE.13Rev2 (see Appendix C, Table 1: ) and 33 sulphur-substituted furan derivatives considered by 
EFSA in FGE.65Rev1 (see Appendix C). Substance [FL-no: 13.192] appeared to be a synonym of 
substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Substance [FL-no: 
13.191] is no longer supported by Industry (DG SANCO, 2012). These two substances [FL-nos: 
13.191 and 13.192] will not be further considered in this FGE. Consequently, from this subgroup only 
two candidate substances [FL-nos: 13.116, 13.190] will be considered in this FGE. 
Group II 
This subgroup comprises one substance [FL-no: 13.006] to be considered in this FGE, which is 
structurally related to five furoic acid esters considered by EFSA in FGE.66Rev1 (see Appendix C, 
Table 12). 
Group III 
This subgroup comprises six substances [FL-nos: 13.021, 13.022, 13.023, 13.024, 13.047 and 13.058] 
structurally related to a group of furfuryl and furoic acid substances evaluated by EFSA in 
FGE.13Rev2 in subgroup Ia. All six substances will be considered in this FGE. 
Group IV 
This subgroup comprises eight substances [FL-nos: 13.029, 13.030, 13.059, 13.069, 13.092, 13.103, 
13.106 and 13.148]. All are alkyl-substituted furans and structurally related to two substances 
evaluated by EFSA in FGE.13Rev2 in subgroup Ic. In FGE.13Rev2 a concern for genotoxicity has 
been identified for these two structurally related substances. However, three of the substances in this 
subgroup are no longer supported by Industry [FL-nos: 13.029, 13.030 and 13.092].9 Consequently, 
only five substances [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] will be considered in this 
FGE. 
Group V 
The six substances in this group are not structurally related to any flavouring group evaluated or 
considered by EFSA. The six substances have been allocated to three subgroups (see below). Only 
five of these six substances (in subgroups V-A and V-B) will be considered in this FGE. 
Subgroup V-A10 
The three substances [FL-nos: 13.052, 13.061 and 13.123]: are furfuryl ethers. These three 
substances will be further considered in this FGE. 
Subgroup V-B 
The two substances [FL-nos: 13.031 and 13.074]: are benzofuran derivatives. Since substance 
[FL-no: 13.031] is an α,β-unsaturated carbonyl, it has been included in FGE.19 subgroup 4.3 
                                                     
9
 Commission Implementing Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 
1334/2008 of the European Parliament and of the Council as regards removal from the Union list of certain flavouring 
substances. Official Journal of the European Communities 14.3.2014, L 74, 58-60. 
10
  The Panel is aware that requested information for subgroup V-A has not been submitted before the deadline as  
 indicated in Regulation EC 872/2012. The EU Commission has communicated that substances [FL-no: 13.052,  
 13.061 and 13.123] are now in the process leading to deletion from the Union List. 
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(EFSA, 2008b) and thereafter concluded to be of no concern with respect to genotoxicity 
based on structural considerations (EFSA Panel, 2008c, 2014). These two substances will be 
further considered in this FGE. 
Subgroup V-C 
The substance previously allocated to this subgroup [FL no: 13.107] is no longer supported for 
use as flavouring substance in Europe. Therefore, this substance will not be considered in this 
FGE (DG SANCO, 2012). 
Group VI 
This subgroup consists of 16 α,β-unsaturated carbonyls. These structures bear a structural alert for 
genotoxicity (EFSA, 2008b) and substances containing this structural characteristic have already been 
evaluated with respect to their genotoxic properties by EFSA in FGE.19 context (Subgroups 4.4b, 4.5 
and 4.6 (EFSA, 2008b)). The substances in this group have been allocated to three subgroups (see 
below). Only the nine substances from subgroup VI-B will be further considered in this FGE. 
Subgroup VI-A 
For six substances (from FGE.19, subgroup 4.6, (EFSA, 2008b)) [FL-nos: 13.034, 13.043, 
13.044, 13.046, 13.137 and 13.150] a need for additional information on genotoxicity was 
identified in FGE.222 (EFSA, 2012a). These six substances will not be considered in this 
revision of the FGE. 
Subgroup VI-B 
This subgroup comprises nine substances. For seven substances in this subgroup (from 
FGE.19, subgroup 4.5, (EFSA, 2008b)) [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 
13.105 and 13.163] a need for additional information on genotoxicity was identified (EFSA, 
2008b). After further considerations in the Panel it was concluded that these substances are 
comparable to acetophenone (EFSA, 2008a), an aromatic α,β-unsaturated ketone, which is not 
genotoxic. Therefore the α,β-unsaturated ketone moiety in these seven furan derivatives is no 
longer considered to represent an alert for genotoxicity (EFSA Panel, 2008c); (see also 
FGE.13Rev2). However, based on other considerations with respect to metabolism and 
possible genotoxic properties of substance [FL-no: 13.054] for all substances in this subgroup 
additional data on genotoxicity were still requested in FGE.67rev1. Based on these additional 
considerations, for the remaining two substances in this subgroup [FL-nos: 13.045 and 
13.138] a concern for genotoxicity has also been identified (see FGE.67rev1). These nine 
substances will be further considered in this FGE. 
Subgroup VI-C 
One substance (from FGE.19, subgroup 4.4b, (EFSA, 2008b)) [FL-no: 13.176] for which a 
need for additional information on genotoxicity was identified (EFSA, 2009). After further 
evaluation of additional data submitted by the Industry, [FL-no: 13.176] has been cleared for 
genotoxicity in FGE.220Rev1 (EFSA CEF Panel, 2011a). Because this substance has closely 
related structural analogues in FGE.99, and no structural analogues in FGE.67, this substance 
will not be further considered in FGE.67, but has been evaluated in FGE.99. 
Conclusion on subgroups 
Of the 40 substances in the JECFA group of furan derivatives (JECFA, 2006a) the following will not 
be dealt with in the present revision of FGE.67: six substances from subgroup VI-A (corresponding to 
FGE.19 subgroup 4.6) for which there is still a genotoxicity concern; one substance from subgroup 
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VI-C [FL-no: 13.176] which has been transferred to FGE.99 for further consideration based on 
structural similarities; one substance from subgroup I [FL-no: 13.192] which is a duplicate of the 
substance [FL-no: 13.178] already evaluated in FGE.13Rev2. The Flavour Industry no longer supports 
the use as flavouring substances for: one substance in subgroup I [FL-no: 13.191], three substances in 
subgroup IV [FL-nos: 13.029, 13.030 and 13.092] and the one substance in subgroup V-C [FL-no: 
13.107]. In conclusion, in the present FGE.67Rev2, 28 substances will be considered. These comprise 
27 of the 40 substances in the JECFA group of furan derivatives and one additional benzofuran also 
evaluated by the JECFA in the group of furfuryl derivatives (JECFA, 2001)  
2.2. Isomers 
2.2.1. Status 
Two substances [FL-nos: 13.058 and 13.190] in the group of JECFA evaluated furan-substituted 
substances have a chiral centre and [FL-no: 13.047] has geometrical isomerism. 
2.2.2. EFSA Considerations 
Information on stereoisomerism is adequate for all substances. 
2.3. Specifications 
2.3.1. Status 
The JECFA specifications are available for all 28 substances (JECFA, 2005). See Table 2. 
2.3.2. EFSA Considerations 
The available specifications are considered adequate for all 28 JECFA-evaluated substances (see Table 
2). 
3. Intake Estimation 
3.1. Status 
For 26 JECFA evaluated substances production volumes are available for the EU and accordingly for 
these 26 substances, MSDI figures for the EU can be calculated, see Appendix D, Table 9. 
3.2. EFSA Considerations 
Tonnage data for use as a flavouring substance in Europe are missing for two [FL-no: 13.066 and 
13.070] flavouring substances considered in this FGE. 
For 14 substances [FL-nos: 13.031, 13.047, 13.058, 13.066, 13.070, 13.074, 13.101, 13.103, 13.105, 
13.106, 13.123, 13.138, 13.148 and 13.163], the Industry has submitted normal and maximum use 
levels (EFFA, 2005) (see Appendix D, Table 13: ). Based on the normal use levels, mTAMDI values 
can be calculated (see Appendix D, Table 14: ). For 12 substances [Fl-nos: 13.031, 13.047, 13.066, 
13.074, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163], the mTAMDI values are 
above the threshold of concern for their respective structural class (90 and 540 µg/person per day for 
structural class III and II, respectively). 
For the remaining 14 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.045, 13.052, 
13.054, 13.059, 13.061, 13.069, 13.083, 13.116 and 13.190] normal and maximum use levels are 
needed to calculate the mTAMDIs. Only seven of these substances [FL-nos: 13.190, 13.006, 13.021, 
13.022, 13.023, 13.024, 13.116 and 13.190] have been evaluated using the Procedure in the present 
FGE. 
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SUMMARY OF SPECIFICATION DATA 
Table 2:  Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d)
 
Spec.gravity 
(e)
 
EFSA comments 
13.006 
1517 
Phenethyl 2-
furoate O
O
O
 
2865 
362 
7149-32-8 
Liquid 
C13H12O3 
216.24 
Insoluble 
Soluble 
275 
 
NMR 
96 % 
1.585-1.593 
1.136-1.142 
 
 
13.021 
1516 
Isopentyl 4-(2-
furan)butyrate 
O O
O
2070 
2080 
7779-66-0 
Liquid 
C13H20O3 
224.30 
Insoluble 
Insoluble 
263-265 
 
NMR 
95 % 
1.551-1.555 
0.975-0.981 
 
 
13.022 
1513 
Ethyl 3(2-
furyl)propionate O
O
O
 
2435 
2091 
10031-90-0 
Solid 
C9H12O3 
168.19 
Very slightly 
soluble 
Soluble 
n.a. 
24-25 
NMR 
95 % 
n.a. 
n.a. 
 
Register name to be 
changed to: Ethyl 
3-(2-
furyl)propionate. 
13.023 
1515 
Isopentyl 3-(2-
furan)propionate O
O
O 2071 
2092 
7779-67-1 
Liquid 
C12H18O3 
210.27 
Insoluble 
Soluble 
258 
 
NMR 
96 % 
1.549-1.557 
0.987-0.993 
 
 
13.024 
1514 
Isobutyl 3-(2-
furyl)propionate O
O
O
 
2198 
2093 
105-01-1 
Liquid 
C11H16O3 
196.25 
Very slightly 
soluble 
Soluble 
105 (4 hPa) 
 
NMR 
96 % 
1.531-1.537 
1.007-1.013 
 
 
13.029 
1488 
2,5-
Dimethylfuran 
O
 
 
2208 
625-86-5 
Liquid 
C6H8O 
96.13 
Slightly 
soluble 
Soluble 
93 
 
IR NMR MS 
95 % 
1.437-1.443 
0.892-0.898 
No longer 
supported by 
industry. 
13.030 
1487 
2-Methylfuran O
 
4179 
2209 
534-22-5 
Liquid 
C5H6O 
82.10 
Slightly 
soluble 
Soluble 
64 
 
IR NMR MS 
97 % 
1.431-1.437 
0.908-0.917 
No longer 
supported by 
industry. 
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Table 2:  Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d)
 
Spec.gravity 
(e)
 
EFSA comments 
13.031 
751 
2-Benzofuran-
carboxaldehyde 
OO
 
3128 
2247 
4265-16-1 
Solid 
C9H6O2 
146.15 
Insoluble 
Slightly 
soluble 
130-131 (17hPa) 
195-198 (cryst) 
MS 
96 % 
n.a. 
n.a. 
 
13.045 
1508 
1-(2-Furyl)-
propan-2-one 
O
O
 
2496 
11837 
6975-60-6 
Liquid 
C7H8O2 
124.14 
Very slightly 
soluble 
(EFFA, 
2014) 
Soluble 
179-180 
 
NMR 
97 % 
1.499-1.505 
1.074-1.080 
 
 
13.047 
1518 
Propyl 3-(2-
furyl)acrylate O
O
O 2945 
11842 
623-22-3 
Liquid 
C10H12O3 
180.20 
Insoluble 
Soluble 
119 (9 hPa) 
 
NMR 
97 % 
1.520-1.526 
1.071-1.077 
(20°) 
Mixture of isomers: 
50-80 % E and 20 -
 50 % Z (EFFA, 
2014) 
 
13.052 
1520 
Furfuryl methyl 
ether 
O
O
 
3159 
10944 
13679-46-4 
Liquid 
C6H8O2 
112.13 
Insoluble 
Soluble 
134-135 
 
NMR 
99 % 
1.454-1.460 
1.013-1.019 
 
 
13.054 
1503 
2-Acetylfuran 
O
O
 
3163 
11653 
1192-62-7 
Liquid 
C6H6O2 
110.11 
Very slightly 
soluble 
Soluble 
67 (13 hPa) 
 
IR 
97 % 
1.505-1.510 
1.102-1.107 
 
 
13.058 
1500 
3-(5-Methyl-2-
furyl) butanal O
O
 
3307 
10355 
31704-80-0 
Liquid 
C9H12O2 
152.19 
Insoluble 
Soluble 
88-91 (16 hPa) 
 
NMR 
98 % 
1.575-1.581 
1.006-1.012 
Racemate. 
13.059 
1491 
2-Pentylfuran O
 
3317 
10966 
3777-69-3 
Liquid 
C9H14O 
138.21 
Slightly 
soluble 
Soluble 
58-60 (13 hPa) 
 
NMR 
99 % 
1.443-1.449 
0.886-0.893 
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Table 2:  Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d)
 
Spec.gravity 
(e)
 
EFSA comments 
13.061 
1522 
Difurfuryl ether 
O
O
O
 
3337 
10930 
4437-22-3 
Liquid 
C10H10O3 
178.19 
Insoluble 
Soluble 
88-89 (1 hPa) 
 
NMR 
97 % 
1.138-1.144 
1.506-1.512 
 
 
13.066 
1506 
3-Acetyl-2,5-
dimethylfuran 
O
O
 
3391 
10921 
10599-70-9 
Liquid 
C8H10O2 
138.17 
Slightly 
soluble 
Soluble 
83 (14 hPa) 
 
NMR 
99 % 
1.484-1.492 
1.027-1.048 
 
 
13.069 
1492 
2-Heptylfuran O 3401 
10952 
3777-71-7 
Liquid 
C11H18O 
166.26 
Insoluble 
Soluble 
209-210 
 
NMR 
99 % 
1.446-1.452 
0.860-0.866 
 
 
13.070 
1512 
2-Hexanoylfuran 
O
O
 
3418 
11180 
14360-50-0 
Liquid 
C10H14O2 
166.22 
Slightly 
soluble 
Soluble 
65-67 (0.7 hPa) 
 
NMR 
99 % 
1.490-1.496 
0.992-0.998 
 
 
13.074 
1495 
2,3-
Dimethylbenzofur
an 
O
 
3535 
11913 
3782-00-1 
Liquid 
C10H10O 
146.19 
Insoluble 
Soluble 
96-98 (20 hPa) 
 
NMR 
97 % 
1.554-1.563 
1.031-1.037 
 
 
13.083 
1504 
2-Acetyl-5-
methylfuran O
O
 
3609 
11038 
1193-79-9 
Liquid 
C7H8O2 
124.14 
Slightly 
soluble 
Soluble 
71-72 (10 hPa) 
 
IR NMR 
99 % 
1.511-1.517 
1.066-1.072 
(20°) 
 
 
13.092 
1489 
2-Ethylfuran O
 
3673 
11706 
3208-16-0 
Liquid 
C6H8O 
96.13 
Insoluble 
Soluble 
92-93 
 
NMR 
95 % 
1.444-1.450 
0.909-0.915 
No longer 
supported by 
industry. 
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Table 2:  Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d)
 
Spec.gravity 
(e)
 
EFSA comments 
13.101 
1505 
2-Acetyl-3,5-
dimethylfuran O
O
 
4071 
 
22940-86-9 
Liquid 
C8H10O2 
138.17 
Insoluble 
Soluble 
195 
18 
MS 
95 % 
1.494-1.500 
1.041-1.047 
 
 
13.103 
1490 
2-Butylfuran O
 
4081 
10927 
4466-24-4 
Liquid 
C8H12O 
124.18 
Insoluble 
Soluble 
139 
 
MS 
95 % 
1.444-1.450 
0.884-0.890 
 
 
13.105 
1507 
2-Butyrylfuran 
O
O
 
4083 
11045 
4208-57-5 
Liquid 
C8H10O2 
138.17 
Insoluble 
Soluble 
195 
 
NMR MS 
95 % 
1.489-1.495 
1.050-1.056 
 
 
13.106 
1493 
2-Decylfuran O 4090 
 
83469-85-6 
Solid 
C14H24O 
208.34 
Insoluble 
Soluble 
 
30 
NMR 
95 % 
n.a. 
n.a. 
 
 
13.107 
1496 
2,4-
Difurfurylfuran 
OO
O
 
4095 
 
64280-32-6 
Solid 
C14H12O3 
228.24 
Insoluble 
Soluble 
 
153 
NMR 
95 % 
n.a. 
n.a. 
No longer 
supported by 
industry. 
13.116 
1523 
2,5-Dimethyl-3-
thioacetoxyfuran 
O
S
O
 
4034 
 
55764-22-2 
Liquid 
C8H10O2S 
170.23 
Practically 
insoluble 
Soluble 
230 
 
IR NMR MS 
98 % 
1.527-1.533 
1.137-1.143 
 
 
13.123 
1521 
Ethyl furfuryl 
ether 
O
O
 
4114 
10940 
6270-56-0 
Liquid 
C7H10O2 
126.15 
Slightly 
soluble 
Soluble 
150 
 
MS 
95 % 
1.449-1.455 
0.982-0.988 
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Table 2:  Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d)
 
Spec.gravity 
(e)
 
EFSA comments 
13.138 
1510 
1-(2-Furyl)butan-
3-one O
O
 
4120 
11084 
699-17-2 
Solid 
C8H10O2 
138.17 
Slightly 
soluble 
Soluble 
n.a. 
37 
MS 
95 % 
n.a. 
n.a. 
 
 
13.148 
1494 
3-Methyl-2(3-
methylbut-2-
enyl)furan 
O
 
4174 
 
15186-51-3 
Liquid 
C10H14O 
150.22 
Slightly 
soluble 
Soluble 
70 (15 hPa) 
 
MS 
98 % 
1.473-1.479 
0.998-1.004 
Register name to be 
changed to: 3-
Methyl-2-(3-
methylbut-2-
enyl)furan. 
13.163 
1509 
2-Pentanoylfuran 
O
O
 
4192 
 
3194-17-0 
Liquid 
C9H12O2 
152.19 
Slightly 
soluble 
Soluble 
101 (13 hPa) 
 
MS 
95 % 
1.486-1.492 
1.009-1.015 
 
 
13.190 
1525 
3-((2-Methyl3-
furyl)thio)-2-
butanone 
O
S
O
 
4056 
 
61296-44-1 
Liquid 
C9H12O2S 
184.25 
Practically 
insoluble 
Soluble 
70 (1 hPa) 
 
IR NMR MS 
99 % 
1.510-1.516 
1.104-1.110 
CASrn in Register 
is not valid; CASrn 
to be changed to: 
61295-44-1 (The 
Good Scents 
Company, 2011). 
Register name to be 
changed to 3-((2-
Methyl-3-
furyl)thio)-2-
butanone.  
Racemate. 
13.191 
1526 
o-Ethyl S-(2-
furylmethyl)thioc
arbonate 
O
S O
O
 
4043 
 
376595-42-5 
Liquid 
C8H10O3S 
186.23 
Practically 
insoluble 
Soluble 
130-135 
 
IR NMR MS 
99 % 
1.504-1.510 
1.167-1.173 
No longer 
supported by 
industry. 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
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(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text taken11 from the JECFA (JECFA, 2009a) 
Genotoxicity testing has been performed on eight [FL-nos: 13.022, (former 13.029), (former 13.030), 
13.034, 13.044, 13.054, 13.148 and (former 13.191)] representative furan-substituted aliphatic 
hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, disulphides 
and ethers in this group (JECFA, 2009a). The results of these tests are summarised in Appendix A, 
Table 3:  of this FGE and described below. 
In vitro 
“In standard Salmonella mutagenicity assays, 2,5-dimethylfuran [former FL-no: 13.029], 3-methyl-2-
(3-methylbut-2-enyl)-furan [FL-no: 13.148], 3-(2-furyl)acrolein [FL-no: 13.034], 4-(2-furyl)-3-buten-
2-one [FL-no: 13.044], ethyl 3-(2-furyl)propanoate [FL-no: 13.022] and O-ethyl S-(2-
furylmethyl)thiocarbonate [former FL-no: 13.191] were not mutagenic in Salmonella typhimurium 
strains TA97, TA98, TA100, TA102, TA1535, TA1537 or TA1538 when tested at concentrations of 
up to 10000 µg/plate, alone or in the presence of an exogenous rat liver metabolic activation system 
(S9-mix) (Wild et al., 1983; Mortelmans et al., 1986; Shinohara et al., 1986; Asquith, 1989; Eder et 
al., 1991a; Zeiger et al., 1992; Lee et al., 1994; Verspeek-Rip, 2000). Likewise, with the exception of a 
single assay in which equivocal results of mutagenicity were reported in S. typhimurium strains TA97 
and TA107 (Zeiger et al., 1992)-methylfuran [former FL-no: 13.030] was consistently negative in 
several other strains of S. typhimurium (i.e. TA98, TA100, TA102 and TA1535) both alone and with 
an exogenous rat liver bioactivation system (S9-mix) (Shinohara et al., 1986; Aeschbacher et al., 
1989). Evaluated alone and with an exogenous bioactivation system in S. typhimurium at 
concentrations of up to 0.660 µmol/plate (54.2 µg/plate), 2-furyl methyl ketone [FL-no: 13.054] 
exhibited a significant positive mutagenic potential only in strain TA98 with bioactivation at the two 
lower concentrations (i.e. 0.165 and 0.330 µmol/plate) (Shinohara et al., 1986). At higher 
concentrations, significant cytotoxicity was observed, which was reflected by a concentration-
dependent decrease in the number of revertants. 
Bacterial mutagenicity testing of furans that can be metabolically oxidized to reactive α,β-unsaturated 
dicarbonyl (2-ene-1,4-dicarbonyl) intermediates is problematic owing to their high bacterial toxicity. 
The cytotoxicity of these substances is believed to arise from their interactions with protein sulfhydryl 
and amino groups (Marnett et al., 1985; Eder et al., 1992). Owing to the nature of the glutathione 
(GSH) conjugation pathway, genotoxicity studies in which high concentrations of α,β-unsaturated 
carbonyl compounds are formed are likely to create oxidative stress. It is anticipated that cells exposed 
to high concentrations of these types of substances will rapidly deplete GSH levels, eventually leading 
to cellular damage and decreased cell viability, as indicated by the above study results. 
O-Ethyl S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] showed no mutagenic potential when 
tested in Escherichia coli WP2uvrA at concentrations of up to 3330 µg/plate, either alone or with a 
bioactivation system (Verspeek-Rip, 2000). Evaluated in E. coli PQ37 under the conditions of the SOS 
chromotest, 3-(2-furyl)-acrolein [FL-no: 13.034] tested negative (Eder et al., 1991); however, in a 
subsequent evaluation, 3-(2-furyl)acrolein [FL-no: 13.034] as well as 2-furyl methyl ketone (2-
acetylfuran) [FL-no: 13.054] were slightly positive in the SOS chromotest without metabolic 
activation, as evidenced by 1.72- and 1.75-fold increases, respectively, in the SOS induction factor 
over a background value of 1 (results were considered to be significant if the induction factor was at 
least 1.5) (Eder et al., 1993). 
In the rec assay, which is based on differential inhibition of growth of repair-deficient strains as a 
measure of DNA-damaging activity, Bacillus subtilis strains H17 (rec+) and M45 (rec-) were 
                                                     
11
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed. 
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incubated with 2-methylfuran [former FL-no: 13.030], 2,5-dimethylfuran [former FL-no: 13.029] and 
2-furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] at concentrations of up to 55000 µg/disc, alone 
and with metabolic activation (Shinohara et al., 1986). 2-Furyl methyl ketone tested negative at a 
concentration of 550 µg/disc, but was reportedly positive at concentrations of 5500 µg/disc and greater 
alone and with metabolic activation. Likewise, 2,5-dimethylfuran was negative at the lowest 
concentration tested (i.e. 190 µg/disc) with metabolic activation, but tested positive at every 
concentration tested in the absence of metabolic activation. In contrast, 2-methylfuran was negative 
with metabolic activation and induced significant differences in the zones of inhibition only without 
metabolic activation. Additionally, 2-methylfuran and 2-furyl methyl ketone were reported to cleave 
the double strand of lambda-phage DNA in the presence of Cu2+; however, a negative control was not 
included, and, therefore, the statistical significance of these results was not ascertained. Also, it should 
be noted that potential concomitant cytotoxicity was not monitored in this study. 
The potential mammalian cell clastogenicities of 2-methylfuran [former FL-no: 13.030], 2,5-
dimethylfuran [former FL-no: 13.029] and 2-furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] were 
evaluated in Chinese hamster ovary (CHO) cells, in which induction of chromosomal aberrations was 
measured. Cells were exposed to substances from commercial sources (purity not given) for 3 hours, 
followed by 20 hours of maintenance. In the absence of exogenous metabolic activation, all three 
compounds produced increases in the number of chromosomal aberrations, mainly chromatid 
exchanges; however, in the presence of rat liver metabolic activation, only the clastogenicity of 2-furyl 
methyl ketone was increased, whereas the clastogenic activities of 2-methylfuran and 2,5-
dimethylfuran were reduced in comparison with test systems without metabolic activation. 
Additionally, the authors noted that when NADP was eliminated from the activation system, the 
reduction in the chromosomal aberrations observed for 2-methylfuran and 2,5-dimethylfuran and the 
increase in the clastogenic activity observed with 2-furyl methyl ketone in the presence of the 
activation system were abolished. This suggests that mixed-function oxidases are integral in the 
metabolism of alkyl furan derivatives. It should be noted that the experiment with 2-furyl methyl 
ketone was performed at a limited number of concentrations (two), the active one of which far 
exceeded (112.6 mmol/l = 13220 µg/ml) standard concentration limits for this assay and was toxic 
(Stich et al., 1981b). 
Beginning in the late 1980s, researchers began studying test conditions (osmolality, ionic strength, low 
pH) that could cause an increase in clastogenic activity (increased chromosomal aberrations and 
micronuclei) in the absence of any chemical-induced effect on DNA (Zajac-Kaye and Ts’o, 1984; 
Brusick, 1986; Bradley et al., 1987; Galloway et al., 1987; Seeberg et al., 1988; Morita et al., 1989; 
Scott et al., 1991). More recent research indicates that extreme culture conditions (hypo- and 
hyperosmolality and high pH) induce apoptosis and necrosis, leading to DNA fragmentation and 
producing false-positive responses in clastogenic assays (Meintieres and Marzin, 2004). 
Apoptosis is a type of cell death that occurs under physiological conditions or in response to external 
stimuli (e.g. DNA-damaging agents, growth factor deprivation or receptor triggering). The mechanism 
of formation of apoptotic cells includes activation of cysteine proteases (caspases), leading to 
increased mitochondrial permeability, release of cytochrome c, DNA cleavage and redistribution of 
phosphatidylserine to the outer layers of the cell membrane, which enhances binding of cells to 
phagocytes. DNA cleavage, owing to irreversible activation of endonucleases, is followed by 
chromatin condensation and oligonucleosomal fragmentation due to double-strand cleavage of DNA 
in nucleosomal linker regions (Saraste and Pulkki, 2000). During chromatin condensation, the nucleus 
may split into a number of dense micronuclei. Fragmented DNA and chromatin condensation due to 
apoptotic events are not easily distinguished from direct action of a specific chemical. 
In consideration of such knowledge, findings of chromosomal aberrations must be evaluated in the 
context of the potential for apoptosis to occur under test conditions. Relatively high concentrations 
(i.e. up to 1923 – 13220 µg/ml or 20 – 150 mmol/l) were used in the study conducted by Stich et al. 
(Stich et al., 1981b). The Km for most enzyme kinetic processes is at or below 100 µmol/l (Bu, 2006; 
Wang and James, 2006), and thus the high concentrations used in this study may not be relevant to the 
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human condition, especially with respect to the low levels of flavouring agents added to food. 
Furthermore, no information was available on culture conditions that may have promoted apoptosis. 
Results of chromosomal aberration and micronuclei assays are problematic to interpret in the absence 
of such information. 
2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of unscheduled 
DNA synthesis (UDS) in human hepatocytes following Organization for Economic Cooperation and 
Development (OECD) guidelines. Human (sex not given) hepatocytes from two batches purchased 
from a commercial provider were incubated with concentrations of compound (purity not given) of 
between 2.19 and 280 µg/ml for 16 hours, and UDS was measured autoradiographically. No UDS was 
elicited, in contrast to the positive control, 2-acetylaminofluorene (Durward, 2007a). 
In a study examining the effect of oxygen scavengers on cadmium chloride–induced chromosomal 
aberrations in Chinese hamster V79 cells, 2,5-dimethylfuran [former FL-no: 13.029] at 96.13 µg/ml (1 
mmol/l) did not increase the frequency of chromosomal aberrations in comparison with control values. 
When 2,5-dimethylfuran at 96.13 µg/ml (1mmol/l) was incubated with the V79 cells in the presence of 
cadmium chloride, no reduction in the clastogenic capacity of cadmium chloride was observed (Ochi 
and Ohsawa, 1985). 
O-Ethyl-S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] was evaluated for potential 
clastogenicity in a series of tests in human peripheral lymphocytes. Doses at which chromosomal 
aberrations were evaluated were based on a preliminary evaluation of effects on the mitotic index in 
the cells. Generally, O-ethyl-S-(2-furylmethyl)thiocarbonate exhibited marked mitogenicity and 
cytotoxicity, and accordingly only a relatively narrow range of concentrations was used. In the first set 
of tests in which an exposure time of 3 hours was utilized, the substance did not induce an increase at 
concentrations ranging between 150 and 350 µg/ml alone or in the presence of a bioactivation system; 
however, in another test employing a 3-hour exposure period with metabolic activation, significant 
and dose-dependent increases in the number of chromosomal aberrations were observed at 
concentrations of 325 and 375 µg/ml, but not at 150 µg/ml. Moreover, following a 24- or 48-hour 
exposure period, O-ethyl-S-(2-furylmethyl)thiocarbonate (up to 280 µg/ml) also induced dose-
dependent and statistically significant increases in the number of chromosomal aberrations in the 
absence of metabolic activation in comparison with a negative control (Meerts, 2000). 
In vivo 
As reported in an abstract, 2-methylfuran [former FL-no: 13.030] (purity not given) did not induce 
chromosomal aberrations in bone marrow cells or spermatocytes of Swiss albino mice evaluated at 24-
hour intervals following administration in the diet at concentrations of 1000, 2000 or 4000 mg/kg 
(approximately 100, 200 and 400 mg/kg body weight (bw) per day, respectively) for a period of 5 
days. No positive control was included. Moreover, the authors noted that 2-methylfuran did not inhibit 
spindle protein synthesis or cell division in the somatic cells. In the germ cells, which were evaluated 
at weekly intervals for a period of 5 weeks following final dosing, in order to cover one full 
spermatogenesis cycle, no structural sperm-head abnormalities were reported (Subramanyam et al., 
1989). 
2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for clastogenic activity in bone 
marrow and germ cells of Swiss albino mice. Groups of two per dose per sampling time were 
administered the compound (99 % pure) orally at 0 (control), 1000, 2000 or 3000 mg/l in 0.5 ml of 
water (approximately 0, 20, 40 and 60 mg/kg bw, respectively) either as a single dose or once daily for 
5 consecutive days. No positive control was included. Bone marrow cells were collected periodically 
for up to 72 hours following dosing, and meiotic and sperm preparations from testes and epididymis, 
respectively, were assessed at 24 hours and weekly for a total of 5 weeks post-dosing. In bone marrow 
cells, the substance at the high dose level was observed to inhibit mitosis beginning at 18 hours 
following single- or multiple-dose treatment. At 24 hours, mitodepression was also observed at the 
high dose level in the single-dose experiment, as well as at the middle and high dose levels in mice 
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administered multiple doses. In the repeat-dose test protocol, the effect remained significant for up to 
36 hours post-treatment. Mitodepression was accompanied by increases in the frequency of structural 
chromosomal aberrations, mainly gaps and breaks, in the bone marrow cells. Specifically, at the high 
dose level (i.e. 3000 mg/l), between 18 and 24 hours following single-dose administration and 12 and 
48 hours following final treatment of multiple-dose groups, the frequency of aberrations was elevated. 
Additionally, in animals receiving multiple doses of 2-furyl methyl ketone, significant increases in the 
number of chromosomal aberrations were also observed at the middle dose level (i.e. 2000 mg/l) 
between 24 and 36 hours post-treatment. In contrast to the dose- and time-dependent increase in 
chromosomal aberrations in the somatic cells, only a single isolated increase in structural 
chromosomal aberrations was observed in mouse spermatocytes 3 weeks following single-dose 
administrations of the substance, and only at the highest dose level. Following multiple-dose 
administration, abnormalities in germ cells were limited to significant increases in polyploidy and XY 
univalents occurring at weeks 3 and 4 at the highest dose level. Furthermore, no sperm-head 
abnormalities were observed at any dose level, irrespective of the treatment protocol. The absence of 
sperm-head abnormalities at all dose levels was indicative of a lack of sperm toxicity of the substance. 
The authors concluded that 2-furyl methyl ketone exhibits only mild clastogenic activity in mouse 
bone marrow and is not clastogenic in germ cells (Sujatha et al., 1993). 
2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of sister chromatid 
exchanges (SCE) in bone marrow of female Swiss albino mice. Groups of two per dose per exposure 
regimen were administered compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either 
once or for 5 consecutive days. 5-Bromodeoxyuridine was injected intraperitoneally to label 
chromatids. The mice were sacrificed at 12, 24 or 48 hours after receiving the last dose, and slides of 
bone marrow were prepared and processed for differential staining. A dose-related increase up to 
about 2-fold in SCE was observed for the 12- and 24-hours groups of both the single-dose regimen 
and the multiple-dose regimen (Sujatha, 2007). 
2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of UDS in 
hepatocytes isolated from livers of dosed male Sprague-Dawley rats. The assay was conducted 
according to Good Laboratory Practices (GLP) and OECD guidelines. In a preliminary range-finding 
toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs of toxicity were observed 
at 20 mg/kg bw. No sex differences were observed, and therefore only males were used in the main 
study. Groups of four rats were administered compound (purity not given) at 0, 7 or 21 mg/kg bw via 
gavage. In experiment 1, the hepatocytes were isolated 16 hours post-dosing; in experiment 2, 
hepatocytes were isolated 2 hours post-dosing and cultured for autoradiographic measurement of 
UDS. No UDS was observed in either experiment, in contrast to the positive controls 2-
acetylaminofluorene and N,N’-dimethylhydrazine (Durward, 2007b). 
O-Ethyl S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] was evaluated for induction of 
micronuclei in bone marrow erythrocytes of NMRI BR mice. Groups of five per sex per dose per 
sampling time were administered single doses of compound (99 % pure) at 0 (vehicle control), 100, 
250 or 500 mg/kg bw in corn oil via gavage. Dosed animals at every dose level and controls were 
killed at 24 hours post-dosing. Additionally, a second group of high-dose mice (i.e. 500 mg/kg bw) 
and the positive control (cyclophosphamide) group were terminated at 48 hours post-dosing. Bone 
marrow smears were prepared from the femurs. No increase in the incidence of micronucleated 
polychromatic erythrocytes (PCE) was observed in dosed mice compared with controls, in contrast to 
the positive control, which induced a 20-fold increase. However, the authors also noted that cells 
obtained from dosed animals did not exhibit a reduction in the ratio of polychromatic to 
normochromatic erythrocytes (NCE), indicating an absence of toxicity, which could be due to lack of 
adequate exposure of bone marrow (Verspeek-Rip, 2001)”. 
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Conclusions on genotoxicity 
“With few exceptions, eight representative substances of this group were consistently negative in 
mutation assays conducted in various strains of S. typhimurium and E. coli under appropriate testing 
conditions. Negative and positive results were obtained in the rec assay in B. subtilis for 2-methylfuran 
and 2,5-dimethylfuran. In mammalian genotoxicity assays conducted in CHO and V79 cells and 
human peripheral lymphocytes, study results were inconsistent, with both negative (2,5-dimethylfuran, 
O-ethyl-S-(2-furylmethyl)thiocarbonate) and positive (2-methylfuran, 2,5-dimethylfuran) results 
reported. Although positive results were reported in the chromosomal aberration assay in CHO cells 
with 2-methylfuran and 2,5-dimethylfuran, relatively high concentrations were utilized (i.e. up to 
13220 and 1923 µg/ml, respectively); the statistical significance of the results was not specified, and 
the potential cytotoxicity was not monitored in the assay. Moreover, as previously discussed, positive 
in vitro results of chromosomal aberrations are difficult to interpret in the presence of concomitant 
cytotoxicity and cell cycle delay, which, based on the results of the studies, are a feature of the furan 
derivatives. Therefore, it may be expected that mammalian cells in culture might not have adequate 
metabolic capacities to counter this toxicity. In fact, with the exception of one assay in which 
clastogenic activity was reported for a single compound (i.e. 2-furyl methyl ketone) with a metabolic 
activation system, results obtained with other representative furan derivatives demonstrated a 
reduction in the frequency of chromosomal aberrations in the presence of metabolic activation. 
Furthermore, unlike the positive results reported for 2,5-dimethylfuran among several other 
compounds evaluated in CHO cells at the high concentrations used in the study of Stich et al. (Stich et 
al., 1981b)-dimethylfuran, tested at lower concentrations in V79 cells, did not exhibit clastogenic 
activity (Ochi and Ohsawa, 1985). The negative findings in the human hepatocyte DNA damage assay 
provide evidence that the chromosomal aberration findings are not due to a DNA-reactive mechanism. 
Three representative compounds were studied in in vivo assays. With 2-methylfuran, no increase in 
chromosomal aberrations was found in either mouse bone marrow cells or spermatocytes. In a study in 
which mild clastogenic activity was reported in mouse bone marrow cells at the middle and high doses 
of 2-furyl methyl ketone (i.e. 40 and 60 mg/kg bw, respectively), at which the authors also reported 
significant mitodepression following single- and multiple dose administrations, no increase in 
chromosomal aberrations was observed in the spermatocytes obtained from the same mice, and the 
weak clastogenic effects achieved statistical significance only after repeated daily exposure to near-
lethal doses. A study from the same laboratory reported induction of SCEs in mouse bone marrow 
cells by 2-furyl methyl ketone. However, 2-furyl methyl ketone did not elicit UDS in hepatocytes 
isolated from rat liver, suggesting that any possible in vivo genotoxicity is not attributable to DNA 
reactivity. The frequency of micronucleus formation in bone marrow cells of mice administered single 
doses of O-ethyl-S-(2-furylmethyl)thiocarbonate was comparable with control values (Verspeek-Rip, 
2001), although adequacy of exposure was not demonstrated. 
In conclusion, results of the in vitro genotoxicity/mutagenicity tests revealed mixed results, with 
positive results reported less frequently in the presence of an activation system. This could indicate 
metabolic detoxication of these substances. The in vivo single-dose studies with 2-furyl methyl ketone 
did not indicate evidence for genotoxicity, whereas two repeat-dose studies showed weak effects for 
induction of chromosomal aberrations and SCEs. However, evidence indicates that 2-furyl methyl 
ketone does not exhibit DNA reactivity. The basis for the positive clastogenicity findings remains 
unclear.” 
For a summary of in vitro / in vivo genotoxicity data considered by JECFA see Appendix A, Table 3 
Table 3: of this FGE. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 28 
4.2. Genotoxicity Studies – Text taken12 from the JECFA (JECFA, 2001) 
The JECFA did not provide a text on the genotoxicity in their evaluation of the group of furfuryl 
alcohol and related substances including flavouring substance [FL-no: 13.031]. The JECFA only 
presented the study results in table format. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA see Appendix A, Table 
6 in this FGE 
4.3. Genotoxicity Studies – Text taken13 from EFSA FGE.13Rev2 (EFSA CEF Panel, 2011c) 
In the following text, which is taken from FGE.13Rev2, the FGE.13-subgrouping is maintained. 
Genotoxicity studies were available only on some of the candidate substances included in main group 
I or on their related supporting substances. For subgroup Ia, data on in vitro genotoxicity were 
provided for the two candidate substances 5-hydroxymethyl furfural (5HMF) [FL-no: 13.139] and 
furoic acid [FL-no: 13.136] as well as for five supporting substances. Data on in vivo genotoxicity 
were only provided on two of the supporting substances from subgroup Ia. New genotoxicity data on 
the candidate substance 5HMF have become available and will be considered in this revision of 
FGE.13. 
For the one candidate substance [FL-no. 13.155] in subgroup Ib no genotoxicity data are available, but 
in vitro and in vivo genotoxicity data are available for the supporting substance 2-acetylfuran [FL-no: 
13.054]. 
For subgroup Ic, data on in vitro genotoxicity were provided for two supporting substances. Data on in 
vivo genotoxicity were only provided for one of the two supporting substances [former FL-no: 13.029 
and former 13.030]. Since the supporting substance for subgroup Ib gives information on genotoxic 
properties of putative metabolites of the candidate substances in subgroup Ic, the information given for 
the evaluation of subgroup Ib is also relevant for subgroup Ic. 
No genotoxicity data were available on candidate or on structurally related substances in main group II 
(i.e. furans with sulphur-containing ring substituents). 
Subgroup Ia 
Candidate substances: 
5-hydroxymethyl furfural [FL-no: 13.139] 
In the in vitro tests, 5HMF gave negative results in the traditional Ames test in strains TA98, TA100, 
TA104, TA1535 and TA1537 in five and positive results in two studies. The validity of these two 
studies could not be assessed. In one of these two studies (Omura et al., 1983) the positive response 
was observed in strain TA100, but not in TA98 and the mutagenic potential was higher in the absence 
of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only 
observed in strain TA100 in the presence of metabolic activation (see Table 4: ). A positive result was 
obtained also in the Umu assay, although only at high concentrations, resulting in reduced cell 
viability (Janzowski et al., 2000) and in a Rec assay on B. subtilis (Shinohara et al., 1986). In V79 
cells, 5HMF induced a small (although statistically significant) increase in chromosomal aberrations, a 
reduction in mitotic index and, only at high concentrations resulting in reduced cell viability, also 
hypoxanthine phosphoribosyl transferase (HPRT) mutations (Janzowski et al., 2000). In TK6 human 
                                                     
12
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed. 
13
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed. 
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lymphoblast cells, 5HMF gave negative results in the HPRT and thymidine kinase (TK) assay (Surh 
and Tannenbaum, 1994). 
In an Ames test with TA104 strain upon inclusion of 3'-Phosphoadenosine-5'-phosphosulfate (PAPS), 
a sulpho-group donor, and rat liver cytosol into the experimental model, 5HMF gave a positive result, 
suggesting that it can be activated to reactive metabolites following sulphation, with formation of 
sulphate-ester, [(sulphoxy)methyl]furfural, (SMF). Indeed, the mutagenic effect could be partly 
suppressed by the addition of sulphotransferase inhibitors. In accordance, SMF in TA104 was 
genotoxic in the absence of any metabolic system (cytotoxicity not specified); the effect was reduced 
by addition of GSH and GSH-transferases and restored when this latter enzyme was inhibited (Lee et 
al., 1995).  
The formation of SMF was supported by the detection of an unstable conjugate, which disappeared 
within 60 minutes, when 5HMF was incubated with 35S-PAPS and liver cytosol. The exact nature of 
SMF was not elucidated, but its molecular mass was consistent with that of the sulphate-ester of 
5HMF (Surh and Tannenbaum, 1994). 
When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-
resistance), without any metabolic activation, a clear positive response was obtained at concentrations 
that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human 
lymphoblasts at the TK and HPRT loci, at concentrations (> 40 microg/ml) reducing cell survival to > 
63 %. No genotoxicity was observed with 5HMF, with its acetate ester or with the sulphation product 
of 2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of both a 
reactive sulphate group and a free aldehyde group. 
An assay for primary DNA damage (Comet assay) did not show an effect of 5HMF in V79 and Caco-2 
cells up to cytotoxic concentrations (80 mM). 5HMF causes a slight but significant increase in DNA 
single strand breaks in primary rat hepatocytes at cytotoxic levels (40 – 100 mM), whereas in human 
colon biopsy material the same effect was seen in the absence of cytotoxicity. 5HMF at non-cytotoxic 
concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 and rat liver 
cells. The effect of sulphate conjugation was not directly studied, but since this activity is present at 
least in primary hepatocytes, it might have contributed to the depletion of GSH and to induction of 
DNA strand breaks in these cells. However, this study was not considered appropriate to evaluate the 
possible mutagenic activity of SMF in mammalian cells and consequently of 5HMF in vivo 
(Janzowski et al., 2000). 
To support the genotoxic potential of 5HMF, some indications for tumorigenic activities of 5HMF 
have been obtained with rats and mice. It has been reported that 5HMF may act as both an initiator and 
a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et al., 
1993; Zang et al., 1993). In addition induction of skin papillomas has been described after topical 
application of doses of 10 or 25 micromol 5HMF to mice (Surh et al., 1994). 
Newly submitted data on 5-hydroxymethylfurfural14(Included in Appendix A, Table 4:  and Table 5:  of 
this FGE) 
Weak mutagenic activity was reported in S. typhimurium TA100 strain in the absence of metabolic 
activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range 
of concentrations of 100 – 10 000 µg/plate; however, negative results were reported in another study 
with TA98 and TA100 strains and E. coli WP2 uvrA/pKM101 in a range of concentrations of 1500 – 
10 000 µg/plate (NTP, 2010). 
                                                     
14
  An in vivo micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of  
 the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the  
 occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited  
 relevance. For these two reasons the study is not further discussed. 
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At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female 
B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw per day of 5HMF via gavage. Slides were 
scanned to determine the frequency of micronuclei in 1000 NCEs in 10 animals per sex per treatment 
group. In addition, the percentage of PCE in a population of 1000 erythrocytes was determined as a 
measure of bone marrow toxicity. No increases in the frequency of micronucleated erythrocytes were 
observed; in addition, no significant dose-related changes in the percentage of immature PCE were 
observed, suggesting that the chemical did not exhibit bone marrow toxicity (NTP, 2010). 
The DNA-damaging potential of 5HMF was tested in vitro in the Comet assay with the following five 
cell lines with various degree of sulphotransferase 1A1 (SULT1A1) expression (Durling et al., 2009): 
two human lines (Caco-2, no detectable ST1A1 activity; HEK293, high SULT1A1 activity); two cell 
lines from Chinese hamster (V79, no detectable SULT1A1 activity and V79-hp-PST, high SULT1A1 
activity) and a one mouse lymphoma line (L5178Y, no detectable SULT1A1 activity). The cell lines 
were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5HMF for 
three hours and subjected to a Comet assay to study DNA damage. 
DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant 
reduction in cell viability (from 11 to 30 %), The concentration of 100 mM is ten times higher than the 
highest concentration (10 mM or 5000 µg/ml) recommended by OECD guidelines for in vitro testing 
with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: Caco-2, 
HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) DNA 
damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 3193 
µg/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 0.01 mM) 
induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The authors 
(Durling et al., 2009) concluded that 5HMF DNA damage in all cell lines was unrelated to the 
expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines 
(Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. 
The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5HMF also 
in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in V79-
hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in extent of 
DNA-damage could be observed. This would indicate absence of a significant contribution of sulphate 
conjugation in the DNA-damaging activity of 5HMF.  
These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of 
SCE in 5HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and 
SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) 
reporting the mutagenicity of 5HMF in a S. typhimurium strain genetically modified and expressing 
human SULT1A1. According to Durling et al. (Durling et al., 2009), the reasons of these discrepancies 
are unknown; one possibility is the different sensitivity of the Comet assay compared to other systems. 
Durling et al. (Durling et al., 2009) concluded that other important mechanisms for the observed DNA 
damage should be investigated, but that under the conditions of the test, 5HMF is a rather weak DNA-
damaging agent. 
In a new publication by Severin et al. (Severin et al., 2010), a dose dependent increase in DNA 
damage was observed in a Comet assay with HepG2 cells exposed to 5HMF (0, 5.35, 7.87, 11.57, 17, 
25, 36.6 mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5HMF. Cytotoxicity was 
observed at the two highest doses (25 and 36.6 mM), with estimated IC50 of 38 mM. HepG2 cells 
express both CYP and SULT enzymes. In the same publication no effect of 5HMF was found in an in 
vitro micronucleus assay in the same cell line exposed to similar doses of 5HMF (20 hours). 5HMF 
was also tested in an Ames test performed according to the OECD guidelines 471. No increase in 
mutants was observed in S. typhimurium strains TA98, TA100, TA1535 and TA1537 exposed to 
5HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no 
additional PAPS was added to the test system (Severin et al., 2010).  
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However, while 5HMF was unable to induce micronuclei in vivo, in mice (90-day study by gavage, 
NTP, 2010) and in vitro, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, 
its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice 
(Dahlberg, 2004) as cited by Glatt and Sommer, 2006 (no further data were available)). 
According to Glatt and Sommer, incubation of DNA with SMF in a cell-free system led to the 
formation of DNA adducts that could be detected by the 32P-postlabelling technique. No adducts were 
formed in incubations with 5HMF instead of SMF. In subsequent experiments, the authors searched 
for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells 
treated with 5HMF. Although mutations were induced, adducts were not seen in these cells under the 
same conditions (no data are available to be listed in the genotoxicity table). The authors hypothesized 
that the lack of DNA adducts might be due to technical problems, since generally DNA adducts are a 
more sensitive endpoint than mutations as observed with many other compounds (Glatt and Sommer, 
2006). 
In conclusion, with respect to the genotoxicity of 5HMF, taking into account additional data on 
metabolism, the following picture emerges. The substance is negative in the conventional Ames test. 
Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into 
the metabolic system, suggesting the formation of a SMF. In accordance, SMF was mutagenic in the 
absence of any metabolic activation system. In an in vitro assay, 5HMF induced concentration-
dependent increase in DNA damage (Comet assay), but this study has major drawbacks and 
inconsistencies and has to be considered of limited validity. A major limitation is the use of too high 
concentrations that can produce unpredictable effects, not related to the real genotoxic potential of 
5HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the 
authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet 
assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage 
were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) 
in the same cell system. In vivo, a non-standard micronucleus assay in peripheral blood erythrocytes 
associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this 
study has limited validity since no bone marrow cell toxicity was observed. 
Metabolic studies indicate that in vivo, in mice B6C3F1 and rats, the principal route of metabolism is 
oxidation of 5HFM to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid 
elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that 
SMF has been detected in plasma from animals given 5HMF, intravenously. This indicates that there 
is a competition for the substrate 5HMF between the oxidation pathway leading to furoic acid 
derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is 
very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. 
Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, 
the half-life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to 
reach the bone marrow and give any positive effect in an in vivo micronucleus test, taking into account 
that SMF will most likely be formed in the liver. However, 5HMF has been found unable to induce 
micronuclei also in vitro, using the HepG2 human cell line, expressing both CYP and SULT enzymes. 
In the rodent bioassays no carcinogenic response was observed and from this it may be concluded that 
the formation of the SMF metabolite is too low to result in a carcinogenic response. Assuming that in 
humans the ratio between the two competing pathways is not more favourable for the formation of 
SMF than in rodents, no genotoxicity or carcinogenicity is expected in humans either. 
Furoic acid [FL-no: 13.136] 
Furoic acid gave negative results in three studies in the Ames test in strains TA98 and TA100. Furoic 
acid was also negative in DNA repair test in E.coli and in a UDS assay using primary rat hepatocytes. 
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Supporting substances 
In vitro genotoxicity data were available for five supporting substances: furfuryl acetate, furfuryl 
alcohol, furfural, 5-methylfurfural and methyl-2-furoate [FL-nos: 13.128, 13.019, 13.018, 13.139 and 
13.002] and in vivo genotoxicity data for the two supporting substances furfuryl alcohol and furfural 
[FL-nos: 13.019 and 13.018]. Most studies were negative, although some positive results were 
reported.  
However, the genotoxicity of furfural has been re-evaluated by the EFSA Panel on Food Additives, 
Flavourings, Processing Aids and Materials in contact with Food (i.e. the former AFC Panel), which 
concluded that furfural did not induce gene mutations in vivo, on the basis of new studies with 
transgenic mice (EFSA, 2004). 
Overall, the genotoxicity data available on the candidate furoic acid and on supporting substances do 
not give rise to concern with respect to genotoxicity of nine furfural-related candidate substances 
included in subgroup Ia [FL-nos: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133 and 
13.136]. Based on newly submitted data on the mutagenic activity of 5HMF [FL-no: 13.139] the 
concern for genotoxicity which was raised because of genotoxic properties of one of its metabolites 
(SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate substances in 
subgroup Ia, which could preclude their evaluation through the Procedure. 
Subgroup Ib 
No data are available for the one candidate substance in subgroup Ib [FL-no: 13.155]. However, 
several studies have been carried out with a structurally related flavouring substance, 2-acetylfuran 
[FL-no: 13.054] (2-furyl methyl ketone).  
In vitro studies 
For the supporting substance 2-acetylfuran [FL-no: 13.054] data were found showing an increased 
mutation frequency in a bacterial reverse gene mutation test in S. typhimurium TA98 with metabolic 
activation, but not in TA100. The study has limited validity. The increase was not concentration-
related and no clear data on cytotoxicity were presented, but a decrease in the number of revertants 
was observed at the highest concentrations, which could indicate cytotoxicity. A second trial was not 
performed (Shinohara et al., 1986). Also with this substance a positive result was obtained in the rec-
assay (Shinohara et al., 1986) and in an SOS-chromo test for bacterial DNA-repair (Eder et al., 1993), 
but the predictive value of these test systems is considered to be limited. With [FL-no: 13.054] also 
chromosomal aberrations in Chinese hamster ovary cells have been reported in a limited study by 
Stich et al. (Stich et al., 1981b). 
2-Acetylfuran [FL-no: 13.054] was evaluated for induction of unscheduled DNA synthesis (UDS) in 
human hepatocytes following OECD guidelines. Human (gender not given) hepatocytes from two 
batches purchased from a commercial provider were incubated with concentrations of the compound 
(purity not given) between 2.19 and 280 µg/ml for 16 hours, and UDS was measured 
autoradiographically. No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene 
(Durward, 2007a) 
In vivo studies 
2-Acetylfuran [FL-no: 13.054] was also evaluated for induction of SCE in bone marrow of female 
Swiss albino mice. Groups of two per dose per exposure regimen were administered compound (99 % 
pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 consecutive days. 5-
Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice were sacrificed at 12, 
24 or 48 hours after receiving the last dose, and slides of bone marrow were prepared and processed 
for differential staining. A dose-related increase up to about 2-fold in SCE was observed for the 12- 
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and 24-hour groups of both the single-dose regimen and the multiple-dose regimen (Sujatha, 2007). 
This study was considered valid. In an earlier study by the same group (Sujatha et al., 1993) this 
substance was reported to cause chromosomal aberrations in mouse bone marrow at oral dose levels 
up to 60 mg/kg bw per day. Also this study was considered valid. 
2-Acetylfuran was evaluated for induction of UDS in hepatocytes isolated from livers of dosed male 
Sprague-Dawley rats. The assay was conducted according to GLP and OECD guidelines. In a 
preliminary range-finding toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs 
of toxicity were observed at 20 mg/kg bw. No sex differences were observed, and therefore only males 
were used in the main study. Groups of four rats were administered test compound (purity not given) 
at 0, 7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were isolated 16 hours post-
dosing; in experiment 2, hepatocytes were isolated 2 hours post-dosing and cultured for 
autoradiographic measurement of UDS. No UDS was observed in either experiment (Durward, 
2007b). 
The candidate and supporting substance in this subgroup are α,β-unsaturated ketones. This structural 
characteristic has been considered as an additional reason for concern for genotoxic potential of these 
substances. However, due to structural similarity with acetophenone (i.e. the α,β-unsaturated double 
bond is part of an aromatic system and therefore less reactive) the concern for genotoxicity, resulting 
from the formation of such α,β-unsaturated ketones has been lifted (EFSA Panel, 2011). Nevertheless, 
the experimentally obtained genotoxicity data indicate that the supporting substance may give rise to 
DNA damage, which may result in chromosomal aberrations rather than gene mutations. Also from 
Section 4 and Annex III (FGE.13Rev2 (EFSA CEF Panel, 2011c), the formation of DNA-reactive 
metabolites may be anticipated. In combination with this, the available genotoxicity data are 
sufficiently strong to raise a concern, which would preclude the evaluation of the candidate substance 
in subgroup Ib through the Procedure. 
Subgroup Ic 
No data are available on the genotoxic properties of the two candidate substances in this subgroup. 
Several studies were found with the supporting substances 2-methylfuran [former FL-no: 13.030] and 
2,5-dimethylfuran [former FL-no: 13.029]. Negative results were obtained in a limited bacterial 
reverse gene mutation test with S. Typhimurium (TA97 and TA100 strains only, no data on 
cytotoxicity, no duplicate trial; (Shinohara et al., 1986)). However, a clear concentration-related 
positive response with limited validity (e.g. no clear data on cytotoxicity; no clear description of 
scoring criteria) was obtained with both substances in a chromosome aberration test in Chinese 
hamster ovary cells with and without metabolic activation in presence or absence of metabolic 
activation (Stich et al., 1981b). Both substances also gave a positive response in a rec-assay for 
bacterial DNA-repair (Shinohara et al., 1986), but the predictive value of this test system is considered 
to be limited. With 2-methylfuran an equivocal result was obtained in a bacterial reverse gene 
mutation assay with S. typhimurium in strain TA97. This test was considered valid (Zeiger et al., 
1992). 
For a 2-alkyl- and 2,5-dialkyl-substituted furans, formation of reactive intermediates cannot be 
excluded (see section 4 and Annex III, FGE.13Rev2 (EFSA CEF Panel, 2011c)). These reactive 
intermediates can bind covalently to DNA, which might result in genotoxic events. In an alternative 
metabolic pathway, these flavouring substances may also be converted to ketones which are 
structurally related to the substances in subgroup Ib and for these substances a concern for 
genotoxicity has been identified. Therefore, owing to the anticipated metabolism of the two candidate 
substances in subgroup Ic into possible genotoxic metabolites a concern for genotoxicity cannot be 
excluded. For the two candidate substances in subgroup Ic [FL-nos: 13.125 and 13.162] this concern 
for genotoxicity would preclude their evaluation through the Procedure. 
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Main group II 
No genotoxicity data were available on any of the 14 sulphur-containing candidate substances in main 
group II, nor on their related supporting substances. As it is anticipated that the predominant metabolic 
attack for these substances will be on the sulphur atom(s), for the candidate substances in main group 
II, ring opening is not considered to be a major metabolic route. The lack of data on the 14 sulphur-
containing candidate substances included in main group II or on related supporting substances does 
not allow to conclude on their potential for genotoxicity. However, this would not preclude the 
evaluation of these 14 candidate substances from subgroup II using the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA see Appendix A, Table 
4Table 4:  and Table 5. 
4.4. EFSA Considerations  
The Panel considered that the entire group of furans used as chemically defined flavouring substances 
(i.e. all flavouring substances discussed in FGE.13Rev2, FGE.65Rev1, FGE.66Rev1 and 
FGE.67Rev1) is a very diverse group. Based on this diversity, the Panel considers it justified to 
differentiate between the various subgroups with respect to the way the substances are metabolised 
and therefore also with respect to their possible genotoxic activity. Information on furan ring oxidation 
and opening, which results in the formation of reactive intermediates, was already considered in 
FGE.13Rev2. In this FGE, for the substances containing oxygenated ring substituents (subgroup 1a of 
FGE.13rev2), ring-opening was not considered a major issue with respect to genotoxicity. This was 
also supported by the fact that for the supporting substance furfural, for which this ring opening also 
has been reported, data show that furfural is not genotoxic in vivo. Therefore for the corresponding 
candidate substances in subgroups II and III in FGE.67rev2 it is also concluded that these are not of 
concern with respect to genotoxicity. For the alkyl-substituted furans in FGE.13rev2 the concern for 
formation of reactive metabolites could not be taken away, because of insufficient data on 
genotoxicity. It may be considered that ring oxidation and opening would be more relevant for these 
alkyl-substituted furans because they lack other simple options for metabolism like hydrolysis and / or 
immediate conjugation. In addition, oxidation of the C1’-carbon of the alkyl substituent results in the 
formation of a ketone and for one such ketone [FL-no: 13.054], data are available to indicate a 
genotoxic potential (see section on genotoxicity on substances in FGE13.Rev2, above and Section 4 
and Annex III in FGE.13Rev2). Therefore, the two candidate alkyl-substituted furans in subgroup Ic 
of FGE.13Rev2 were not evaluated via the Procedure. The same would apply to the five alkyl-
substituted furans [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] in group IV in FGE.67rev2. 
Apart from the alkylfurans (subgroup IV, supported by subgroup Ic from FGE.13rev2), simple 
hydrolysis / conjugation reactions are also not possible for the substances in subgroup V-A. As ethers 
[FL-nos: 13.052, 13.061 and 13.123] are more resistant to hydrolysis than the corresponding esters, it 
may be anticipated that these ethers can also be more prone to ring oxidations and opening than the 
substances in subgroup Ia in FGE.13Rev2 or group III in FGE.67. Therefore, for the substances in this 
subgroup a concern for genotoxicity cannot be excluded. The concern is not identified for 2,3-
dimethylbenzofuran [FL-no: 13.074] (subgroup V-B), because for this substance furan ring opening is 
considered unlikely due to the two methyl substituents at the double bond in the furan ring. The other 
substance in subgroup V-B [FL-no: 13.031] has been allocated to FGE.219 for consideration of 
genotoxic potential, because this substance is an α,β-unsaturated aldehyde. Afterwards, the Panel 
considered that since the double bond in α-position to the carbonyl group is part of an aromatic 
system, the reactivity of this double bond is less than in non-aromatic α,β-unsaturated carbonyls, and 
for that reason the concern for genotoxicity of this candidate substance [FL-no: 13.031] has been 
waived and further testing is no longer required. (EFSA Panel, 2008c, 2014). 
Seven of the nine substances in subgroup VI-B are α,β-unsaturated ketones [FL-nos: 13.054, 13.066, 
13.070, 13.083, 13.101, 13.105 and 13.163]. This structural characteristic has been considered as an 
additional reason for concern for genotoxic potential of these substances. However, due to structural 
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similarity with acetophenone (i.e. the α,β-unsaturated double bond is part of an aromatic system and 
therefore less reactive) the concern for genotoxicity, resulting from the formation of such α,β-
unsaturated ketones has been lifted (EFSA Panel, 2008c). Nevertheless, the experimentally obtained 
genotoxicity data indicate that substance [FL-no: 13.054] may give rise to DNA damage, which may 
result in chromosomal aberrations rather than gene mutations. The formation of DNA-reactive 
metabolites may be anticipated (EFSA CEF Panel, 2011c). In combination with this, the available 
genotoxicity data are sufficiently strong to raise a concern, which would preclude the evaluation of the 
candidate substance in subgroup VI-B through the Procedure. Based on the concern raised by the 
genotoxicity data on [FL-no: 13.054] and the anticipation that keto-reduction is less favourable for 
biotransformation than e.g. alcohol or aldehyde oxidation and conjugation, the Panel considered it also 
necessary to re-evaluate the two remaining alkoyl-substituted furans in subgroup VI-B [FL-nos: 
13.045 and 13.138]. In similarity with the other ketones in this subgroup VI-B in FGE.67Rev1 
(supported by subgroup Ib in FGE.13Rev2), for these two substances now also a concern for 
genotoxicity is identified.  
No data on genotoxicity are available for the previously evaluated (FGE.13Rev2) furans with sulphur-
containing ring substituents. As it is anticipated that the predominant metabolic attack for these 
substances will be on the sulphur atom(s), for these substances ring opening is also not considered to 
be a major metabolic route. Although the genotoxicity of these substances could not be properly 
assessed, this did not preclude the evaluation of these substances through the Procedure. The same 
would apply to the two sulphur-containing substances [FL-nos: 13.116 and 13.190] in subgroup I in 
the present FGE.67Rev2. 
Thus, in FGE.67rev2 the Panel concluded that 11 of the 28 substances evaluated in the FGE could be 
evaluated through the Procedure [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 
13.058, 13.074, 13.116 and 13.190]. For all 17 substances in groups IV, V-A and VI-B ([FL-nos: 
13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 
13.106, 13.123, 13.138, 13.148 and 13.163] a concern for genotoxicity was identified, precluding 
these substances to be evaluated through the Procedure. 
5. New Toxicity Data Evaluated by the Panel in FGE.67Rev2 
In the previous revision of FGE.67 (rev1) the Panel concluded that no NOAEL could be identified to 
support the evaluation of 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] at step B4 of the Procedure. 
The Industry has now submitted a new 90-day toxicity study for 3-(5-methyl-2-furyl) butanal which 
will be evaluated in the present revision of FGE.67. 
5.1. A 14-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats 
In a 14 day dietary study, groups (3/sex per dietary intake level) of male and female Crl:CD(SD) rats 
were fed a diet designed to provide 0 (dietary control), 50, 300 and 750 mg/kg bw of 3-(5-methyl-2-
furyl) butanal, daily  (Kappeler, 2013a). Due to the exploratory nature of this non-GLP study, 
homogeneity, concentration, and stability analyses of the test diets were not conducted. Calculated 
from nominal dietary concentrations and the measured feed intake, the estimated dietary exposure 
levels were 0, 52, 303 and 740 mg/kg bw per day for males and 0, 52, 298 and 772 mg/kg bw per day 
for females. Clinical observations were recorded daily and body weights and food consumption 
observations were made on Days 0, 7 and 14. All animals were observed twice daily for mortality or 
moribundity. No mortality was observed throughout the course of the study and no remarkable 
changes in the general condition of the rats were observed. Gross examination was comparable to 
controls for all test groups. There were however reductions in final body weight (not statistically 
significant) and body weight gain for males and females at the 300 and 750 mg/kg dietary 
concentrations from Day 0-7 and this continued into Day 7-14 for the 750 mg/kg males. This was 
attributed to reduced palatability of high concentrations of 3-(5-methyl-2-furyl) butanal in the diet. 
The dose levels in the subsequent 90-day oral toxicity study in rats (Kappeler, 2013b) were selected 
based on the findings in this oral 14-day study. 
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5.2. A 90-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats 
A 90-day oral toxicity study in Crl:CD(SD) rats was performed with 3-(5-methyl-2-furyl) butanal [FL-
no: 13.058] (Kappeler, 2013b). The study was performed according to OECD Guideline (TG 408) and 
under GLP. The substance (purity 99.5%) was administered via the diet to four groups of male and 
female Crl:CD(SD) rats (10/sex/dietary intake level), at doses designed to provide 0 (feed control), 10, 
50 and 250 mg/kg bw per day. The feed was refreshed every seven days. By the end of the week the 
concentration in the feed had declined by 59%. Thus, the actual daily intakes were 0, 5.9, 30 and 150 
mg/kg bw for males and females, when calculated based on body weights, feed consumption and 
concentration of the substance in the feed at the end of the seven day period. 
Clinical observations of toxicity were performed on a daily basis and detailed physical exams, weekly. 
Animals were observed for signs of mortality and moribundity twice daily. Animals were weighed on 
day 0 at the start of the study and weekly thereafter. Body weights and food consumption were 
measured weekly. Ophthalmic examinations were performed during the week prior to the study and 
during week 13 of the study. Clinical pathology (haematology, coagulation, serum chemistry and urine 
analysis) were performed at necropsy. At termination of the study all survivors were sacrificed and 
subject to full necropsy. The following tissues were weighed wet post dissection: adrenals, brain, 
epididymis, heart, kidneys, liver, ovaries, testes, spleen, thymus, uterus with oviducts. For all animals, 
all required tissues were preserved for future histopathological examination. The dietary control 
groups and the high dietary concentration groups were subject to complete microscopic examination in 
addition to any gross lesions. Since the liver was a target organ, complete histopathology examinations 
of the liver were performed for all three test concentration groups. 
There were no unscheduled deaths or clinical observations of toxicity during the study. No gross 
observations were attributed to 3-(5-methyl-2-furyl) butanal in the diet. There were no observed 
statistically significant effects on haematology and coagulation or serum chemistry parameters. 
Ophthalmic and macroscopic examinations were unremarkable and urine analysis showed no effects at 
any test concentration. No change in histopathology was observed except for the liver. Relative liver 
weights were increased for the 150 mg/kg bw per day male group. This finding correlated to minimal 
(5/10 animals), mild (4/10 animals) or moderate (1/10 animals) centrilobular, hepatocellular 
vacuolation characterised by scattered hepatocytes with a single large intracytoplasmic vacuole. In the 
study report there was no further detailed information as to the nature of this histological change, 
which was  considered adverse and related to the presence of 3-(5-methyl-2-furyl) butanal in the diet. 
The same histopathological change in the liver was also observed in the mid-dose (”minimal in 4/10 
animals”) and the low-dose group (”minimal” in 2/10 animals); none had a more severe score. Since 
the histopathological observation was also seen in the control group (”mild” in 1/10 animals) the 
histological change in the low-dose is not considered adverse (Kappeler, 2013b).  
Based on this 90-day dietary toxicity study and based on the toxicological endpoints of liver pathology 
in the mid- and high dose males, which were observed at a higher incidence than in the controls, the 
CEF Panel derived a no-adverse-effect level (NOAEL) for 3-(5-methyl-2-furyl) butanal of 5.9 mg/kg 
bw per day. In females no toxicity was observed at dose levels up to 150 mg/kg bw per day (top dose). 
A summary of the toxicity data is given in Appendix A, Table 7. 
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6. Application of the Procedure 
6.1. JECFA Statement on the Application of the Procedure to 40 furan-substituted 
substances evaluated by JECFA15 (JECFA, 2009a) 
As stated above, the main concern with this group arises primarily from the carcinogenicity of furan 
itself, which is believed to involve a reactive genotoxic metabolite formed by epoxidation and opening 
of the furan ring. Furan is not a member of this group of flavouring agents, but all the members of the 
group contain a furan ring with either one or two substituents of varying complexity. In some 
flavouring agents, a substituent is present on one side of the furan ring only, whereas in others, 
substituents are present on both sides. The presence of an extended side-chain attached to the furan 
ring would reduce the potential for epoxidation of the double bond and provide a site for detoxication 
via metabolism and elimination. The alkylated furan with the simplest structure and which would be 
predicted to have the greatest potential for ring oxidation is 2-methylfuran [former FL-no: 13.030]; 
there is evidence from studies in vitro and in vivo that this compound undergoes bioactivation to a 
reactive ring-opened metabolite that binds covalently to both protein and DNA. Data are not available 
on the influence of the nature and position of the ring substitution on potential for metabolic activation 
and adduct formation. After administration of a single dose, 2-methylfuran produced liver toxicity in 
rats from 50 mg/kg bw, but hepatotoxicity has not been reported for other members of this group in 
more extensive studies. 
Testing for genotoxicity has been performed on eight members of this group of flavouring agents. The 
results of the studies of genotoxicity/mutagenicity in vitro that were already available to the 
Committee (the JECFA) at its previous meeting were both positive and negative, with most positive 
results reported for chromosomal aberration. These, however, were less frequent in the presence of 
metabolic activation, indicating possible metabolic detoxication rather than bioactivation. 2-
Methylfuran [former FL-no: 13.030], for example, produced chromosomal aberrations in vitro, but the 
clastogenic activity was lower in the presence of a metabolising system. The limited data available on 
genotoxicity in vivo showed no evidence of chromosomal aberration in mouse bone marrow or 
spermatocytes for 2-methylfuran. 2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] also induced 
no chromosomal aberrations in mouse spermatocytes, but a weak, transient increase in chromosomal 
aberrations was observed in mouse bone marrow, associated with mitodepression. O-Ethyl-S-(2- 
furylmethyl)thiocarbonate [former FL-no: 13.191] appeared not to induce micronucleus formation in 
mouse bone marrow. 
The new data on 2-furyl methyl ketone [FL-no: 13.054] available to the Committee (the JECFA) at its 
present meeting were a study on UDS in cultured hepatocytes in vitro, a study on UDS in rat liver in 
vivo/in vitro and a test for SCEs in mouse bone marrow in vivo. 2-Furyl methyl ketone did not induce 
UDS either in vitro or in vivo/in vitro. However, it did induce SCEs, confirming the concern for 
clastogenicity as expressed by the Committee (the JECFA) at its previous meeting. The Committee 
(the JECFA) at its present meeting therefore considered that the new data available did not resolve the 
concerns expressed previously. 
The Committee (the JECFA) concluded that the Procedure for the Safety Evaluation of Flavouring 
Agents could not be applied to this group because of the unresolved toxicological concerns. Studies 
that would assist in the safety evaluation include investigations of the influence of the nature and 
position of ring substitution on metabolism and on covalent binding to macromolecules. Depending on 
the findings, additional studies might include assays related to the mutagenic and carcinogenic 
potential of representative members of this group.” 
                                                     
15
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed 
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6.2. JECFA Statement on the Application of the Procedure to one furfuryl alcohol related 
substance [FL-no: 13.031] evaluated by the JECFA16 (JECFA, 2001) 
Step 1 
In applying the Procedure for the Safety Evaluation of Flavouring Agents to the above-mentioned 
substances, the Committee assigned substance 2-benzofurancarboxaldehyde (JECFA No. 751) [FL-no: 
13.031] to structural class III. 
Step 2 
The JECFA provided no statement on the possible metabolism of substance [FL-no: 13.031]. The 
JECFA concluded that the evaluation of all substances (thus including substance [FL- no: 13.031]) in 
this group proceeded via the B-side of the scheme (i.e. they cannot be predicted to be readily 
metabolised to innocuous products). 
Step B3 
The estimated daily per capita intakes of substance [FL-no: 13.031] is below the threshold of concern 
for its structural class (i.e. 90 µg per day for structural class III). Accordingly, the evaluation of this 
substance proceeded to step B4. 
Step B4 
For 2-benzofurancarboxaldehyde [FL-no: 13.031], the NOEL of 25 mg/kg bw per day in a 90-day 
feeding study in rats (Posternak et al., 1969) provides an adequate margin of safety (> 105) in relation 
to the known levels of intake of this substance. 
6.3. Application of the Procedure to 27 Furfuryl and furan derivatives with and without 
additional side-chain substituents and heteroatoms by EFSA17 in FGE.13Rev2 (EFSA 
CEF Panel, 2011c) 
In FGE.13Rev2 data have been presented, which indicate that the candidate substance 5-
hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] from subgroup Ia may be metabolised to 5-
[(sulphoxy)methyl]furfural (SMF), which shows genotoxic potential in vitro. Sufficient data have been 
provided to mitigate this concern with respect to genotoxic potential in vivo.  
Based on genotoxicity data for the substance 2-acetylfuran [FL-no: 13.054] supporting to the 
candidate substance in subgroup Ib [FL-no: 13.155], a concern for genotoxicity is raised for candidate 
substance [FL-no: 13.155].  
For the two substances, 2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] from 
subgroup Ic, genotoxicity may be anticipated based on formation of DNA-reactive metabolites and 
based on information available for the candidate substance in subgroup Ib [FL-no: 13.155].  
In absence of sufficient experimental data on genotoxicity on these or structurally related substances, 
the Procedure cannot be applied to the candidate substance in subgroup Ib and the two candidate 
substances in subgroup Ic. A further extensive discussion on the genotoxicity of the candidate 
substances has been presented in Section 8.4 (FGE.13Rev2). 
                                                     
16
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed. 
17
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
 FGE has been removed. 
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Thus, the Procedure for the safety evaluation of flavouring substances as outlined in Annex I 
(FGE.13Rev2) has been applied to 24 candidate substances from chemical group 14. The stepwise 
evaluations of the 24 substances are summarised in Appendix C. 
Step 1 
Five [FL-nos: 13.122, 13.130, 13.136, 13.139 and 13.145] of the 24 candidate substances evaluated 
via the Procedure are classified into structural class II and 19 [FL-nos: 13.011, 13.102, 13.108, 13.113, 
13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 
13.178, 13.185 and 13.199] are classified into structural class III according to the decision tree 
approach by Cramer et al. (Cramer et al., 1978), see Appendix C. 
Step 2 
Taking into account the metabolic pathways described in Section 4 (FGE.13Rev2), none of the 
candidate substances is predicted to be metabolised to innocuous products. Therefore, the evaluation 
of the 24 candidate substances proceeds via the B-side of the evaluation scheme. 
Step B3 
The five candidate substances, which have been assigned to structural class II, have estimated 
European daily per capita intakes (MSDI) ranging from 0.0024 to 0.39 µg. These intakes are below 
the threshold of concern of 540 µg/person per day for structural class II. The estimated daily per 
capita intakes of the 19 candidate substances assigned to structural class III range from 0.0012 to 37 
µg, which are also below the threshold of concern for the structural class of 90 µg/person per day. 
Therefore, the safety evaluation proceeds to step B4 for all 24 candidate substances. 
Step B4 
Subgroup Ia structurally related to furfurylalcohol [FL-nos: 13.011, 13.102, 13.122, 13.127, 13.129, 
13.130, 13.132, 13.133, 13.136 and 13.139]:  
Considering that the ten candidate substances of subgroup Ia are metabolised to yield furfural and 
furoic acid or furanacrylic acid, the toxicity of the esters of furfuryl alcohol [FL-nos: 13.127, 13.129, 
13.130, 13.132 and 13.133], furoic acid [FL-nos: 13.102 and 13.122] and furanacrylic acid [FL-no: 
13.011] is expected to be similar to that of the structurally related supporting substance furfural [FL-
no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major 
metabolite of furfural. For furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg bw per day has been 
recently established by EFSA (EFSA, 2004). The estimated daily per capita intakes based on the 
MSDI approach expressed in µg/kg bw per day of candidate substances in subgroup Ia of the present 
FGE.13Rev2 are more than 30000 fold below the ADI value. 
For 5HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 
13-week subchronic studies and chronic studies in B6C3F1 mice and F344/N rats (NTP, 2010). The 
carcinogenicity study in mice demonstrated that 5HMF may induce liver tumours, but these are 
considered irrelevant for humans. In contrast, no carcinogenic responses have been reported in the 
study with rats. The data have shown that the critical effect is cytoplasmic alterations in renal proximal 
tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw for 5 days per 
week and above with an intermittent dose regimen of five days per week. For this effects a BMDL of 
20.2 mg/kg bw per day for 5 days/week can be derived, which would be equivalent to 14.4 mg/kg bw 
per day, when corrected for continuous daily administration (see Section 8.2 and Annex V 
(FGE.13Rev2)). When this BMDL of 14.4 mg/kg bw per day derived from the 13-weeks study in mice 
is compared to the MSDI of 0.39 µg/capita per day for this substance, a margin of safety of 2.2 × 106 
can be calculated. From this it is concluded that 5HMF [FL-no: 13.139] does not raise a safety concern 
as a flavouring substance, at its current level of use in foods. 
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Since no toxicity data are available on the sulphur-containing candidate substances in main group II, 
the relevant No Observed Adverse Effect Level (NOAEL) values originate from structurally related 
supporting substances. 
Subgroup IIa sulphides [FL-nos: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199]: 
The candidate substances ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-
no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] are expected to participate in the 
same metabolic pathways as the supporting substance furfuryl isopropyl sulfide [FL-no: 13.032] and 
therefore to have same toxicological properties. No effects were observed for furfuryl isopropyl 
sulfide in a 90-day dietary study with rats at a single dose level (1.34 mg/kg bw per day) (Posternak et 
al., 1969). Comparison of the only level tested with no effect taken as a no observed adverse effect 
level (NOAEL) with the estimated daily per capita intakes based on the MSDI approach and 
expressed in µg/kg bw per day for ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl 
sulfide [FL-no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] provides adequate 
margins of safety > 105. 
After ester hydrolysis, the candidate substances methyl (2-furfurylthio)acetate and methyl 3-
furfurylthio)propionate [FL-nos: 13.141 and 13.143] are anticipated to be metabolised and to have 
toxicological properties similar to the supporting substance ethyl-3-(2-furfurylthio)propionate [FL-no: 
13.093]. For this substance an NOAEL of 5.78 mg/kg bw per day has been identified in a 90-day study 
(Bio-Research Laboratory, 1980). Comparison of this NOAEL with the estimated daily per capita 
intakes based on the MSDI approach and expressed in µg/kg bw per day of methyl (2-
furfurylthio)acetate and methyl 3-furfurylthio)propionate [FL-nos: 13.141 and 13.143] provides an 
adequate margin of safety of 3.2 × 107 for both substances. 
Candidate substances 1-(2-furfurylthio)propanone [FL no: 13.135] and 3-[(2-methyl-3-furyl)thio]-
butanal [FL-no: 13.199] may be evaluated by comparison of their exposure estimates with the NOAEL 
from supporting substance 3-[(2-methyl-3-furyl)thio]-4-heptanone [FL-no: 13.077]. 3-[(2-Methyl-3-
furyl)thio]-4-heptanone was tested in rats at a single dose level of 3.76 mg/kg bw per day in the diet 
for 90 days without treatment-related effects (Gallo et al., 1976). Comparison of the estimated daily 
per capita intake based on the MSDI approach for 3-[(2-methyl-3-furyl)thio]-butanal [FL-no: 13.199] 
with the NOAEL of 3.76 mg/kg bw per day for the supporting substance provided an adequate margin 
of safety of 1.9 × 105. Comparison of the estimated daily per capita intake based on the MSDI 
approach for 1-(2-furfurylthio)propanone [FL-no: 13.135] with the NOAEL of 3.76 mg/kg bw per day 
for the supporting substance provides an adequate margin of safety of 2.1 × 107. 
Subgroup IIb thiols [FL-no: 13.108 and 13.149]: 
The candidate substances 5-methyl-2-furanmethanethiol [FL-no: 13.149] is structurally related to the 
supporting substance 2-furanmethanethiol [FL-no: 13.026]. The NOAEL of 2-furanmethanethiol in a 
multiple dose level 91-day oral gavage study with rats was 3 mg/kg bw per day (Phillips et al., 1977). 
Comparison of the NOAEL for 2-furanmethanethiol with the estimated daily per capita intake based 
on the MSDI approach expressed in µg/kg bw per day of 5-methyl-2-furanmethanethiol [FL-no: 
13.149] provides an adequate margin of safety of 3.7 × 105. 
The candidate substance 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] is structurally related 
to the supporting substance 2-methyl-3-thioacetoxy-4,5-dihydrofuran [FL-no: 13.086] from subgroup 
IIe (of FGE13Rev1). Several subchronic studies have been carried out with this supporting substance. 
A NOAEL of 1.4 mg/kg bw per day has been derived in a multiple dose level 13 weeks dietary study 
with rats (Munday and Gellatly, 1973). Comparison of the NOAEL for 2-methyl-3-thioacetoxy-4,5-
dihydrofuran with the estimated daily per capita intake based on the MSDI approach expressed in 
µg/kg bw per day of 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] provided an adequate 
margin of safety of 2.3 × 103. 
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Subgroup IIc disulphides [FL-nos: 13.113, 13.144, 13.178 and 13.185]: 
In the previous version of this FGE, the candidate substance 2,5-dimethyl-3-(methyldithio)furan [FL-
no: 13.113] was evaluated against a NOAEL which turned out to belong to a structurally unrelated 
substance. Therefore this evaluation was not valid and thus substance [FL-no: 13.113] had to be 
reconsidered. It may be anticipated that this disulphide will be subject to fission of the disulphide 
bridge. The resulting furan-containing fragment, which is more reactive than the disulphide itself, 
could be evaluated by comparison with the toxicity of 2-methyl-3-furanthiol [FL-no: 13.055] from 
subgroup IIb. The NOAEL of 2-methyl-3-furanthiol in a multiple dose level 90-day oral gavage study 
with rats was 5 mg/kg bw per day (Oser, 1970b). When the NOAEL for 2-methyl-3-furanthiol is 
compared with the estimated daily per capita intake based on the MSDI approach expressed in µg/kg 
bw per day for 2,5-dimethyl-3-(methyldithio)furan [FL-no: 13.113] an adequate margin of safety of  
25 × 107 can be calculated. 
For the candidate substances methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-furfuryl 3-oxo-
2-butyl disulphide [FL-no: 13.185] a NOAEL for a comparable substance is not available. However, 
after fission of the disulphide bridge the resulting furan-containing fragment, which is more reactive 
than the disulphide itself, could be evaluated by comparison with the toxicity of furfuryl mercaptan 
[FL-no: 13.026] from subgroup IIb. The NOAEL of furfuryl mercaptan in a multiple dose level 91-day 
oral gavage study with rats was 3 mg/kg bw per day (Phillips et al., 1977). When the NOAEL for 
furfuryl mercaptan is compared with the estimated daily per capita intakes based on the MSDI 
approach expressed in µg/kg bw per day for methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-
furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185], adequate margins of safety of 75 × 106 and  
16 × 106, respectively, can be calculated. 
The Panel noted that the candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is 
identical to [FL-no: 13.192]. The latter substance has been assigned the JECFA number 1524 in the 
report of the 69th meeting (JECFA, 2009a). For this substance, in the JECFA evaluation, an MSDI for 
Europe of 0.24 µg per capita per day was given. This figure, which is higher and more recent than the 
exposure estimate in the previous version of this FGE (0.0012 µg per capita per day), will be used in 
the current revision of this FGE. The candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 
13.178] is structurally related to the supporting substance bis(2-methyl-3-furyl) disulfide [FL-no: 
13.016] which has been tested in two single-dose-level 90-day dietary studies with rats at 5 mg/kg bw 
per day and 0.45 mg/kg bw per day, respectively (Oser, 1970a; Morgareidge and Oser, 1970a). 
Treatment-related effects were seen at the intake level of 5.0 mg/kg bw per day, but the intake level of 
0.45 mg/kg bw per day was determined to be a NOAEL. The disulphide bridge fission products are 
related to [FL-no: 13.026] (of subgroup IIb), for which a NOAEL of 3 mg/kg bw per day has been 
derived. When the estimated daily per capita intake based on the MSDI approach expressed in µg/kg 
bw per day of 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is compared to this NOAEL an 
adequate margins of safety of 7.5 × 105 can be calculated for [FL-no: 13.178].  
Alternatively, the two fission products may be considered separately. These fission products are [FL 
no: 13.055] and [FL-no: 13.026], for which NOAELs of 5 mg/kg bw per day and 3 mg/kg bw per day, 
respectively, have been derived (Oser, 1970b; Phillips et al., 1977). Exposure to [FL-no: 13.178] at the 
level of its MSDI would correspond to exposures to [FL-no: 13.026] and [FL-no: 13.055] of 0.12 µg 
per person per day for both fragments. Comparison of these exposure estimates to the NOAELs for 
these two fragments provides adequate margins of safety of 1.5 × 106 and 2.5 × 106 for [FL-no: 
13.026] and [FL-no: 13.055], respectively. 
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Subgroup IId polysulphide [FL-no: 13.146]: 
The one candidate flavouring substance in this subgroup methyl furfuryl trisulphide [FL-no: 13.146] is 
a trisulphide which may be anticipated to release perthiols upon metabolism. Similar reactive products 
may be anticipated for bis-(2-methyl-3-furyl)tetrasulphide [FL-no: 13.017] for which a NOAEL of 
0.56 mg/kg bw per day in a 90-day study has been derived (Morgareidge and Oser, 1970b). 
Comparison of this NOAEL with the estimated daily per capita intake of methyl furfuryl trisulphide 
[FL-no: 13.146] based on the MSDI approach expressed in µg/kg bw per day of 0.0024 µg provides an 
adequate margin of safety of 14 × 106. 
Summary: 
For the ten, seven, two, four and one substances in subgroups Ia [FL-nos: 13.011, 13.102, 13.122, 
13.127, 13.129, 13.130, 13.132, 13.133, 13.136 and 13.139], IIa [FL-nos: 13.114, 13.124, 13.135, 
13.141, 13.143, 13.145 and 13.199], IIb [FL-no: 13.108 and 13.149], IIc [FL-nos: 13.113, 13.144, 
13.178 and 13.185] and IId [FL-no: 13.146], respectively, which have been evaluated through the 
Procedure, it can be concluded at step B4 of the Procedure that these 24 candidate substances do not 
pose a safety concern when used as flavouring substances at the estimated levels of intake based on 
the MSDI approach 
6.4. EFSA Considerations 
For seven of the 28 flavouring substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 
and 13.190] in FGE.67rev2, the classification according to Cramer et al., 1977 was revised from 
structural class II to III. These revisions are due to the question of natural occurrence for the 
substances involved and were consistent with FGE.13Rev2 and FGE.65Rev1. The Panel notes that for 
the substances involved, this will not affect the final conclusions. 
The Panel agrees with the JECFA (JECFA, 2009a) for 17 of the 28 substances [FL-nos: 13.045, 
13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 
13.123, 13.138, 13.148 and 13.163] in the group of furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters, sulphides, disulphides and ethers that these 
substances cannot be evaluated through the Procedure, based on concerns with respect to genotoxicity. 
The Panel also agrees with the conclusion reached by the JECFA at its 55th meeting (JECFA, 2001) 
that substance [FL-no: 13.031] can be evaluated using the Procedure, and that this substances poses no 
safety concern when used as a flavouring substance. 
Contrary to the JECFA (JECFA, 2009a) and in line with the decisions taken in previous FGEs 
(FGE.13.Rev2, FGE.66Rev1, FGE.67; (EFSA CEF Panel, 2011c; EFSA CEF Panel, 2011b; EFSA 
CEF Panel, 2010b), the Panel considers that the remaining 10 substances [FL-nos: 13.006, 13.021, 
13.022, 13.023, 13.024, 13.047, 13.058, 13.074, 13.116 and 13.190] can be evaluated using the 
Procedure. 
Step 1 
The 10 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.047, 13.058, 13.074, 13.116, 
and 13.190] have been allocated to structural class III according to the Cramer et al. decision tree.  
Step 2 
In line with the previous evaluations in FGE.13Rev2 (EFSA CEF Panel, 2011c), FGE.66Rev1 (EFSA 
CEF Panel, 2011b) and FGE.65Rev1 (EFSA CEF Panel, 2015), none of the 10 substances can be 
anticipated to be metabolised to innocuous products. Therefore all 10 substances should be evaluated 
through the B-side of the Procedure. 
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Step B3 
At step B3 of the Procedure, all 10 substances have exposure estimates less than the thresholds for 
their respective classes, and therefore these substances should proceed to step B4 of the Procedure. 
Step B4 
Subgroup I 
2,5-Dimethyl-3-thioacetoxyfuran [FL-no: 13.116] 
At step B4 of the Procedure the exposure estimate of 3 µg per capita per day for [FL-no: 13.116] can 
be compared to the NOAEL of 0.73 mg/kg bw per day for the supporting substance 2,5-dimethyl-3-
(isopentylthio)furan [FL-no: 13.041] (FGE.65Rev1 (EFSA CEF Panel, 2015) as determined in a 90-
day study reported by Morgareidge et al. (Morgareidge et al., 1974) and Cox et al., (Cox et al., 1974). 
An adequate margin of safety of 14.6 × 103 can be calculated. 
3-((2-Methyl3-furyl)thio)-2-butanone [FL-no: 13.190] 
At step B4 of the Procedure the exposure estimate of 0.012 µg per capita per day for [FL-no: 13.190] 
can be compared to the NOAEL of 3.76 mg/kg bw per day for the supporting substance 3-((2-methyl-
3-furyl)thio)heptan-4-one [FL-no: 13.077] (FGE.65Rev1 (EFSA CEF Panel, 2015) as determined in a 
90-day study reported by Gallo et al. (Gallo et al., 1976). An adequate margin of safety of 1.9 × 107 
can be calculated. 
Subgroup II 
Phenethyl 2-furoate [FL-no: 13.006] 
After hydrolysis this substance will yield 2-furoic acid [FL no: 13.019] and phenethyl alcohol [FL no: 
02.019]. At an exposure at the level of the MSDI (0.012 µg per capita per day), the respective 
amounts of 2-furoic acid and phenethyl alcohol would amount to 0.006 µg per person per day and 
0.007 µg per person per day, respectively. In FGE.13Rev1 2-furoic acid has been evaluated by 
comparison with the ADI of 0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004). 
Phenethyl alcohol was considered of no safety concern at step A3 of the Procedure by the Panel in 
FGE.53. Based on these considerations, it is concluded that at the estimated level of exposure, based 
on the MSDI approach, phenethyl 2-furoate [FL-no: 13.006] is of no safety concern. 
Subgroup III 
Isopentyl 4-(2-furan)butyrate [FL-no: 13.021], Ethyl 3(2-furyl)propionate [FL-no: 13.022], Isopentyl 
3-(2-furan)propionate [FL-no: 13.023] and Isobutyl 3-(2-furyl)propionate [FL-no: 13.024] 
At step B4 of the Procedure for substance [FL-no: 13.024] a NOAEL of 35 mg/kg bw per day, 
determined in a 90-day study, has been reported (Lough et al., 1985). When at step B4 the NOAEL for 
this substance is compared to its exposure estimate of 0.12 µg per capita per day based on the MSDI 
approach, an adequate margin of safety of 18 × 106 can be calculated. The same NOAEL can also be 
used to evaluate [FL-nos: 13.021, 13.022 and 13.023], for which exposure estimates of 0.24, 0.012 and 
0.24 µg per capita per day were calculated. Comparison of these MSDI exposure estimates with the 
NOAEL for [FL-no: 13.024] provides adequate margins of safety of 8.9 × 106,  
1.8 × 108 and 8.9 × 106 for [FL-nos: 13.021, 13.022 and 13.023], respectively. 
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Propyl 3-(2-furyl)acrylate [FL-no: 13.047] 
This substance can be anticipated to be hydrolysed into propanol and 2-furanacrylic acid. The latter 
fragment should be further considered. At an exposure at the level of the MSDI (2.2 µg per capita per 
day) for [FL no: 13.047], the amount of 2-furanacrylic acid released would amount to 1.7 µg per 
person per day. In FGE.13Rev1 2-furanacrylic acid has been evaluated by comparison with the ADI of 
0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004). It may be concluded that at the 
estimated level of exposure, based on the MSDI approach, propyl 3-(2-furyl)acrylate [FL-no: 13.047] 
is of no safety concern. 
3-(5-Methyl-2-furyl) butanal [FL-no: 13.058] 
For [FL-no: 13.058] a NOAEL of 5.9 mg/kg bw per day was derived, based on a 90-day study with 
dietary exposure (Kappeler, 2013b). When at step B4 the NOAEL for this substance is compared to its 
exposure estimate of 0.0012 µg per capita per day based on the MSDI approach, an adequate margin 
of safety of 3 × 108 can be calculated. 
Subgroup V-B 
2,3-Dimethylbenzofuran [FL-no: 13.074] 
At step B4 of the Procedure for substance [FL-no: 13.074] a NOAEL of 0.6 mg/kg bw per day, 
determined in a 90-day study has been reported (Long et al. (Long, 1977). When at step B4 the 
NOAEL for this substance is compared to its exposure estimate of 0.52 µg per capita per day based on 
the MSDI approach, an adequate margin of safety of 69 × 103 can be calculated. 
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CONCLUSION  
The present revision of FGE.67, FGE.67Rev2, which has been made due to new toxicity data provided 
for 3-(5-methyl-2-furyl) butanal, deals with 28 substances. Twenty-seven candidate substances 
considered in this FGE were previously considered by the JECFA in a group of 40 furan-substituted 
aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, 
disulphides and ethers. One of these 40 substances [FL-no: 13.192] appeared to be a synonym of 
substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Therefore this substance 
[FL-no: 13.192] will not be further considered in this FGE and should be removed from the Register. 
Another substance [FL-no: 13.176] has been evaluated in FGE.99 rather than FGE.67, because of 
better structural similarity with candidate substances in FGE.99. Furthermore, one candidate substance 
[FL-no: 13.031] from FGE.66Rev1 has been included in this revision of FGE.67, because this 
substance has better structural similarity to a candidate flavouring substance [FL-no: 13.074] in 
FGE.67 than to the other candidate flavouring substances in FGE.66Rev1.  
Thirteen of the 40 substances considered by JECFA are α,β-unsaturated carbonyls, which have been 
evaluated by EFSA in FGE.19 context with respect to a concern for a possible genotoxic potential. 
This concern for genotoxicity could not be alleviated for six substances [FL-nos: 13.034, 13.043, 
13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 subgroup 4.6. These six substances 
were therefore not further considered in this FGE. 
For five substances the Flavourings Industry has announced that they are no longer supported for use 
as flavouring substances in Europe [former FL-no: 13.029, 13.030, 13.092, 13.107 and 13.191]. 
Therefore, these substances have been withdrawn from the safety evaluation in the present FGE. 
The 28 candidate substances considered in this FGE [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 
13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 13.069, 13.070, 13.074, 
13.083, 13.101, 13.103, 13.105, 13.106, 13.116, 13.123, 13.138, 13.148, 13.163 and 13.190] have 
been allocated to various subgroups, based on their chemical structures. These substances are 
structurally related to the group of 27 furfuryl and furan derivatives evaluated by EFSA in 
FGE.13Rev2. Part of the substances is also structurally related to a group of 33 sulphur-substituted 
furan derivatives used as flavouring agents, evaluated by EFSA in FGE.65Rev1 and another part is 
structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1. 
For five alkyl-substituted furans [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] and for three 
furfuryl ethers [FL-nos: 13.052, 13.061 and 13.123] a concern for genotoxicity was identified. For 
seven α,β-unsaturated substances [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 
13.163], corresponding to FGE.19 subgroup 4.5 the concern for genotoxicity with respect to this α,β-
unsaturation could be ruled out based on additional evaluation of their chemical structures. However, 
based on available genotoxicity data, a concern for genotoxicity was still identified, which was also 
relevant for two other alkoyl substituted furans [FL-nos: 13.045 and 13.138]. 
Thus, the Panel agrees with JECFA for 17 of the 28 substances [FL-nos: 13.045, 13.052, 13.054, 
13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 
13.148 and 13.163] that these substances cannot be evaluated through the procedure, based on 
concerns with respect to genotoxicity. 
On the basis of the new data on toxicity for 3-(-methyl-2-furyl) butanal [FL-no: 13.058] an appropriate 
NOAEL of 5.9mg/kg bw per day was derived, supporting the evaluation of this candidate substance. 
In line with the decisions taken in previous FGEs (FGE.13Rev2, FGE.65Rev1 and FGE.66Rev1), the 
Panel considers that 11 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 
13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure. It was concluded for all 11 
substances, that they would be of no safety concern at their estimated intake levels based on the MSDI 
approach.  
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In order to determine whether the conclusion for the evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity are available for all 28 substances. For 11 furan 
derivatives [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 
and 13.190] the Panel concluded that the materials of commerce would be of no safety concern at 
estimated levels of intake as flavouring substances based on the MSDI approach. 
The mTAMDI could be calculated for four of the 11 substances that were evaluated through the 
Procedure. For three substances [FL-nos: 13.031, 13.047 and 13.074] the mTAMDI exceeds the 
threshold for the corresponding structural class and therefore more reliable exposure data are required. 
For seven substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190], use levels 
are needed in order to calculate the mTAMDIs and identify those flavouring substances that need 
more refined exposure assessment to finalise the evaluation. On the basis of such additional data these 
flavouring substances should be reconsidered along the steps of the Procedure. Then, additional 
toxicological data might become necessary.  
 
For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 
13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] additional toxicity / genotoxicity 
data are required. The Panel noted further that for 7 of these 17 substances [FL-nos: 13.045, 13.052, 
13.054, 13.059, 13.061, 13.069 and 13.083,], use levels have not yet been submitted. 
The Panel is aware that for the substances in subgroup V-A [FL-nos: 13.052, 13.061 and 13.123] the 
requested information has not been submitted before the deadline as indicated in Regulation EC 
872/2012. The European Commission has communicated that these three substances are now in the 
process leading to deletion from the Union List. 
An overview of the evaluation status of the substances in the present FGE is given in Appendix B, 
Table 8. 
 
 
 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 47 
DOCUMENTATION AS PROVIDED TO EFSA 
1. Asquith JC, 1989. Bacterial reverse mutation assay ST 15C 89. Firmenich SA. Toxicol study no. 
M/AMES/18216. September 1989. Unpublished report submitted by EFFA to FLAVIS 
Secretariat. 
2. Beevers, 2014. Furan-2(5H)-one: Combined Comet assay in the liver and a bone marrow 
micronucleus test in treated rats. Covance Laboratories Ltd. Study no. 8262050. 10 April 2014. 
Unpublished final report submitted by EFFA to FLAVIS Secretariat. 
3. Bio-Research Laboratory, 1980. Ethyl-beta-furfural-alpha-thiopropionate (EFTP). Unpublished 
report submitted by EFFA to FLAVIS Secretariat. 
4. CIVO-TNO, 2003. In vivo gene mutation by use of lambdaZ-transgenic mice with furfural. 
Steenwinkel, M.-J.S.T. Project no. 01044074. 1 May 2003. Unpublished report submitted to 
EFSA. 
5. Cox GE, Bailey DE and Morgareidge K, 1974. 90-day feeding study in rats with compound 14935 
(2-mercapto-3-butanol). Food and Drug Research Laboratories, Inc. Lab. no. 2107d. December 
30, 1974. Unpublished report submitted by EFFA to SCF. 
6. DG SANCO (Directorate General for Health and Consumer Affairs), 2012. Information from DG 
SANCO 07/02 2012, concerning two lists of 85 and 15 non-supported substances and one list of 
30 substances for which no data have been submitted or which are duplicates. FLAVIS.2.23rev1. 
7. DG SANTE (Directorate General for Health and Food safety), 2015. Information from DG 
SANTE concerning the status of the substances [FL-nos: 13.052, 13.061 and 13.123] in FGE.67 
(http://ec.europa.eu/food/committees/regulatory/scfcah/toxic/docs/sum_20150211_en.pdf). 
8. Durward R, 2007a. Furyl methyl ketone: unscheduled DNA synthesis (UDS) assay liver in vitro. 
Safepharm Laboratories Ltd. Project no. 1834/0005. Unpublished report submitted by EFFA to 
FLAVIS Secretariat. 
9. Durward R, 2007b. Furyl methyl ketone: in vivo liver unscheduled DNA synthesis (UDS) assay. 
Safepharm Laboratories Ltd. Project no. 1834/0004. Unpublished report submitted by EFFA to 
FLAVIS Secretariat. 
10. EFFA (European Flavour and Fragrance Association), 2005. Submission 2004/Add. 2003-3. 
Assessment of 40 flavouring substances of the chemical groups 14 (Annex I of 1565/2000/EC), 
aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids, and related esters, sulfides, 
disulfides and ethers containing furan substitution used as flavouring substances. 12 April 2005. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
11. EFFA (European Flavour and Fragrance Association), 2013. Addendum of Additional Data 
Relevant to the Flavouring Group Evaluation of the Chemical Group 14 (Annex I of 
1565/2000/EC) Furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic 
acids and related esters, sulfides, disulfides and ethers evaluated by EFSA in FGE.67Rev1. 
Addendum to FGE.67Rev1. 06/04/2013. FLAVIS/8.214. 
12. EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish 
Food Institute, Technical University of Denmark, dated 25 April 2014. Information on substances 
[FL-no: 13.031, 13.045 and 13.047] in FGE.67Rev2. FLAVIS/8.236. 
13. Gallo MA, Cox GE and Babish JG, 1976. 90-Day feeding study in rats with compound 75-15963 
(3-[(2-methyl-3-furyl)-thio]-4-heptanone). Food and Drug Research Laboratories, Inc. Lab. no. 
2689d. December 30, 1976. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 48 
14. Gudi R and Schadly EH, 1996. In vitro mammalian cytogenetic test with an independent repeat 
assay of furfural, final report, with cover letter dated 11/22/1996 (sanitized). Furfural. 
Microbiological Associates, Inc. EPA Doc 88970000074S, microfiche no. OTS0559061. 
November 19, 1996. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
15. IOFI (International Organization of the Flavor Industry), 2013. Addendum of Additional Data 
Relevant to the Flavouring Group Evaluation of the Chemical Group 14 (Annex I of 
1565/2000/EC) Consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, 
ketones, carboxylic acids and related esters, sulphides, disulfides and ethers Evaluated by JECFA 
at the 65th meeting [JECFA/WHO FAS 56] and re-evaluated at the 69th meeting [JECFA/WHO 
FAS 60] as Evaluated by EFSA in FGE.67. Addendum to FGE.67. 30/12/2013. FLAVIS/8.230. 
16. Kappeler, K.V., 2013a. A 14-day oral (dietary) toxicity study of 3-(5-methyl-2-furyl) butanal in 
Sprague-Dawley rats. Study number WIL-968001. WIL Research, Ashland, OH, USA. 
Unpublished report to the International Organization of the Flavor Industry (IOFI), Brussels, 
Belgium. 
17. Kappeler, K.V., 2013b. A 90-day oral (dietary) toxicity study of 3-(5-methyl-2-furyl) butanal in 
rats. Study number WIL-968002. WIL Research, Ashland, OH, USA. Unpublished report to the 
International Organization of the Flavor Industry (IOFI), Brussels, Belgium. 
18. Long DW, 1977. Acute oral toxicity and 3 month oral toxicity study in the rat. 2,3-
Dimethylbenzofuran. Institut Francais de Recherches et Essais Biologiques. IFREB-R 770261. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
19. Lough R, Trepanier S, Bier C, Losos G, Broxup B, Tellier P, Osborne BE and Proctor BG, 1985. 
A combined 28-day and 90-day toxicity study of four test articles [2-furyl methyl ketone, 
benzopherone, 3-(2-furyl) acrolein and isobutyl 3-(2-furyl) propionate] administered orally (in the 
diet) to the albino rat. Bio-Research Laboratories Ltd. Project no. 81238. January 30, 1985. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
20. Meerts Ir IATM, 2000. Evaluation of the ability of coffee precursor to induce chromosome 
aberrations in cultured peripheral human lymphocytes. NOTOX B.V., Hambakenwetering 7, 
5231DD's-Hertogenbosch. NOTOX project 301286. Date 18/12/2000. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
21. Morgareidge K and Oser BL, 1970a. 90-Day feeding studies in rats with bis-(2-methyl-3-furyl)-
disulfide (31001). Food and Drug Research Laboratories, Inc. Lab. no. 0028. August 24, 1970. 
Report submitted by EFFA to FLAVIS Secretariat. 
22. Morgareidge K and Oser BL, 1970b. 90-Day feeding studies in rats with bis-(2-methyl-3-furyl)-
tetrasulfide (31058). Food and Drug Research Laboratories, Inc. Lab. no. 0031. August 24, 1970. 
Report submitted by EFFA to FLAVIS Secretariat. 
23. Morgareidge K, Cox GE and Bailey DE, 1974. 90-Day feeding study in rats with compound 
15124 (2, 5-dimethyl-3-thioisovalerylfuran). Food and Drug Research Laboratories, Inc. Lab. No. 
2107g. December 30, 1974. Report submitted by EFFA to FLAVIS Secretariat. 
24. Munday R and Gellatly JB, 1973. Biological evaluation of feeding trial with DUS-5. Part 4. 13-
week rat. Unilever Research Colworth/ Welwyn. NCW 73 1159. Project CW 22390. July 11, 
1972. Report submitted by EFFA to FLAVIS Secretariat. 
25. Oser BL, 1970a. 90-Day feeding studies with bis-(2-methyl-3-furyl) disulfide in rats. Food and 
Drug Research Laboratories, Inc. Lab. no. 90616. January 22, 1970. Unpublished report submitted 
by EFFA to FLAVIS Secretariat. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 49 
26. Oser BL, 1970b. 90-Day feeding studies with 2-methyl-3-furanthiol in rats. Food and Drug 
Research Laboratories, Inc. Lab. no. 90615. January 22, 1970. Unpublished report submitted by 
EFFA to FLAVIS Secretariat. 
27. Verspeek-Rip CM, 2000. Evaluation of the mutagenic activity of coffee precursor in the 
Salmonella typhimurium reverse mutation assay and the Escherichia coli reverse mutation assay 
(with independent repeat). NOTOX B.V., 's-Hertogenbosch. NOTOX project 301275. 25 
September, 2000. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
28. Verspeek-Rip CM, 2001. Micronucleus test in bone marrow cells of the mouse with coffee 
precursor. NOTOX B.V, 's-Hertogenbosch. NOTOX project 312143. 27 December, 2000. 
Unpublished report submitted by EFFA to FLAVIS Secretariat. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 50 
REFERENCES 
Aaron CS, Harbach PR, Wiser SK, Grzegorczyk CR and Smith AL, 1989. The in vitro unscheduled 
DNA synthesis (UDS) assay in rat primary hepatocytes: Evaluation of 2-furoic acid and 7 drug 
candidates. Mutation Research 223(2), 163-169. 
Adams TB, Lake BG, Beamad JA, Price RJ, Ford RA and Goodman JI, 1998. An investigation of the 
effect of furfural on the unscheduled DNA synthesis in cultured human liver slices. Toxicologist 
42(1-S), 79. 
Adams TB, McGowen MM, Williams MC, Cohen SM, Feron VJ, Goodman JI, Marnett LJ, Munro 
IC, Portoghese PS, Smith RL, Waddell WJ, 2007. The FEMA GRAS assessment of aromatic 
substituted secondary alcohols, ketones, and related esters used as flavor ingredients. Food Chem. 
Toxicol., 45(2), 171-201. 
Aeschbacher HU, Chappus C, Manganel M and Aeschbach R, 1981. Investigation of maillard 
products in bacterial mutagenicity test systems. Progress in Food and Nutrition Science 5, 279-
294. 
Aeschbacher HU, Wolleb U, Loliger J, Spadone JC and Liardon R, 1989. Contribution of coffee 
aroma constituents to the mutagenicity of coffee. Food and Chemical Toxicology 27(4), 227-232. 
Archer MC, Bruce WR, Chan CC, Corpet DE, Medline A, Roncucci L, Stamp D and Zhang X-M, 
1992. Aberrant crypt foci and microadenoma as markers for colon cancer. Environmental Health 
Perspectives 98(0), 195-197. 
Bradley MO, Taylor VL, Armstrong MJ and Galloway SM, 1987. Relationship among cytotoxicity, 
lysosomal breakdown, chromosome aberrations and DNA double-strand breaks. Mutation 
Research 189, 69-79. 
Bruce WR, Archer MC, Corpet DE, Medline A, Minkin S, Stamp D, Yin Y and Zhang XM, 1993. 
Diet, aberrant crypt foci and colorectal cancer. Mutation Research 290, 111-118. 
Brusick DJ, 1986. Genotoxic effects in cultured mammalian cells produced by low pH treatment 
conditions and increased ion concentrations. Environmental Mutagenesis 8, 879-886. 
Bu HZ, 2006. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic 
reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. 
Current Drug Metabolism, 7(3), 231-249 
Burka LT and MR Boyd, 1985. Furans. In: Anders MW (Ed.). Bioactivation of Foreign Compounds. 
Academic Press, Orlando, pp. 243-257. 
Burka LT, Washburn KD and Irwin RD, 1991. Disposition of [14C]furan in the male F344 rat. 
Journal of Toxicology and Environmental Health 34, 245-257. 
Byrns MC, Vu CC, Neidigh JW, Abad J-L, Jones RA and Peterson LA, 2006. Detection of DNA 
adducts derived from the reactive metabolite of furan, cis-2-butene-1,4-dial. Chemical Research in 
Toxicology 19(3), 414-420. 
Costa M, Zhitkovich A, Harris M, Paustenbach D and Gargas M, 1997. DNA-protein cross-links 
produced by various chemicals in cultured human lymphoma cells. Journal of Toxicology and 
Environmental Health 50(5), 433-449. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 51 
Cramer GM, Ford RA and Hall RL, 1978. Estimation of toxic hazard - a decision tree approach. Food 
and Cosmetics Toxicology 16(3), 255-276. 
Dahlberg J, 2004. ”Genotoxiciteten av HMF: s metabolit SMF studerad med det 
flödescytometerbaserade mikrokärntestet in vivo”, Examination work supervised by Abramsson-
Zetterberg L, University of Uppsala, Uppsala, 34 pp. (as cited by Glatt and Sommer 2006). 
Dillon D, Combes R and Zeiger E, 1998. The effectiveness of Salmonella strains TA100, TA102 and 
TA104 for detecting mutagenicity of some aldehydes and peroxides. Mutagenesis 13(1), 19-26. 
Ding W, Petibone DM, Latendresse JR, Pearce MG, Muskhelishvili L, White GA, Chang CW, 
Mittelstaedt RA, Shaddock JG, McDaniel LP, Doerge DR, Morris SM, Bishop ME, Manjanatha 
MG, Aidoo A, Heflich RH, 2012. In vivo genotoxicity of furan in F344 rats at cancer bioassay 
doses. Toxicol. Appl. Pharmacol., 261, 164-171. 
Duerksen-Hughes PJ, Yang J and Ozcan O, 1999. p53 induction as a genotoxic test for twenty-five 
chemicals undergoing in vivo carcinogenicity testing. Environmental Health Perspectives 107(10), 
805-812. 
Durling LJK, Busk L and Hellman BE, 2009. Evaluation of the DNA damaging effect of the heat-
induced food toxicant 5-hydroxymethylfurfural (HMF) in various cell lines with different activities 
of sulfotransferases. Food Chem Toxicol. 47, 880-884. 
Eder E, Hoffman C and Deininger C, 1991a. Identification and characterization of deoxyguanosine 
adducts of methyl vinyl ketone and ethyl vinyl ketone. Genotoxicity of the ketones in the SOS 
chromotest. Chemical Research in Toxicology 4, 50-57. 
Eder E, Deininger C and Muth D, 1991b. Genotoxicity of P-nitrocinnamaldehyde and related a,ß-
unsaturated carbonyl compounds in two bacterial assays. Mutagenesis 6(4), 261-269. 
Eder E, Deininger C, Neudecker T and Deininger D, 1992. Mutagenicity of beta-alkyl substituted 
acrolein congeners in the Salmonella thyphimurium strain TA100 and genotoxicity testing in the 
SOS chromotest. Environmental and Molecular Mutagenesis 19, 338-345. 
Eder E, Scheckenbach S, Deininger C and Hoffman C, 1993. The possible role of a,ß-unsaturated 
carbonyl compounds in mutagenesis and carcinogenesis. Toxicology Letters 67, 87-103. 
Edwards A, 1999. Draft report. An in vivo unscheduled DNA synthesis assay in the mouse with 
furfural. Report no. 3389/1/1/99. BIBRA International, Carshalton. 
EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Food Additives, 
Flavourings, Processing Aids and Materials in contact with food on a request from the 
Commission related to furfural and furfural diethylacetal. The EFSA Journal 2004, 67, 1-27. 
EFSA (European Food Safety Authority), 2008a. Scientific Opinion of the Scientific Panel on Food 
Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring 
Group Evaluation 69: Consideration of aromatic substituted secondary alcohols, ketones and 
related esters evaluated by JECFA (57th meeting) structurally related to aromatic ketones from 
chemical group 21 evaluated by EFSA in FGE.16 (2006) (Commission Regulation (EC) No 
1565/2000 of 18 July 2000). The EFSA Journal 2008, 869, 1-35. 
EFSA (European Food Safety Authority), 2008b. Minutes of the 26th Plenary meeting of the 
Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with 
Food, Held in Parma on 27 - 29 November 2007. [Online]. Available from: 
http://www.efsa.europa.eu/EFSA/Event_Meeting/afc_minutes_26thplen_en.pdf. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 52 
EFSA (European Food Safety Authority), 2008c. Scientific Opinion. List of alpha, beta-unsaturated 
aldehydes and ketones representative of FGE.19 substances for genotoxicity testing - Statement of 
the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF). The 
EFSA Journal 2008, 910, 1-7. 
EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Scientific Panel on Food 
Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring 
Group Evaluation 220: a,ß-Unsaturated ketones and precursors from chemical subgroup 4.4 of 
FGE.19: 3(2H)-Furanones (Commission Regulation (EC) No 1565/2000 of 18 July 2000). The 
EFSA Journal 2009, 1061, 1-23. 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2010b. Scientific Opinion on Flavouring Group Evaluation 67 (FGE.67): Consideration of 
40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and 
related esters, sulfides, disulfides and ethers evaluated by JECFA (65th meeting, and re-evaluated 
at the 69th meeting). EFSA Journal 2010;8(10):1404, 76 pp. doi:10.2903/j.efsa.2010.1404 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2011a. Scientific Opinion on Flavouring Group Evaluation 220, Revision 1 
(FGE.220Rev1): a,ß-Unsaturated ketones and precursors from chemical subgroup 4.4 of FGE.19: 
3(2H)-Furanones. EFSA Journal 2011;9(3):1841, 26 pp. doi:10.2903/j.efsa.2011.1841 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2011b. Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1): 
Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th 
meeting). EFSA Journal 2011;9(9):2314, 44 pp. doi:10.2903/j.efsa.2011.2314 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2011c. Scientific Opinion on Flavouring Group Evaluation 13, Revision 2 (FGE.13Rev2): 
Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms 
from chemical group 14. EFSA Journal 2011;9(8):2313, 126 pp. doi:10.2903/j.efsa.2011.2313 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2012a. Scientific Opinion on Flavouring Group Evaluation 222: Consideration of 
genotoxicity data on representatives for alpha,beta-unsaturated furyl derivatives with the α,β-
unsaturation in the side chain from subgroup 4.6 of FGE.19 by EFSA. EFSA Journal 
2012;10(5):2748. 18 pp. doi:10.2903/j.efsa.2012.2748 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2012b; Scientific Statement on List of Representative Substances for Testing. EFSA Journal 
2012;10(3):2639. 9 pp. doi:10.2903/j.efsa.2012.2639  
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids), 2014. Statement of the Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF) on List of alpha, beta-Unsaturated Aldehydes and Ketones representative 
of FGE.19 substances for Genotoxicity Testing. The EFSA Journal (2008) 910, 1-7. 
EFSA CEF Panel (EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids 
(CEF), 2015. Scientific Opinion on Flavouring Group Evaluation 65, Revision 1 (FGE.65Rev1): 
Consideration of sulfur-substituted furan derivatives used as flavouring agents evaluated by 
JECFA (59th meeting) structurally related to a subgroup of substances within the group of 
‘Furfuryl and furan derivatives with and without additional side-chain substituents and 
heteroatoms from chemical group 14’ evaluated by EFSA in FGE.13Rev2 (2011). EFSA journal 
2015;13(2):4024, 44 pp. doi:10.2903/j.efsa.2015.4024 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 53 
Florin I, Rutberg L, Curvall M and Enzell CR, 1980. Screening of tobacco smoke constituents for 
mutagenicity using the Ames' test. Toxicology 18, 219-232. 
Galloway SM, Armstrong MJ, Reuben C, Colman S, Brown B, Cannon C, Bloom AD, Nakamura F, 
Ahmed M, Duk S, Rimpo J, Margolin BH, Resnick MA, Anderson B and Zeiger E, 1987. 
Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: 
evaluations of 108 chemicals. Environmental and Molecular Mutagenesis 10(Suppl. 10), 1-175. 
Gill S, Bondy G, Lefebvre DE, Becalski A,  Kavanagh M, Hou Y, Turcotte AM, Barker M, Weld M, 
Vavasour E and Cooke GM, 2010. Subchronic oral toxicity study of furan in fischer-344 rats. 
Toxicologic Pathology 38, 619-630. 
Gill S, Kavanagh M, Barker M, Weld M, Vavasour E, Hou Y and Cooke GM, 2011. Subchronic oral 
toxicity study of furan in B6C3F1 mice. Toxicologic Pathology 39, 787-794. 
Glatt HR and Sommer Y, 2006. Health risks by 5-hydroxymethylfurfural (HMF) and related 
compounds. In: Acrylamide and Other Health Hazardous Compounds in Heat-treated Foods (Skog 
K., Alexander J., eds.), Woodhead Publishing, Cambridge, 2006, 328-357. 
Glatt H, Schneider H and Liu Y, 2005. V79-hCYP2E1-hSULT1A1, a cell line for the sensitive 
detection of genotoxic effects induced by carbohydrate pyrolysis products and other food-borne 
chemicals. Mutation Research 580, 41-52. 
Gomez-Arroyo S and Souza VS, 1985. In vitro and occupational induction of sister-chromatid 
exchanges in human lymphocytes with furfuryl alcohol and furfural. Mutation Research 156, 233-
238. 
Ichikawa M, Yamamoto K, Tanaka A, Swaminathan S, Hatcher JF, Erturk E and Bryan GT, 1986. 
Mutagenicity of 3,4-diphenyl-5-nitrofuran analogs in Salmonella typhimurium. Carcinogenesis 
7(8), 1339-1344. 
Jansson T, Curvall M, Hedin A and Enzell C, 1986. In vitro studies of biological effects of cigarette 
smoke condensate. II. Induction of sister-chromatid in human lymphocytes by weakly acidic, 
semivolatile constituents. Mutation Research 169, 129-139. 
Janzowski C, Glaab V, Samimi E, Schlatter J and Eisenbrand G, 2000. 5-Hydroxymethylfurfural: 
assessment of mutagenicity, DNA-damaging potential and reactivity towards cellular glutathione. 
Food and Chemical Toxicology 38(9), 801-809. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1995. Evaluation of certain food 
additives and contaminants. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on 
Food Additives. 14-23 February 1995. WHO Technical Report Series, no. 859. Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1996. Toxicological evaluation of 
certain food additives. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food 
Additives and contaminants. WHO Food Additives Series: 35. IPCS, WHO, Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1997. Evaluation of certain food 
additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food 
Additives. Geneva, 6-15 February 1996. WHO Technical Report Series, no. 868. Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1999. Evaluation of certain food 
additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food 
Additives. Rome, 17-26 June 1997. WHO Technical Report Series, no. 884. Geneva. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 54 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2001. Safety evaluation of certain 
food additives and contaminants. Fifty-fifth Meeting of the Joint FAO/WHO Expert Committee on 
Food Additives, WHO Food Additives Series: 46. IPCS, WHO, Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2004. Safety evaluation of certain 
food additives and contaminants. Sixty-first Meeting of the Joint FAO/WHO Expert Committee on 
Food Additives, WHO Food Additives Series: 52. IPCS, WHO, Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2005. Compendium of food 
additive specifications. Addendum 13. Joint FAO/WHO Expert Committee of Food Additives 65th 
session. Geneva, 7-16 June 2005. FAO Food and Nutrition paper 52 Add. 13. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2006a. Evaluation of certain food 
additives. Sixty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO 
Technical Report Series, no. 934. Geneva, 7-16 June 2005. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2006b. Sixty-seventh Meeting. 
Rome, 20-29 June 2006, Summary and Conclusions. Issued 7 July 2006. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2009a. Safety evaluation of certain 
food additives and contaminants. Sixty-ninth Meeting of the Joint FAO/WHO Expert Committee 
on Food Additives, WHO Food Additives Series: 60. IPCS, WHO, Geneva 2009. 
http://whqlibdoc.who.int/publications/2009/9789241660600_eng.pdf (May 2009). 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2009b. Evaluation of certain food 
additives. Sixty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO 
Technical Report Series, no. 952. Rome, 17-26 June 2008. 
http://whqlibdoc.who.int/trs/WHO_TRS_952_eng.pdf (May 2009). 
Kerckaert GA, Isfort RJ, Carr GJ, Aardema MJ and LeBoeuf RA, 1996. A comprehensive protocol 
for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. Mutation Research 
356, 64-84. 
Kim SB, Hayase F and Kato H, 1987b. Desmutagenic effect of a-dicarbonyl and a-hydroxycarbonyl 
compounds against mutagenic heterocyclic amines. Mutation Research 177, 9-15. 
Kitamura S, Koga H, Tatsumi K, Yoshimura H and Horiuchi T, 1978. Relationship between 
biological activities and enzymatic reduction of nitrofuran derivatives. Journal of Pharmacobio-
Dynamics 1, 15-21. 
Kowalski LA, Assi KP, Wee RK-H and Madden Z, 2001. In vitro prediction of carcinogenicity using 
a bovine papillomavirus DNA-carrying C3H/10T1/2 cell line (T1). II: Results from the testing of 
100 chemicals. Environmental and Molecular Mutagenesis 37(3), 231-240. 
Lee H, Bian SS and Chen YL, 1994. Genotoxicity of 1,3-dithiane and 1,4-dithiane in the CHO/SCE 
assay and the Salmonella/microsomal test. Mutation Research 321, 213-218. 
Lee YC, Shlyankevich M, Jeong HK, Douglas JS and Surh YJ, 1995. Bioactivation of 5-
hydroxylmethyl-2-furaldehyde to an electrophilic and mutagenic allylic sulfuric acid ester. 
Biochemical and Biophysical Research Communications 209(3), 996-1002. 
Loquet C, Toussaint G and LeTalaer JY, 1981. Studies on the mutagenic constituents of apple brandy 
and various alcoholic beverages collected in western France, a high incidence area for oesophageal 
cancer. Mutation Research 88, 155-164. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 55 
Majeska JB and McGregor DB, 1992. Effects of plate preparation on results in microbial mutation 
assays. Environmental and Molecular Mutagenesis. 19(3), 244-252. 
Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H and Ames BN, 1985. Naturally-
occurring carbonyl compounds are mutagens in Salmonella tester strain TA104. Mutation 
Research 148, 25-34. 
Matsui S, Yamamoto R and Yamada H, 1989. The Bacillus Subtilis/Microsome rec-assay for the 
detection of DNA damaging substances which may occur in chlorinated and ozonated waters. 
Water Science & Technology 21, 875-887. 
McDaniel LP, Ding W, Dobrovolsky VN, Shaddock JG Jr, Mittelstaedt RA, Doerge DR, Heflich RH, 
2012. Genotoxicity of furan in Big Blue rats. Mutat. Res., 742, 72-78. 
McGregor DB, McConville ML, Prentice RDM and Riach CG, 1981. Mutagenic activity of 123 
compounds with known carcinogenic potential. Presented at 7th International Symposium on 
Chemical & Toxicological Aspects of Environmental Quality. September 7-10, London. Inveresk 
Research International Limited, Musselburgh. 
McGregor DB, Brown A, Cattanach P, Edwards I, McBride D and Caspary WJ, 1988. Responses of 
the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay II: 18 coded chemicals. 
Environmental and Molecular Mutagenesis 11, 91-118. 
McMahon RE, Cline JC and Thompson CZ, 1979. Assay of 855 test chemicals in ten tester strains 
using a new modification of the ames test for bacterial mutagens. Cancer Research 39, 682-693. 
Meintieres S and Marzin D, 2004. Apoptosis may contribute to false-positive results in the in vitro 
micronucleus test performed in extreme osmolality, ionic strength and PH conditions. Mutation 
Research 560, 101-118. 
Morita T, Watanabe Y, Takeda K and Okumura K, 1989. Effects of pH in the in vitro chromosomal 
aberration test. Mutation Research 225, 55-60. 
Moro S, Chipman JK, Antczak P, Turan N, Dekant W, Falciani F, Mally A, 2012. Identification and 
pathway mapping of furan target proteins reveal mitochondrial energy production and redox 
regulation as critical targets of furan toxicity. Toxicol. Sci., 126, 336-352. 
Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B and Zeiger E, 1986. Salmonella 
mutagenicity tests II. Results from the testing of 270 chemicals. Environmental and Molecular 
Mutagenesis 8(Suppl. 7), 1-119. 
Moser GJ, Foley J, Burnett M, Goldsworthy TL and Maronpot R, 2009. Furan-induced dose–
responserelationshipsforlivercytotoxicity, cell proliferation,andtumorigenicity(furan-induced liver 
tumorigenicity). Experimental and Toxicologic Pathology 61, 101–111. 
Muñoz ER and Barnett MB, 1999. Meiotic nondisjunction induced by furfural in Drosophila 
melanogaster females. Environ. Molec. Mutagen. 34(1), 61-63. 
Nakamura SI, Oda Y, Shimada T, Oki I and Sugimoto K, 1987. SOS-inducing activity of chemical 
carcinogens and mutagens in Salmonella typhimurium TA1535/pSK1002: examination with 151 
chemicals. Mutation Research 192, 239-246. 
Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A, 2012. Furan 
carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo. Mol. Nutr. Food Res., 
56(9), 1363-1374. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 56 
Nishi Y, Miyakawa Y and Kato K, 1989. Chromosome aberrations induced by pyrolysates of 
carbohydrates in Chinese hamster V79 cells. Mutation Research 227, 117-123. 
NTP (National Toxicology Program), 1990. NTP technical report on the toxicology and 
carcinogenesis studies of furfural (CAS no. 98-01-1) in F344/N rats and B6C3F1 mice (gavage 
studies). March 1990. NTP-TR 382. NIH Publication no. 90-2837. 
NTP (National Toxicology Program), 1999a. Toxicology and carcinogenesis studies of furfuryl 
alcohol (CAS no. 98-00-0) in F344/N rats and B6C3F1 mice (inhalation studies). February 1999. 
NTP-TR 482. NIH Publication no. 99-3972. NC. 
NTP (National Toxicology Program), 1999b. NTP report on carcinogens background for furan. March 
1999. Prepared for the November 18-19, 1996, Meeting of the Report on Carcinogens 
Subcommittee of the Board of Scientific Counselors. Prepared by Integrated Laboratory Systems 
Research Triangle Park, NC. 
NTP (National Toxicology Program), 2010. National Toxicology Program. Toxicology and 
carcinogenesis studies of 5-(hydroxymethyl)-2-furfural (CAS No. 67-47-0) in F344/N rats and 
B6C3F1 mice (gavage studies). National Toxicology Program, Research Triangle, NC, USA. TR-
554. NIH Publication No. 10-5895. [Online] 
http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/TR554.pdf 
Ochi T and Ohsawa M, 1985. Participation of active oxygen species in the induction of chromosomal 
aberrations by cadmium chloride in cultured Chinese hamster cells. Mutation Research 143, 137-
142. 
Omura H, Jahan N, Shinohara K and Murakami H, 1983. Formation of mutagens by the maillard 
reaction. In: Waller GR and Feather MS (Eds.). The Maillard Reaction in Foods and Nutrition. 
ACS Symposium Series, 215. American Chemical Society, Washington D.C., pp. 537-563. 
Osawa T and Namiki M, 1982. Mutagen formation in the reaction of nitrite with the food components 
analogous to sorbic acid. Agricultural and Biological Chemistry 45, 2299-2304. 
Phillips JC, Gaunt IF, Hardy J, Kiss IS, Gangolli SD and Butterworth KR, 1977. Short-term toxicity 
of furfuryl mercaptan in rats. Food and Cosmetics Toxicology 15, 383-387. 
Phillips BJ, Jackson LI, Tate B, Price RJ, Adams TB, Ford RA, Goodinan JI and Lake BJ, 1997. 
Furfural does not induce unscheduled DNA synthesis (UDS) in the in vivo rat hepatocyte DNA 
repair assay. Presented 1997 Society of Toxicol. Annu. Meeting, Cincinnati Ohio. 
Posternak NM, Linder A and Vodoz CA, 1969. Summaries of toxicological data. Toxicological tests 
on flavouring matters. Food and Cosmetics Toxicology 7, 405-407. 
Ravindranath V and Boyd MR, 1985. Metabolic activation of 2-methylfuran by rat microsomal 
systems. Toxicology and Applied Pharmacology 78, 370-376. 
Ravindranath V, Burka LT and Boyd MR, 1983. Isolation and characterization of the reactive 
metabolites of 2-methylfuran (2-MF) and 3-methylfuran (3-MF). Pharmacologist 25, 171. 
Ravindranath V, Burka LT and Boyd MR, 1984. Reactive metabolites from the bioactivation of toxic 
methylfurans. Science 224, 884-886. 
Ravindranath V, McMenamin MG, Dees JH and Boyd MR, 1986. 2-Methylfuran toxicity in rats - role 
of metabolic activarion in vivo. Toxicology and Applied Pharmacology 85, 78-91. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 57 
Reynolds SH, Stowers SJ, Patterson RM, Maronpot RR, Aaronson SA and Anderson MW, 1987. 
Activated oncogenes in B6C3F1 mouse liver tumors: Implications for risk assessment. Science 
237, 1309-1316. 
Rodriquez-Arnaiz R, Morales PR, Moctezuma RV and Salas RMB, 1989. Evidence for the absence of 
mutagenic activity of furfuryl alcohol in tests of germ cells in Drosophila melanogaster. Mutation 
Research 223, 309-311. 
Rodriquez-Arnaiz R, Morales PR and Zimmering S, 1992. Evaluation in Drosophila melanogaster of 
the mutagenic potential of furfural in the mei-9(a) test for chromosome loss in germ-line cells. 
Mutation Research 280, 75-80. 
Saraste A and Pulkki K, 2000. Morphologic and biochemical hallmarks of apoptosis. Cardiovascular 
Res. 45, 528-537. 
SCF (Scientific Committee for Food), 1999. Opinion on a programme for the evaluation of flavouring 
substances (expressed on 2 December 1999). Scientific Committee on Food. 
SCF/CS/FLAV/TASK/11 Final 6/12/1999. Annex I to the minutes of the 119th Plenary meeting. 
European Commission, Health & Consumer Protection Directorate-General. 
Scott D, Galloway SM, Marshall RR, Ishidate M, Brusick D, Ashby J and Myhr BC, 1991. 
Genotoxicity under extreme culture conditions. A report from ICPEMC task group 9. Mutation 
Research 257(2), 147-205. 
Seeberg AH, Mosesso P and Forster R, 1988. High-dose-level effects in mutagenicity assays utilizing 
mammalian cells in culture. Mutagenesis 3(3), 213-218. 
Severin I, Dumont C, Jondeau-Cabaton A, Graillot V and Chagnon M-C, 2010. Genotoxic activities 
of the food contaminant 5-hydroxymethylfurfural using different in vitro bioassays. Toxicology 
Letters 192, 189-194. 
Shane BS, Troxclair AM, McMillin DJ and Henry CB, 1988. Comparative mutagenicity of nine 
brands of coffee to Salmonella typhimurium TA100, TA102, and TA104. Environmental and 
Molecular Mutagenesis 11, 195-206. 
Shinohara K, Kim E and Omura H, 1986. Furans as the mutagens formed by amino-carbonyl 
reactions. In: Fujimaki M, Namiki M and Kato H, (Eds.). Amino-Carbonyl Reactions in Food and 
Biological Systems. Elsevier, New York. 
Sommer Y, Hollnagel H, Schneider H and Glatt HR, 2003. Metabolism of 5-hydroxymethyl-2-
furfural (HMF) to the mutagen, 5-sulfoxymethyl-2-furfural (SMF) by individual human 
sulfotransferases. Naunyn Schmiederberg's Arch. Pharmacol. 367, Issue Supplement 1, R166. 
Soska J, Koukalova B and Ebringer L, 1981. Mutagenic activities of simple nitrofuran derivatives. I. 
Comparison of related compounds in the phage inductest, chloroplast-bleaching and bacterial 
repair and mutagenicity tests. Mutation Research 81(1), 21-26. 
Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR and Tennant RW, 
2000. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional 
carcinogenicity bioassays. Toxicol. Sci. 53(2), 213-223. 
Stich HF, Rosin MP, San RHC, Wu CH and Powrie WD, 1981a. Intake, formation and release of 
mutagens by man. Banbury Rep. 7, 247-266. 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 58 
Stich HF, Rosin MP, Wu CH and Powrie WD, 1981b. Clastogenicity of furans found in food. Cancer 
Letters 13, 89-95. 
Subramanyam S, Sailaja D and Rathnaprabha D, 1989. Genotoxic assay of two dietary furans by 
some in vivo cytogenetic parameters. Environmental and Molecular Mutagenesis 14(15), 239. 
Sujatha PS and Subramanyam S, 1994. Clastogenicity of furfuryl alcohol in a mouse bone marrow 
system. Medical Science Research 22(4), 281-284. 
Sujatha PS, Jayanthi A and Subramanyam S, 1993. Evaluation of the clastogenic potential of 2-furyl 
methyl ketone in an in vivo mouse system. Medical Science Research 21(18), 675-678. 
Sujatha PS, 2007. Genotoxic evaluation of furfuryl alcohol and 2-furyl methyl ketone by sister 
chromatid exchange (SCE) analysis. Journal of Health Science 53(1), 124-127. 
Surh Y-J and Tannenbaum SR, 1994. Activation of the Maillard reaction product 5-
(hydroxymethyl)furfural to strong mutagens via allylic sulfonation and chlorination. Chemical 
Research in Toxicology 7, 313-318. 
Surh Y-J, Liem A, Miller JA and Tannenbaum SR, 1994. 5-Sulfooxymethylfurfural as a possible 
ultimate mutagenic and carcinogenic metabolite of the Maillard reaction product, 5-
hydroxymethylfurfural. Carcinogenesis 15(10), 2375-2377. 
The Good Scents Company, 2011. Information on substance [FL-no: 13.190] 3-((2-Methyl-3-
furyl)thio)-2-butanone. http://www.thegoodscentscompany.com. 
Wang LQ and James MO, 2006. Inhibition of sulfotransferases by xenobiotics. Current Drug 
Metabolism. 7(1), 83-104 
Wild D, King MT, Gocke E and Eckhard K, 1983. Study of artificial flavouring substances for 
mutagenicity in the Salmonella/microsome, BASC and micronucleus tests. Food and Chemical 
Toxicology 21(6), 707-719. 
Woodruff RC, Mason JM, Valencia R and Zimmering S, 1985. Chemical mutagenesis testing in 
Drosophila. V. Results of 53 coded compounds tested for the National Toxicology Program. 
Environmental Mutagenesis 7, 677-702. 
Zajac-Kaye M and Ts'o POP, 1984. DNAase I encapsulation in liposomes can induce neoplastic 
transformation of Syrian hamster embryo cells in culture. Cell 39, 427-437. 
Zang XM, Chan CC, Stamp D, Minkin S, Archer MC and Bruce WR, 1993. Initiation and promotion 
of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2-furaldehyde in thermolyzed sucrose. 
Carcinogenesis 14, 773-775. 
Zdzienicka M, Tudek B, Zielenska M and Szymczyk T, 1978. Mutagenic activity of furfural in 
Salmonella typhimurium TA 100. Mutation Research 58, 205-209. 
Zeiger E, Anderson B, Haworth S, Lawlor T and Mortelmans K, 1992. Salmonella mutagenicity tests: 
V. Results from the testing of 311 chemicals. Environmental and Molecular Mutagenesis 19(21), 
2-141. 
 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 59 
Appendix A.  Summary of Genotoxicity and Toxicity Data  
Table 3:  Genotoxicity Data for 40 Furan-Substituted Substances Evaluted by the JECFA (JECFA, 2009a) 
FL-no: 
JECFA-no: 
Chemical name End-point Test system Concentration/dose Results References 
In vitro 
13.030 
1487 
2-Methylfuran Reverse mutation S. typhimurium TA98 and 
TA100 
0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)(a) 
Negative(b) (Shinohara et al., 
1986)  
Reverse mutation S. typhimurium TA98, 
TA100, TA102 and 
TA1535 
Up to 10 000 µg/plate Negative(b,c,d) (Zeiger et al., 1992)  
Reverse mutation S. typhimurium TA97 and 
TA104 
Up to 10 000 µg/plate Equivocal(b,c,d) (Zeiger et al., 1992)  
Reverse mutation S. typhimurium TA98, 
TA100 and TA102 
11 nmol/plate to 1.1 mmol/ 
plate (0.9 - 90310 
µg/plate)(a) 
Negative(b) (Aeschbacher et al., 
1989)  
DNA damage B. subtilis H17 (rec+) and 
M45 (rec-) 
0.16, 16 or 1600 µg/disc Negative 
Positive(b,e) 
(Shinohara et al., 
1986)  
Chromosomal aberration CHO cells 0 - 150 mmol/l (0 - 12315 
µg/ml)(a) 
Positive(b,f) (Stich et al., 1981b) 
13.029 
1488 
2,5-Dimethylfuran Reverse mutation S. typhimurium TA98 and 
TA100 
0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)(g) 
Negative(b) (Shinohara et al., 
1986) 
Reverse mutation S. typhimurium TA98 and 
TA100  
Not specified Negative(b) (Lee et al., 1994) 
Reverse mutation S. typhimurium TA97, 
TA98, TA100 and TA1535 
Up to 3333 µg/plate Negative(b,c,d) (Zeiger et al., 1992) 
DNA damage B. subtilis H17 (rec+) and 
M45 (rec-)  
190, 1900 or 9500 µg/disc Negative 
Positive(b,h) 
(Shinohara et al., 
1986) 
Chromosomal aberration Chinese hamster V79 cells 1 mmol/l (96.13 µg/ml)(g) Negative (Ochi and Ohsawa, 
1985) 
Chromosomal aberration CHO cells 0 - 20 mmol/l (0 - 1923 
µg/ml)(g) 
Positive(b,f) (Stich et al., 1981b) 
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Table 3:  Genotoxicity Data for 40 Furan-Substituted Substances Evaluted by the JECFA (JECFA, 2009a) 
FL-no: 
JECFA-no: 
Chemical name End-point Test system Concentration/dose Results References 
13.148 
1494 
3-Methyl-2-(3-
methylbut-2-enyl)-
furan  
Reverse mutation S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
3.2, 16, 80, 400 or 2000 
µg/plate 
Negative(b) (Asquith, 1989) 
13.034 
 
3-(2-Furyl)acrolein 
  
Reverse mutation S. typhimurium TA100  Not specified Negative(b,c) (Eder et al., 1991b) 
DNA damage (SOS 
chromotest) 
E. coli PQ37  Not specified Negative(i) (Eder et al., 1991b) 
     
DNA damage (SOS 
chromotest) 
E. coli PQ37  Not specified Weakly 
positive(j) 
(Eder et al., 1993) 
13.054 
1503 
 
2-Furyl methyl ketone 
  
Reverse mutation S. typhimurium TA98 and 
TA100 
0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)(j) 
Negative 
Positive(b,k) 
(Shinohara et al., 
1986) 
DNA damage E. coli PQ37 (SOS 
chromotest)  
Not specified Slightly 
positive(j) 
(Eder et al., 1993) 
DNA damage B. subtilis H17 (rec+) and 
M45 (rec-) 
550, 5500 or 55000 µg/disc Negative 
Positive(b,l) 
(Shinohara et al., 
1986) 
Chromosomal aberration CHO cells 0 - 112.6 mmol/l (0 - 13220 
µg/ml)(j) 
Positive(b,m,n) (Stich et al., 1981b) 
UDS Human hepatocytes 2.19, 4.38, 8.75, 17.5, 35, 
70, 140 or 280 µg/ml 
Negative (Durward, 2007a) 
13.044 
1511 
4-(2-Furyl)-3-buten-2-
one 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535 and 
TA1537  
33, 100, 333, 1000, 2166 or 
3333 µg/ plate 
Negative(b,c,o) (Mortelmans et al., 
1986) 
13.022 
1513 
Ethyl 3-(2-
furyl)propanoate 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA1538 
Up to 3600 µg/plate Negative(b) (Wild et al., 1983) 
13.191 
1526 
O-Ethyl-S-(2-
furylmethyl)thio- 
carbonate 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
33, 100, 333, 1000 or 3330 
µg/plate 
Negative(b,p) (Verspeek-Rip, 
2000) 
Reverse mutation E. coli WP2uvrA 33, 100, 333, 1000 or 3330 
µg/plate 
Negative(b,q) (Verspeek-Rip, 
2000) 
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Table 3:  Genotoxicity Data for 40 Furan-Substituted Substances Evaluted by the JECFA (JECFA, 2009a) 
FL-no: 
JECFA-no: 
Chemical name End-point Test system Concentration/dose Results References 
Chromosomal aberration Human peripheral 
lymphocytes 
150, 300 or 350 µg/ml Negative(b,r) (Meerts, 2000) 
Chromosomal aberration Human peripheral 
lymphocytes 
130, 240 or 280 µg/ml Positive(i,s) (Meerts, 2000) 
Chromosomal aberration Human peripheral 
lymphocytes 
100, 130 or 240 µg/ml Positive(i,t) (Meerts, 2000) 
Chromosomal aberration Human peripheral 
lymphocytes 
150, 325 or 375 µg/ml Negative 
Positive(r,u,v) 
(Meerts, 2000) 
In vivo 
13.030 
1487 
2-Methylfuran Chromosomal aberration Mouse bone marrow cells 
and spermatocytes 
1000, 2000 or 4000 mg/kg 
(100, 200 or 400 mg/kg bw 
per day)(w) 
Negative (Subramanyam et 
al., 1989) 
13.054 
1503 
2-Furyl methyl ketone  Chromosomal aberration Mouse bone marrow 1000, 2000 or 3000 mg/l 
(20, 40 or 60 mg/kg bw)(x) 
Positive(y,z) (Sujatha et al., 
1993) 
Chromosomal aberration Mouse spermatocytes  1000, 2000 or 3000 mg/l 
(20, 40 or 60 mg/kg bw)(x) 
Negative(aa) (Sujatha et al., 
1993) 
SCE Mouse bone marrow 1000, 2000 or 3000 mg/l 
(20, 40 or 60 mg/kg bw)(x) 
Positive (Sujatha, 2007) 
UDS Rat liver 7 or 21 mg/kg bw Negative (Durward, 2007b) 
13.191 
1526 
O-Ethyl-S-(2-
furylmethyl)thio-
carbonate 
Micronucleus induction Mouse bone marrow 100, 250 or 500 mg/kg 
bw(bb) 
Negative (Verspeek-Rip, 
2001) 
CHO: Chinese hamster ovary; SCE, sister chromatid exchange; UDS, unscheduled DNA synthesis. 
(a): Calculated using relative molecular mass of 2-methylfuran = 82.1. 
(b): With and without metabolic activation. 
(c): Preincubation method. 
(d): Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations. 
(e): Negative at all concentrations with metabolic activation; positive without metabolic activation. 
(f): Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified). 
(g): Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13. 
(h): Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 µg/disc, but positive at higher concentrations. 
(i): Without metabolic activation. 
(j): Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11. 
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(k): Positive only in strain TA98 with an increase in the presence of metabolic activation. 
(l): Negative at 550 µg/disc; positive at 5500 and 55 000 µg/disc (with and without metabolic activation). 
(m): Cytotoxicity was observed at 12 398 µg/ml (112.6 mmol/l) in the presence of metabolic activation. 
(n): Clastogenic activity increased with metabolic activation (statistical significance of results was not specified). 
(o): Cytotoxicity was observed at 3333 µg/plate in all S. typhimurium strains and at 2166 µg/plate in S. typhimurium strains TA100 and TA1537. 
(p): Cytotoxicity was observed at the 3330 µg/plate level in all S. typhimurium strains and at 1000 µg/plate in S. typhimurium strains TA100 and TA1535. 
(q): Cytotoxicity was observed at 3330 µg/plate in the absence of metabolic activation. 
(r): 3-hour continuous exposure time. 
(s): 24-hour continuous exposure time. 
(t): 48-hour continuous exposure time. 
(u): With metabolic activation. 
(v): Statistically significant dose-dependent increases in chromosomal aberrations were seen at the two highest concentrations only, 325 and 375 µg/ml. 
(w): Mice received 2-methylfuran in the diet for 5 consecutive days at 24-hour intervals. 
(x): Two experimental protocols were utilised. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally 
administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-h intervals between doses. 
(y): No effects observed at 20 mg/kg bw dose level and only mild, but significant (p < 0.05) effects seen at higher concentrations in bone marrow cells. 
(z): Chromosomal aberrations were observed in the presence of significant mitodepression. 
(aa): A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically 
significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats. 
(bb): Single dose administered by gavage. 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Main group I – Non-sulphur-containing Furan Derivatives 
(Furfuryl alcohol 
[13.019]) 
Ames test  S. typhimurium TA98, TA100, 
TA1535 and TA1537  
294 µg/plate  Negative(a) (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100, 
TA1535 and TA1537 
10000 µg/plate  Negative(a) (Mortelmans et al., 
1986) 
(NTP, 1999a) 
 
Ames test  S. typhimurium TA100  2500 - 12500 µg/ml  Negative(a) (Stich et al., 1981a)  
Ames test  S. typhimurium TA98, TA100 
and TA102  
198000 µg/plate  Negative(a) (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA98 and 
TA100  
81 - 323 µg/plate  Negative(a) (Shinohara et al., 
1986) 
 
Modified Ames test  S. typhimurium TA1535, TA100 
and TA1537  
200000 µg/ml  Positive(a) (McGregor et al., 
1981) 
 
Rec assay  B. subtilis  2000 - 20000 µg/disk  Positive(a) (Shinohara et al., 
1986) 
 
Sister chromatid 
exchange  
CHO cells  245 µg/ml Positive(a) (Stich et al., 1981a)  
Sister chromatid 
exchange  
CHO cells  500 µg/ml Positive/weakly 
positive(b) 
Negative(c) 
(NTP, 1999a)  
Sister chromatid 
exchange  
Human Lymphocytes  Up to 196 µg/ml Negative (Jansson et al., 
1986) 
 
Sister chromatid 
exchange  
Human  
Lymphocytes  
Up to 970 µg/ml Negative (Gomez-Arroyo 
and Souza, 1985) 
 
Chromosomal 
aberration  
CHO cells  2000 µg/ml Positive (Stich et al., 1981a)  
Chromosomal 
aberration  
CHO cells  1600 µg/ml  Negative(a) (NTP, 1999a)  
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
SHE test  Syrian hamster embryo cells  NR Negative(c) (Kerckaert et al., 
1996) 
 
Gene Conversion 
Assay  
S. cerevisiae strain D7  13500 - 16000 µg/ml  Positive(b) (Stich et al., 1981b)  
      
Mammalian cell 
assay  
Mouse embryo fibroblast cells 
(T1) 
10 µg/ml  Negative(b) (Kowalski et al., 
2001) 
 
p53 – induction 
assay  
Mouse embryo fibroblast cells 
(NCTC 929)  
50 µg/ml  Negative(b) (Duerksen-Hughes 
et al., 1999) 
 
(Furfuryl acetate 
[13.128]) 
Ames test  S. typhimurium TA1535, TA98 
and TA100  
33 - 666 µg/plate  Positive(b) (Mortelmans et al., 
1986) 
 
(Furfural [13.018]) Ames test  S. typhimurium TA 1535, 
TA100, TA1537, TA1538, 
TA98  
0.1 - 1000 µg/ml  Negative(a) (McMahon et al., 
1979) 
 
Ames test  S. typhimurium TA100, TA98 
and TA1535  
Up to 3460 µg/plate  
5766 µg/plate  
Negative(a) 
Positive(b) (weak)  
(Loquet et al., 
1981) 
 
Ames test  S. typhimurium TA100, TA98 
and TA102  
Up to 115320 
µg/plate  
Negative(a) (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA100 and 
TA98  
15 - 63 µg/plate  Negative(a) (Shinohara et al., 
1986) 
 
Ames test  S. typhimurium TA104 5 - 500 µg/plate  Positive(c) (Shane et al., 1988)  
Ames test  S. typhimurium TA100 and 
TA102  
5 - 500 µg/plate  Negative(c) (Shane et al., 1988)  
Ames test  S. typhimurium TA104 and 
TA102 
96 µg/plate  Negative  (Marnett et al., 
1985) 
 
Ames test  S. typhimurium TA98, TA100 
and TA1535  
Up to 6667 µg/plate  Negative(a) (Mortelmans et al., 
1986) 
 
Ames test  S. typhimurium TA98, TA100  Up to 1000 µg  Negative(b) (Osawa and 
Namiki, 1982) 
 
Ames test  S. typhimurium TA98, TA100, 
TA1535, TA1537  
33 - 6666 µg/plate  Negative(a) 
TA100 
equivocal(b) 
(NTP, 1990)  
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium TA100  8000 µg/plate  Positive(a) (Zdzienicka et al., 
1978) 
 
Ames test  S. typhimurium TA98  8000 µg/plate  Negative(a) (Zdzienicka et al., 
1978) 
 
Ames test  S. typhimurium TA100, TA102  100 - 10000 µg/plate  Negative(b) (Dillon et al., 1998)  
Ames test  S. typhimurium TA104  100 - 10000 µg/plate  Equivocal(b) (Dillon et al., 1998)  
Ames test  S. typhimurium TA102, TA104  100 - 10000 µg/plate  Negative(c) (Dillon et al., 1998)  
Ames test  S. typhimurium TA100  100 - 10000 µg/plate Equivocal(c) (Dillon et al., 1998)  
Modified Ames test  S. typhimurium TA100  426 µg/plate Negative  (Kim et al.,, 9987)  
Modified Ames test  S. typhimurium TA100, TA1535 
and TA1537  
200000 µg/ml Negative  (McGregor et al., 
1981) 
 
      
Modified Ames test  E. coli WP2 and WP2 uvrA  0.1 - 1000 µg/ml Negative(a) (McMahon et al., 
1979) 
 
SOS induction  S. typhimurium TA1535/ 
pSK1002  
1932 µg/ml Negative(a) (Nakamura et al., 
1987) 
 
Rec-assay  B. subtilis H17 and M45  Up to 1000 µg Negative (Osawa and 
Namiki, 1982) 
 
Rec-assay  B. subtilis H17 and M45  0.6 ml  Negative(a) (Matsui et al., 
1989) 
 
Rec-assay  B. subtilis strains H17 and M45  1700 - 17000 µg/disk Positive(a) (Shinohara et al., 
1986) 
 
Forward mutation 
assay  
L5178Y tk+/- Mouse 
Lymphoma Cells  
25 - 100 µg/ml  
200 µg/ml 
Negative(a) 
Positive(b) 
(McGregor et al., 
1988) 
 
Sister chromatid 
exchange  
CHO cells  2500 - 4000 µg/ml Positive(a) (Stich et al., 1981a)  
Sister chromatid 
exchange  
CHO cells  Up to 1170 µg/ml  Positive(a) (NTP, 1990)  
Sister chromatid 
exchange  
Human  
Lymphocytes  
Up to 0.035 mM(d) 
0.07 - 0.14 Mm(d) 
Negative(a) 
Positive(a) 
(Gomez-Arroyo 
and Souza, 1985) 
 
Chromosomal 
aberration  
CHO cells  500 µg/ml 
1000 - 2000 µg/ml 
Negative 
Positive 
(Nishi et al., 1989)  
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Chromosomal 
aberration  
CHO cells  Up to 40 mM (3840 
mg) 
Positive(a) (Stich et al., 1981a)  
Chromosomal 
aberration  
CHO cells  3000 µg/ml Positive (Stich et al., 1981b)  
Chromosomal 
aberration  
CHO cells  375 µg/ml(b) 
750 µg/ml(c) 
Positive (Gudi and Schadly, 
1996) 
 
Chromosomal 
aberration  
CHO cells  Up to 1230 µg/ml Positive(a) (NTP, 1990)  
Unscheduled DNA 
Synthesis  
Human liver slices  0.005 - 10 mM Negative (Adams et al., 
1998) 
 
DNA-protein cross-
links  
EBV- human Burkitt’s 
lymphoma cells  
25 mM Positive(e) (Costa et al., 1997)  
5-Hydroxymethyl-
furfuraldehyde 
[13.139] 
Ames test  S. typhimurium TA98, TA100  0.2 - 1 µmol/plate Negative  (Surh et al., 1994) The study is 
considered valid 
Purity 99 %. 
      
      
Ames test  S. typhimurium TA98, TA100  0.2 - 2.0 µg/plate Positive(c) (Omura et al., 
1983) 
Positive dose related 
response in TA100 
only, most potent 
without S9. Purity 
and other 
experimental details 
not reported. The 
validity of the study 
can not be evaluated. 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium TA98, TA100  0.17 - 0.66 
µmol/plate 
Positive(c) (Shinohara et al., 
1986) 
Positive results only 
obtained in TA 100 
with S9. Reverse 
dose-response 
relationship. 
Experimental details 
are lacking. 
Ames test  S. typhimurium TA104  0.1 - 0.8 mM Negative(b) 
Positive 
(Lee et al., 1995) Positive result was 
obtained by inclusion 
of PAPS and the rat 
liver cytosol in the 
assay. The study is 
considered valid. 
Ames test  S. typhimurium TA98, TA100  1 - 50 µl/plate(c)  Negative(a) (Aeschbacher et al., 
1981) 
The study is 
considered valid. 
Ames test  S. typhimurium TA100  4.44 µM/plate Negative(b) (Kim et al.,, 9987) Single dose only. 
Ames test  S. typhimurium TA98, TA100, 
TA1535, TA1537  
3 µmol/plate Negative(a) (Florin et al., 1980) Spot test. The study 
is considered valid. 
Ames test  S. typhimurium TA100  10 µg/plate Negative(b) (Majeska and 
McGregor, 1992) 
The study is 
considered valid. 
Ames test S. typhimurium TA97, TA98, 
TA102, TA1535 
100 - 10000 µg/plate Negative(a) (NTP, 2010)  
Ames test S. typhimurium TA100 100 - 10000 µg/plate Weakly positive(b) (NTP, 2010)  
Ames test S. typhimurium TA100 and 
TA98 
1500 - 10000 
µg/plate 
Negative(a) (NTP, 2010)  
Ames test S. typhimurium TA98, TA100, 
TA1535, TA1537 
At 0.5 µg/mL up to 
5000 µg/mL 
Negative(a) (Severin et al., 
2010) 
 
Reverse mutation 
assay 
E. coli WP2 uvrA/pKM101 1500  - 10000 
µg/plate 
Negative(a) (NTP, 2010)  
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Micronucleus assay HepG2 cells 0, 5.35, 7.87, 11.57, 
17, 25, 36.6 mM 
Negative(y) (Severin et al., 
2010) 
 
SCE induction V79-hCYP2E1-hSULT1A1 cells 19.8 - 3808 µM Positive (Glatt et al., 2005)  
SCE induction V79-Mz cells 238 - 3808 µM Positive(z) (Glatt et al., 2005)  
Umu assay  S. typhimurium  
TA1535  
20 mM Positive(f) (Janzowski et al., 
2000) 
Positive results were 
only obtained at high 
concentrations 
resulting in reduced 
cell viability and 
growth. The study is 
considered valid but 
interpretation of data 
is questionable. 
Rec assay  B. subtilis  
H 17 rec+; M 45 rec-  
0.25 - 12.5 mg/disk Positive(a) (Shinohara et al., 
1986) 
Experimental details 
are lacking. The 
validity of the study 
can not be evaluated. 
Chromosomal 
aberration  
Chinese hamster V79 cells  Up to 2000 µg/ml Positive10 (Nishi et al., 1989) Weak positive 
response were only 
obtained at high 
concentrations. The 
study is considered 
valid. 
Comet assay  V79, Caco-2, primary human 
colon cells and primary rat 
hepatocytes  
Up to 80 mM Negative(b) (Janzowski et al., 
2000) 
The study is 
considered valid but 
interpretation of data 
is questionable. 
Comet assay HepG2 cells 0, 5.35, 7.87, 11.57, 
17, 25, 36.6 mM 
Positive(x,y) (Severin et al., 
2010) 
 
Comet assay Human Caco-2 cells 3153 - 12611 µg/mL 
(25 - 100 mM) 
Positive(v) (Durling et al., 
2009) 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Comet assay Human HEK293 cells 3153 - 12611 µg/mL 
(25 - 100 mM) 
Positive(v) (Durling et al., 
2009) 
 
Comet assay Mouse lymphoma L5178Y cells 3153 - 12611 µg/mL 
(25 - 100 mM) 
Positive(v) (Durling et al., 
2009) 
 
Comet assay Chinese hamster V-79 cells 315 - 12611 µg/mL 
(2.5 - 100 mM) 
Positive(w) (Durling et al., 
2009) 
 
Comet assay Chinese hamster V-79-hP-PST 
cells 
315 - 12611 µg/mL 
(2.5 - 100 mM) 
Positive(w) (Durling et al., 
2009) 
 
HPRT assay  V79 cells  Up to 140 mM Positive(a,h )  (Janzowski et al., 
2000) 
Positive response 
were only obtained at 
high concentrations 
resulting in reduced 
cell viability and 
growth. The study is 
considered valid but 
interpretation of data 
is questionable. 
HPRT and tk assay  TK6 human lymphoblast cells  20 - 75 µg/ml Negative  (Surh and 
Tannenbaum, 1994)  
The study is 
considered valid. 
(5-Methylfurfural 
[13.001]) 
Ames test S. typhimurium TA1537, TA100 
and TA1535  
288 µg/plate Negative(a) (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100 
and TA102  
96100 µg/plate Negative(a) (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA98 and 
TA100  
79 - 316 µg/plate Negative(a) (Shinohara et al., 
1986) 
 
Rec-assay  B. subtilis strains H17 and M45  0.55 - 5500 µg/disk Positive(a) (Shinohara et al., 
1986) 
 
Sister chromatid 
exchange  
CHO cells  2200 - 4070 µg/ml Positive(a) (Stich et al., 1981a)  
2-Furoic acid 
[13.136] 
Ames test  S. typhimurium TA98, TA100  25 - 100 µg/plate Negative(b) (Ichikawa et al., 
1986) 
The study is 
considered valid. 
Ames test  S. typhimurium TA100   Negative  (Soska et al., 1981) Dose not reported. 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
The validity of the 
study cannot be 
evaluated. 
Ames test  S. typhimurium TA100  1000 µg/plate Negative  (Kitamura et al., 
1978) 
The study is 
considered valid. 
DNA repair test  E. coli WP2l WP2 uvrA, WP67, 
WP100, CM 561, CM 571, CM 
611  
1000 µg/disk Negative  (Soska et al., 1981) The study is 
considered valid. 
Unscheduled DNA 
synthesis  
Primary rat hepatocytes  1000 µg/ml Negative(g,i)  (Aaron et al., 1989) Study performed in 
accordance with 
GLP. The study is 
considered valid. 
(Methyl-2-furoate 
[13.002]) 
Ames test  S. typhimurium TA98, TA100  100 µg/plate Negative(g)  (Ichikawa et al., 
1986) 
 
       
(2-Furyl methyl 
ketoneAcetylfuran 
[13.054])  
UDS  Human hepatocytes  2.19, 4.38, 8.75, 17.5, 
35, 70, 140 or 280 
µg/ml 
Negative  (Durward, 2007a)  New study submitted 
to JECFA for the 
69th meeting. 
Reverse mutation  S. typhimurium TA98 and 
TA100  
0.165, 0.330, 0.495 or 
0.660 µmol/plate 
(13.5, 27.1, 40.6 or 
54.2 µg/plate)(q) 
Negative/positive(
a,r)
  
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  E. coli PQ37 (SOS chromotest)  Not specified Slightly positive  (Eder et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  B. subtilis H17 (rec+) and M45 
(rec-)  
550, 5500 or 55000 
µg/disc 
Negative/ 
positive(a,s)  
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration 
CHO cells 0 - 112.6 mmol/l 
(0 - 13220 µg/ml)(q) 
Positive(s,t,u) (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
(2-Methylfuran 
[13.030]) 
  
Reverse mutation S. typhimurium TA98 and 
TA100  
0.165, 0.330, 0.495 or 
0.660 µmol/plate 
(13.5, 27.1, 40.6 or 
54.2 µg/plate)(j) 
Negative(a) (Shinohara et al., 
1986)  
Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 and TA1535  
Up to 10 000 µg/plate Negative(a,k,l)  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation S. typhimurium TA97 and 
TA104  
Up to 10 000 µg/plate Equivocal(a,k,l)  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation S. typhimurium TA98, TA100 
and TA102 
11 nmol/plate to 1,1 
mmol/ plate (0,9 - 90 
310 µg/plate)(j) 
Negative(a) (Aeschbacher et al., 
1989)  
Study reported by 
JECFA at the 65th 
meeting. 
DNA damage B. subtilis H17 (rec+) and M45 
(rec-) 
0.16, 16 or 1600 
µg/disc 
Negative/positive(
a,m)
 
(Shinohara et al., 
1986)  
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration  
CHO cells 0 - 150 mmol/l 
(0 - 12315 µg/ml)(j) 
Positive(a,n) (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
(2,5-Dimethylfuran 
[13.029])  
Reverse mutation  S. typhimurium TA98 and 
TA100 
0.165, 0.330, 0.495 or 
0.660 µmol/plate 
(13.5, 27.1, 40.6 or 
54.2 µg/plate)(o) 
Negative(a) (Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation S. typhimurium TA98 and 
TA100  
Not specified Negative(a) (Lee et al., 1994) Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation S. typhimurium TA97, TA98, 
TA100 and TA1535 
Up to 3333 µg/plate Negative(a,k,l) (Zeiger et al., 1992) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage B. subtilis H17 (rec+) and M45 
(rec-)  
190, 1900 or 9500 
µg/disc 
Negative/positive(
a,p)
 
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
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Table 4:  Genotoxicity Data (in vitro) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object  Concentration Result  Reference  Comments 
Chromosomal 
aberration 
Chinese hamster V79 cells 1 mmol/l (96.13 
µg/ml)(o) 
Negative  (Ochi and Ohsawa, 
1985) 
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration 
CHO cells  0 - 20 mmol/l(0 -
 1923 µg/ml)(o) 
Positive(a,n) (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
*: Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
NR: Not Reported. 
(a): With and without S9 metabolic activation.  
(b): Without S9 metabolic activation.  
(c): With S9 metabolic activation. 
(d): Concentration that was added to the culture. 
(e): Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death). 
(f): At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.  
(g): Metabolic activation not reported.  
(h): Effects occurred at concentrations inhibiting cellular growth. 
(i): Dose levels above 300 µg/ml were cytotoxic.  
(j): Calculated using relative molecular mass of 2-methylfuran = 82.1. 
(k): Preincubation method. 
(l): Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations. 
(m): Negative at all concentrations with metabolic activation; positive without metabolic activation. 
(n): Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified). 
(o): Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13. 
(p): Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 µg/disc, but positive at higher concentrations. 
(q): Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11. 
(r): Positive only in strain TA98 with an increase in the presence of metabolic activation. 
(s): Negative at 550 µg/disc; positive at 5500 and 55 000 µg/disc (with and without metabolic activation). 
(t): Cytotoxicity was observed at 12 398 µg/ml (112.6 mmol/l) in the presence of metabolic activation. 
(u): Clastogenic activity increased with metabolic activation (statistical significance of results was not specified). 
(v): Positive only at the highest concentration tested with significant decrease in cell viability. 
(w): Positive at high concentration with significantly reduced cell viability. 
(x): Cytotoxic at the two highest doses. 
(y): 20 hours of exposure. 
(z): Weakly positive but statistically significant at each concentration. 
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Table 5:  Genotoxicity (In Vivo) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object Route Dose Result Reference 
(Furfuryl alcohol 
[13.019]) 
Sex-linked recessive 
lethal test  
D. melanogaster  Injection Up to 6500 mg/kg  Negative  (Rodriquez-Arnaiz et 
al., 1989) 
Sister chromatid 
exchange  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration 
assay  
Mouse bone marrow 
cells 
Drinking water 0.5 mg/kg  
1 - 2 mg/kg 
Negative 
Positive 
(Sujatha and 
Subramanyam, 1994) 
Sister chromatid 
exchange  
Mouse bone marrow 
cells  
IP injection 300 mg/kg Negative (NTP, 1999a) 
Chromosomal aberration 
assay  
Mouse bone marrow 
cells  
IP injection 300 mg/kg Negative  (NTP, 1999a) 
Micronucleus assay  Mouse bone marrow 
cells 
IP injection 250 mg/kg Negative  (NTP, 1999a) 
Mouse bioassay  Tg·AC transgenic mice  Dermal exposure 1.5 mg; 5 day/week for 20 
weeks  
Negative (Spalding et al., 2000) 
(Furfural  
[13.018]) 
Sex-linked recessive 
lethal test  
D. melanogaster  Diet 1000 mg/kg  Negative  (Woodruff et al., 1985) 
Sex-linked recessive 
lethal test  
D. melanogaster Injection 100 mg/kg  Positive (Woodruff et al., 1985) 
Sex-linked recessive 
lethal test  
D. melanogaster Injection Up to 6500 mg/kg  Negative (Rodriquez-Arnaiz et 
al., 1989) 
Chromosome Loss  D. melanogaster Oral or injected 3750 - 5000 mg/kg. Mated 
with repair-proficient females  
Negative  (Rodriquez-Arnaiz et 
al., 1992) 
Chromosome Loss  D. melanogaster Oral or injected 3750 - 5000 mg/kg. Mated 
with repair-deficient females  
Positive (Rodriquez-Arnaiz et 
al., 1992) 
Reciprocal translocations  D. melanogaster Injection 100 mg/kg  Negative (Woodruff et al., 1985) 
Nondisjunction assay  D. melanogaster 
(females)  
Inhalation 1.5 %  Negative(a) (Muñoz and Barnett, 
1999) 
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Table 5:  Genotoxicity (In Vivo) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object Route Dose Result Reference 
Sister chromatid 
exchange  
Mouse bone marrow 
cells  
Injection 50 - 200 mg/kg  Negative (NTP, 1990) 
Sperm head abnormalities  Mouse Oral 4000 mg/kg daily for 5 weeks  Negative (Subramanyam et al., 
1989) 
Somatic chromosome 
mutations  
Swiss albino mouse 
(bone marrow cells)  
 1000 - 2000 mg/kg, 4000 
mg/kg for 5 days  
Negative  
Positive  
(Subramanyam et al., 
1989) 
      
Sister chromatid 
exchange  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo and 
Souza, 1985) 
Unscheduled DNA 
synthesis  
Mouse  Oral 50 - 320 mg/kg Negative (Edwards, 1999) 
Unscheduled DNA 
synthesis  
F344 Rat  Oral 5 - 50 mg/kg Negative (Phillips et al., 1997) 
Gene mutation in the 
λlacZ-gene in liver 
Transgenic mouse 
CD2F1 (BALB/c x 
DBA/2) 
Oral 75 - 300 mg/kg Negative (CIVO-TNO, 2003) 
(2-Furyl methyl 
ketone  
[13.054]) 
SCE(g) Mouse bone marrow  1000, 2000 or 3000 mg/l (20, 
40 or 60 mg/kg bw)(b) 
Positive (Sujatha, 2007) 
UDS(g) Rat liver  7 or 21 mg/kg bw Negative (Durward, 2007b) 
Chromosomal 
aberration(h) 
Mouse bone marrow  1000, 2000 or 3000 mg/l (20, 
40 or 60 mg/kg bw)(b) 
Positive(c,d) (Sujatha et al., 1993) 
Chromosomal 
aberration(h) 
Mouse spermatocytes  1000, 2000 or 3000 mg/l (20, 
40 or 60 mg/ kg bw)(b) 
Negative(e) (Sujatha et al., 1993) 
(2-Methylfuran 
[13.030]) 
Chromosomal 
aberration(h) 
Mouse bone marrow 
cells and 
spermatocytes 
 1000, 2000 or 4000 mg/kg 
(100, 200 or 400 mg/kg bw 
per day) (f) 
Negative (Subramanyam et al., 
1989) 
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Table 5:  Genotoxicity (In Vivo) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
Chemical Name 
[FL-no:]* 
Test system Test Object Route Dose Result Reference 
5-Hydroxymethyl-
furfural 
[13.139] 
Micronucleus assay Mouse peripheral 
blood cells 
 47, 94, 188, 375 or 750 mg/kg 
bw per day 
Negative (NTP, 2010) 
*: Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
(a): Exposure to 1 % solutions did not affect the flies’ behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of 
nondisjunction. 
(b): Two experimental protocols were utilised. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally 
administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-hour intervals between doses. 
(c): No effects observed at 20 mg/kg bw dose level and only mild, but significant (P < 0.05) effects seen at higher concentrations in bone marrow cells. 
(d): Chromosomal aberrations were observed in the presence of significant mitodepression. 
(e): A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically 
significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats. 
(f): Mice received 2-methylfuran in the diet for 5 consecutive days at 24 hours intervals. 
(g): New study submitted to JECFA for the 69th meeting. 
(h): Study reported by JECFA at the 65th meeting. 
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Table 6:  Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001) 
Chemical name 
FL-no/JECFA-no 
End-point Test system Concentration Results Reference 
Furfuryl alcohol 
13.019/451 
Reverse mutation  S. typhimurium TA98, TA100, 
TA1535, TA1537 
294 µg/plate Negative(a,b) (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 
Up to10 000 µg/plate Negative(a,b) (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA100 2500 - 12500µg/ml  Negative(a,b) (Stich et al., 1981a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
Up to 198000 µg/plate Negative(a,b) (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100 81 - 323 µg/plate Negative(a,b) (Shinohara et al., 1986) 
Reverse mutation  k TA1535, TA100, TA1537 
(modified assay) 
200000 µg/ml Positive(a,b) (McGregor et al., 1981) 
DNA repair and H17 (rec+) k M45 (rec–) µg/disc 2000 - 20000  Positive(a,b) (Shinohara et al., 1986) 
Sister chromatid exchange  Chinese hamster ovary cells 245 µg/ml Positive(a,b) (Stich et al., 1981b) 
Sister chomatid exchange Human lymphocytes Up to 196 µg/ml Negative (Jansson et al., 1986) 
Siser chromatid exchange Human lymphocytes Up to 970 µg/ml Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration Chinese hamster ovary cells 2000 µg/ml Positive (Stich et al., 1981b) 
Gene conversion  S. cerevisiae strain D7 13500 - 16000 µg/ml Positive(a) (Stich et al., 1981a) 
Sex-linked recessive l lethal 
mutation 
D. melanogaster Up to 6500 mg/kg by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Sister chromatid exchange Adult human lymphocytes 32300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and 
Souza, 1985) 
Sister chomatid exchange Adult human lymphocytes 32300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration Mouse bone-marrow cells 0.5 mg/kg bw in drinking-water 
1 - 2 mg/kg bw in drinking-water 
Negative 
Positive 
(Sujatha and 
Subramanyam, 1994) 
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Table 6:  Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001) 
Chemical name 
FL-no/JECFA-no 
End-point Test system Concentration Results Reference 
Furfuryl acetate 
13.128/739 
Reverse mutation S. typhimurium TA1535, 
TA98, TA100 
33 - 666 µg/plate Positive(a,b) (Mortelmans et al., 1986) 
      
Furfural 
13.018/450 
Reverse mutation S. typhimurium TA 1535, 
TA100, TA1537, TA1538, 
TA98 
0.1 - 1000 µg/ml Negative(a,b) (McMahon et al., 1979) 
Reverse mutation S. typhimurium TA100, TA98, 
TA1535 
Up to 3460 µg/plate  
5766 µg/plate 
Negative(a,b) 
Positive(a) 
(weakly) 
(Loquet et al., 1981) 
Reverse mutation S. typhimurium TA100, TA98, 
TA102 
Up to 115 320 µg/plate Negative(a,b) (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA100, TA98 15 - 63 µg/plate Negative(a,b) (Shinohara et al., 1986) 
Reverse mutation S. typhimurium TA104 5 - 500 µg/plate Positive(b) (Shane et al., 1988) 
Reverse mutation S. typhimurium TA100, 
TA102  
5 - 500 µg/plate Negative(b) (Shane et al., 1988) 
Reverse mutation S. typhimurium TA104, 
TA102 
96 µg/plate Negative (Marnett et al., 1985) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 
Up to 6667 µg/plate Negative(a,b) (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA98, TA100 Up to 1000 µg Negative(a) (Osawa and Namiki, 
1982) 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537  
33 - 6666 µg/plate Negative(a,b  
Equivocal in 
TA100(a 
(NTP, 1990) 
Reverse mutation S. typhimurium TA100  8000 µg/plate Positive(a,b) (Zdzienicka et al., 1978) 
Reverse mutation  S. typhimurium TA98 8000 µg/plate Negative(a,b) (Zdzienicka et al., 1978) 
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Table 6:  Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001) 
Chemical name 
FL-no/JECFA-no 
End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA100, 
TA102 
100 - 10000 µg/plate Negative(a) (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA104 100 - 10000 µg/plate Equivocal(a) (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA102, 
TA104 
100 - 10000 µg/plate Negative(b) (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 100 - 10000 µg/plate Equivocal(b) (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 
(modified assay) 
426 µg/plate Negative(a,b) (Kim et al.,, 9987) 
Reverse mutation S. typhimurium TA100, 
TA1535, TA1537 (modified 
assay) 
200000 µg/ml Negative (McGregor et al., 1981) 
Reverse mutation E. coli WP2, WP2 uvrA 
(modified assay) 
0.1 - 1000 µg/ml Negative(a,b) (McMahon et al., 1979) 
SOS induction  S. typhimurium TA1535/ 
pSK1002 
1932 µg/ml Negative(a,b) (Nakamura et al., 1987) 
DNA repair B. subtilis H17 (rec+) and 
M45 (rec–) 
Up to 1000 µg Negative(a (Osawa and Namiki, 
1982) 
DNA repair B. subtilis H17 (rec+) and 
M45 (rec–) 
0.6 ml Negative(a,b) (Matsui et al., 1989) 
DNA repair B. subtilis H17 (rec+) and 
M45 (rec–) 
1700 - 17000 µg/disc Positive(a,b) (Shinohara et al., 1986) 
Forward mutation L5178Y mouse lymphoma 
cells, Tk+/– locus 
25 - 100 µg/ml 
200 µg/ml 
Negative(a) 
Positive(a) 
(McGregor et al., 1988) 
Sister chromatid exchange Chinese hamster ovary cells 2500 - 4000 µg/ml Positive(a,b) (Stich et al., 1981b) 
Sister chromatid exchange Chinese hamster ovary cells Up to 1170 µg/ml Positive(a,b) (NTP, 1990) 
Sister chromatid exchange Human lymphocytes Up to 0.035 mmol/L(a 
0.07 - 0.14 mmol/L(c 
Negative(a,b) 
Positive(a,b) 
(Gomez-Arroyo and 
Souza, 1985) 
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Table 6:  Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001) 
Chemical name 
FL-no/JECFA-no 
End-point Test system Concentration Results Reference 
Chromosomal aberration Chinese hamster ovary cells 500 µg/ml 
1000 - 2000 µg/ml 
Negative 
Positive 
(Nishi et al., 1989) 
Chromosomal aberration Chinese hamster ovary cells Up to 40 mmol/L 
(3840 mg) 
Positive(a,b) (Stich et al., 1981b) 
Chromosomal aberration Chinese hamster ovary cells 3000 µg/ml Positive (Stich et al., 1981a) 
Chromosomal aberration Chinese hamster ovary cells Up to 1230 µg/ml Positive(a,b) (NTP, 1990) 
Unscheduled DNA synthesis Human liver slices 0.005 - 10 mmol/L  Negative (Adams et al., 1998) 
Sex-linked recessive lethal 
mutation 
D. melanogaster 1000 mg/kg of diet Negative (Woodruff et al., 1985) 
Sex-linked recessive lethal 
mutation 
D. melanogaster 100 mg/kg by injection Positive (Woodruff et al., 1985) 
Sex-linked recessive lethal 
mutation 
D. melanogaster Up to 6500 mg/kg by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
     
Chromosomal loss D. melanogaster Oral or injected dose of 3750 -
 5000 mg/kg of diet. Mated with 
repair-proficient females 
Negative (Rodriquez-Arnaiz et al., 
1992) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750 -
 5000 mg/kg of diet. Mated with 
repair-deficient females 
Positive (Rodriquez-Arnaiz et al., 
1992) 
Reciprocal trans- location D. melanogaster 100 mg/kg by injection Negative (Woodruff et al., 1985) 
Sister chromatid exchange Mouse bone-marrow cells 50 - 200 mg/kg bw by injection Negative (NTP, 1990) 
Spermhead abnormalities Mice 4000 mg/kg of diet daily for 5 
weeks 
Negative (Subramanyam et al., 
1989) 
Somatic chromo-somal 
mutation  
Swiss albino mouse bone- 
marrow cells 
1000 - 2000 mg/kg of diet Negative (Subramanyam et al., 
1989) 4000 mg/kg bw for 5 days Positive 
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Table 6:  Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001) 
Chemical name 
FL-no/JECFA-no 
End-point Test system Concentration Results Reference 
Sister chromatid exchange Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and 
Souza, 1985) 
Chromosomal aberration Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and 
Souza, 1985) 
Unscheduled DNA synthesis B6C3F1 mice  50 - 320 mg/kg bw orally Negative (Edwards, 1999) 
Unscheduled DNA synthesis Fischer 344 rats 5 - 50 mg/kg bw orally Negative (Phillips et al., 1997) 
5-Methylfurfural 
13.001/745 
Reverse mutation S. typhimurium TA1537, 
TA100, TA1535 
288 µg/plate Negative(a,b) (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, 
TA102  
96100 µg/plate Negative(a,b) (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100 79 - 316 µg/plate Negative(a,b) (Shinohara et al., 1986) 
DNA repair B. subtilis H17 (rec+) and M45 
(rec–) 
0.55 - 5500 µg/disk Positive(a,b) (Shinohara et al., 1986) 
Sister chromatid exchange Chinese hamster ovary cells 2200 - 4070 µg/ml Positive(a,b) (Stich et al., 1981b) 
(a): Without metabolic activation from a 9000 g supernatant of rat liver. 
(b): With metabolic activation 
(c): Concentration added to culture 
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Table 7:  Summary of Toxicity Data Evaluated by the Panel in FGE.67Rev2 
Chemical Name  
[FL-no:] 
Species; Sex 
No/group 
Route  Doses 
(mg/kg bw per day) 
Duration 
(days) 
NOAEL 
(mg/kg bw per 
day) 
Reference  Comments 
3-(5-methyl-2-furyl) butanal  
[FL-no: 13.058] 
Rat; M & F 
3/sex perdose 
level 
Diet 0 (dietary control), 50, 
300 and 750 
14  Kappeler, 2013a Study not 
suitable for 
derivation of a 
NOAEL 
Rat; M & F 
10/sex perdose 
level 
 0, 5.9, 30 and 150 98 5.9 Kappeler, 2013b  
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Appendix B.  Overview of Evaluation Status 
The conclusions for the substances in the various subgroups are summarized in the table below. In 
addition, in this table it is indicated for which substances additional data (EU production volumes, 
genotoxicity data, 90-day toxicity study) is required, and the substance with which additional toxicity 
testing should be performed (EFSA, 2012b, 2014). 
Table 8:  Overview of Evaluation Status 
Subgroup FL-no of candidates in 
the present FGE  
genotoxicity status  NOAEL required? 
I 13.116 
13.190 
Not of concern  NOAELs available 
II 13.006 Not of concern NOAEL available 
III 13.021 
13.022 
13.023 
13.024 
13.047 
13.058 
Not of concern NOAELs available 
IV 13.059 
13.069 
13.103 
13.106 
13.148 
Awaiting evaluation of 2-
pentylfuran 
NOAEL required for 2-
pentylfuran [FL-no: 13.059] 
V-A 13.052 
13.061 
13.123 
Awaiting submission of 
further data 
NOAEL required for [FL-no: 
13.052] 
V-B 13.031 
13.074 
Not of concern  NOAELs available 
VI-A 13.034 
13.043 
13.044 
13.046 
13.137 
13.150 
Under consideration in 
FGE.222 
No NOAELs available. NOAEL 
required for [FL-no: 13.034 and 
13.044]  
VI-B 13.045 
13.054 
13.066 
13.070 
13.083 
13.101 
13.105 
13.138 
13.163 
Further data required NOAEL required for 13.054; NB: 
No EU production volumes 
available for [FL-no: 13.066 and 
13.070] 
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Appendix C.  Summary of Safety Evaluations 
Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.029 
1488 
2,5-Dimethylfuran O
 
0.012 
0.02 
Class II 
No evaluation 
 Genotoxicity data 
required. No longer 
supported by industry.  
 
13.030 
1487 
2-Methylfuran O
 
0.21 
0.3 
Class II 
No evaluation 
 Genotoxicity data 
required. No longer 
supported by industry.   
 
13.045 
1508 
1-(2-Furyl)-propan-
2-one 
O
O
 
0.037 
0.02 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.052 
1520 
Furfuryl methyl 
ether 
O
O
 
0.024 
0.09 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.054 
1503 
2-Acetylfuran 
O
O
 
46 
13 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.059 
1491 
2-Pentylfuran O
 
0.18 
0.03 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.061 
1522 
Difurfuryl ether 
O
O
O
 
0.12 
0.09 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
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Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.069 
1492 
2-Heptylfuran O 0.012 
0.9 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.083 
1504 
2-Acetyl-5-
methylfuran O
O
 
0.37 
0.1 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.092 
1489 
2-Ethylfuran O
 
0.061 
0.5 
Class II 
No evaluation 
 Genotoxicity data 
required. No longer 
supported by industry.  
 
13.101 
1505 
2-Acetyl-3,5-
dimethylfuran O
O
 
0.0012 
0.002 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.103 
1490 
2-Butylfuran O
 
0.24 
0.5 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.105 
1507 
2-Butyrylfuran 
O
O
 
0.12 
0.2 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.106 
1493 
2-Decylfuran O 0.0012 
0.002 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
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Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.123 
1521 
Ethyl furfuryl ether O
O
 
0.0012 
0.002 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.138 
1510 
1-(2-Furyl)butan-3-
one O
O
 
2.2 
3 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.148 
1494 
3-Methyl-2(3-
methylbut-2-
enyl)furan 
O
 
0.12 
0.2 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
Register name to be 
changed to: 3-
Methyl-2-(3-
methylbut-2-
enyl)furan. 
13.163 
1509 
2-Pentanoylfuran 
O
O
 
0.061 
0.09 
Class II 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists 
 
13.031 
751 
2-
Benzofurancarboxal
dehyde 
OO
 
0.012 
0.01 
Class III 
B3: Intake below 
threshold 
B4: Adequate 
NOAEL exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.047 
1518 
Propyl 3-(2-
furyl)acrylate O
O
O 2.2 
1 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.058 
1500 
3-(5-Methyl-2-
furyl) butanal O
O
 
0.0012 
0.5 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach.. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
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Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.066 
1506 
3-Acetyl-2,5-
dimethylfuran 
O
O
 
ND 
2 
Class III 
No evaluation 
 Genotoxicity data 
required. Toxicity data 
required. No adequate 
NOAEL exists. No EU 
production volume 
available. 
 
13.070 
1512 
2-Hexanoylfuran 
O
O
 
ND 
0.9 
Class III 
No evaluation 
 Genotoxicity data 
required Toxicity data 
required. No adequate 
NOAEL exists. No EU 
production volume 
available. 
 
13.107 
1496 
2,4-Difurfurylfuran OO
O
0.0012 
0.002 
Class III 
No evaluation 
 Genotoxicity data 
required. No longer 
supported by industry.   
 
13.190 
1525 
3-((2-Methyl3-
furyl)thio)-2-
butanone 
O
S
O
 
0.012 
0.02 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Register name to be 
changed to 3-((2-
Methyl-3-furyl)thio)-
2-butanone. 
Racemate (The Good 
Scents Company, 
2011). 
13.191 
1526 
o-Ethyl S-(2-
furylmethyl)thiocar
bonate 
O
S O
O
 
0.61 
0.9 
Class III 
No evaluation 
 Genotoxicity data 
required. No longer 
supported by industry. 
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Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.006 
1517 
Phenethyl 2-furoate 
O
O
O 0.012 
0.2 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.021 
1516 
Isopentyl 4-(2-
furan)butyrate 
O O
O
0.24 
0.09 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.022 
1513 
Ethyl 3(2-
furyl)propionate O
O
O
 
0.012 
0.07 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Register name to be 
changed to: Ethyl 3-
(2-furyl)propionate 
13.023 
1515 
Isopentyl 3-(2-
furan)propionate O
O
O 0.24 
0.09 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.024 
1514 
Isobutyl 3-(2-
furyl)propionate O
O
O 0.12 
24 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
13.074 
1495 
2,3-
Dimethylbenzofura
n 
O
 
0.52 
0.01 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
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Table 9:  Summary of Safety Evaluation of  Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome 
on the 
named 
compound 
(d or e)
 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
13.116 
1523 
2,5-Dimethyl-3-
thioacetoxyfuran 
O
S
O
 
3.0 
4 
Class III 
No evaluation 
 No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 89 
 
Table 10:  Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
FL-no EU Register name Structural formula MSDI(a) 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure path(c) 
Outcome on 
the named 
compound 
(d or e)
 
Outcome on 
the material 
of commerce 
(f, g  or h)
 
Evaluation 
remarks 
13.122 
 
Ethyl 2-furoate O
O
O
 
0.39 Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.130 
759 
Furfuryl butyrate 
O
O
O
 
0.24 Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.136 
 
2-Furoic acid 
O
OH
O
 
0.013 Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.139 
 
5-Hydroxymethylfurfur-
aldehyde 
O
OHO
 
0.39 Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.145 
 
Methyl 5-methylfurfuryl 
sulfide 
S
O
 
0.0024 Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.155 
 
2-Methyl-5-propionylfuran 
O
O
 
0.011 Class II 
No evaluation 
  a 
13.125 
 
2-Ethyl-5-methylfuran O
 
0.011 Class II 
No evaluation 
  b 
13.162 
 
2-Octylfuran O
 
0.011 
 
Class II 
No evaluation 
  b 
13.011 
 
Ethyl furfuracrylate 
O
O
O
 
0.12 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.102 
 
Butyl 2-furoate O
O
O
 
0.12 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
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Table 10:  Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
FL-no EU Register name Structural formula MSDI(a) 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure path(c) 
Outcome on 
the named 
compound 
(d or e)
 
Outcome on 
the material 
of commerce 
(f, g  or h)
 
Evaluation 
remarks 
13.108 
 
4,5-Dihydro-3-mercapto-2-
methylfuran 
O
SH
 
37 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.113 
 
2,5-Dimethyl-3-
(methyldithio)furan 
O
S
S
 
0.0012 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.114 
 
2,5-Dimethyl-3-
(methylthio)furan 
O
S
 
0.0024 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.124 
 
Ethyl furfuryl sulfide 
S
O
 
0.18 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.127 
 
Furfuryl 2-methylbutyrate 
O
O
O
 
0.73 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.129 
 
Furfuryl but-2-enoate O
O
O
 
0.11 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.132 
 
Furfuryl hexanoate O
O
O
 
0.58 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.133 
 
Furfuryl isobutyrate 
O
O
O
 
0.89 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.135 
 
1-(2-
Furfurylthio)propanone 
O
S
O
 
0.61 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
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Table 10:  Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 
FL-no EU Register name Structural formula MSDI(a) 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure path(c) 
Outcome on 
the named 
compound 
(d or e)
 
Outcome on 
the material 
of commerce 
(f, g  or h)
 
Evaluation 
remarks 
13.141 
 
Methyl (2-
furfurylthio)acetate 
O
S
O
O
 
0.011 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.143 
 
Methyl 3-
(furfurylthio)propionate 
O
OS
O
 
0.011 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.144 
 
Methyl 5-methylfurfuryl 
disulfide 
O
S
S
 
0.0024 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.146 
 
Methyl furfuryl trisulfide 
S
S
S
O
 
0.0024 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.149 
 
5-Methyl-2-
furanmethanethiol 
O
SH
 
0.37 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.178 
 
3-(Furfuryldithio)-2-
methylfuran 
O
O
S
S
 
0.24 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.185 
 
2-Furfuryl 3-oxo-2-butyl 
disulphide O
S
S
O
 
0.011 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
13.199 
 
3-[(2-Methyl-3-furyl)thio]-
butanal 
o
s O
 
1.2 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
d f  
(a): EU MSDI: Amount added to food as flavour in (kg / year) × 109 / (0.1 × population in Europe (= 375 × 106) × 0.6 × 365) = µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
Flavouring Group Evaluation 67 Revision 2
 
EFSA Journal 2015;13(5):4115 92 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.016 
1066 
bis-(2-Methyl-3-
furyl) disulfide 
O
S
S
O
 
0.27 
0.7 
Class II 
B3: Intake below 
threshold,  
B4: Adequate 
NOAEL exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.026 
1072 
2-Furan-
methanethiol 
O
SH
 
29 
11 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.050 
1081 
Difurfuryl 
disulfide 
S
SO
O
 
3.3 
0.7 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.053 
1076 
Methyl furfuryl 
sulfide S
O
 
0.97 
0.1 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.055 
1060 
2-Methylfuran-3-
thiol 
O
SH
 
0.52 
0.9 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is "95" 
and secondary 
components "Bis(2-
methyl-3-
furyl)disulfide".  
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.064 
1078 
Methyl furfuryl 
disulfide S
SO
 
0.85 
0.04 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.152 
1061 
2-Methyl-3-
(methylthio)furan 
O
S
 
1.2 
0.1 
Class II 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.015 
1067 
bis-(2,5-
Dimethyl-3-furyl) 
disulfide 
O
S
S
O
 
0.012 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.017 
1068 
bis-(2-Methyl-3-
furyl) tetrasulfide 
O
OS
S
S
S
 
0.97 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
        
13.032 
1077 
Furfuryl isopropyl 
sulfide O
S
 
0.0012 
0.1 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.033 
1074 
S-Furfuryl 
acetothioate O
S
O
 
0.43 
0.05 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.040 
1071 
(S)-2,5-Dimethyl-
3-thiofuroylfuran 
O
O
S
O
 
0.012 
0.01 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
JECFA evaluated (S)-
2,5-dimethyl-3-
thiofuroylfuran (CASrn 
as in Register). No safety 
concern at the estimated 
level of intake based on 
the MSDI approach. 
13.041 
1070 
2,5-Dimethyl-3-
(isopentylthio)fur
an 
O
S
O
 
0.49 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
Registername to be 
changed to 2,5-dimethyl-
3-(isovalerylthio)furan. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
        
        
13.051 
1073 
S-Furfuryl 
thioformate 
O
S O
 
1.3 
0.02 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.056 
1080 
Difurfuryl sulfide 
S
OO
 
0.73 
0.005 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d Toxicity data are 
required. No 
adequate NOAEL 
exists. 
The Panel is aware that 
data were not submitted 
before the deadline as 
indicated in Commission 
Implementing Regulation 
(EC) No 872/2012.  
This substance is in the 
process of being deleted 
from the Union List (DG 
SANCO, 2015). 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.063 
1075 
S-Furfuryl 
propanethioate 
O
S
O
 
0.012 
0.005 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.065 
1062 
2-Methyl-5-
(methylthio)furan 
O S
 
1.1 
0.02 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.071 
1063 
2,5-
Dimethylfuran-3-
thiol 
O
SH
 
0.024 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.075 
1086 
2,6-Dimethyl-3-
((2-methyl-3-
furyl)thio)heptan-
4-one 
O
S
O
 
1.8 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is "94" 
and secondary 
components "2,6-
Dimethyl-2-[(2-methyl-
3-furyl)thio]-4-
heptanone". 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.077 
1085 
3-((2-Methyl-3-
furyl)thio)heptan-
4-one 
O
S
O
 
2.9 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.078 
1087 
4-((2-Methyl-3-
furyl)thio)nonan-
5-one 
O
S
O
0.73 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.079 
1064 
Methyl 2-methyl-
3-furyl disulfide 
O
S
S
 
0.73 
0.05 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is “97” 
and secondary 
components “up to 3% 
bis(2-methyl-3-
furyl)disulphide”. No 
safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.082 
1065 
Propyl 2-methyl-
3-furyl disulfide 
O
S
S
 
0.12 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is “97” 
and secondary 
components “up to 2% 
bis(2-methyl-3-
furyl)disulfide and 
propyl disulfide”. No 
safety concern at the 
estimated level of intake 
based on the MSDI 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
approach. 
13.086 
1089 
4,5-Dihydro-2-
methyl-3-
thioacetoxyfuran 
O
S
O
 
0.49 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.093 
1088 
Ethyl 3-(2-
furfurylthio)propi
onate 
OS
O
O 0.012 
0.2 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.142 
1083 
S-Methyl 2-
furanthiocarboxyl
ate 
O
S
O
 
0.37 
0.1 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.151 
1082 
2-Methyl-3,5 and 
6-
(furfurylthio)pyra
zine 
2 or 5 or 6 -Methyl-3-(furfurylthio)pyrazine
N
N
O
S
0.37 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is “99” 
and "Mixture of isomers: 
70 % 2,3-; 29 % 2,6-; 
trace 2,5-". No safety 
concern at the estimated 
level of intake based on 
the MSDI approach. 
13.153 
1069 
2-Methyl-3-furyl 
thioacetate 
O
S
O
 
0.012 
0.07 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
According to JECFA: 
Min. assay value is “92” 
and secondary 
components “cis- and 
trans-2-Methyl-3-
tetrahydrofuranthiol 
acetate”. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.160 
1090 
2-
Methyltetrahydrof
uran-3-thiol 
O
SH
 
55 
0.7 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI. 
According to JECFA: 
Min. assay value is “97” 
and “71 % trans and 26 
% cis isomer”. 
13.193 
1091 
2,5-Dimethyl-
tetrahydro-3-
furanthiol 
O
SH
 
0.012 
0.9 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI. 
According to JECFA: 
Min. assay value is “96 
(mixture of 4 
stereoisomers)”.  
Composition of 
stereoisomeric mixture to 
be specified. 
13.194 
1092 
2,5-
Dimethyltetrahydr
o-3-furyl thio 
acetate 
O
S
O
 
0.012 
2 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI. 
According to JECFA: 
Min. assay value is “90 
(mixture of 4 
stereoisomers)” and 
secondary components 
“2,5-Dimethyl-
tetrahydrofuran-3-thiol, 
Dimethyltetrahydro-3-
furyl dithioacetate”.  
Composition of 
stereoisomeric mixture to 
be specified. 
13.196 
1084 
4-[(2-
Furanylmethyl)thi
o]-2-pentanone 
O
S
O
 
0.012 
0.6 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 11:  Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation 
procedure path(c) 
Outcome on 
the named 
compound(d),(e) 
EFSA conclusion 
on the named 
compound(f) 
EFSA conclusion on the 
material of commerce 
13.197 
1079 
Furyl propyl 
disulfide 
O
S
S
 
0.024 
3 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/capita per day , Class II = 540 µg/capita per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 12:  Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound(d or 
e)
 
EFSA conclusion on the 
named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion 
on the material 
of commerce 
13.001 
745 
5-Methylfurfural O O
 
180 
25 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.002 
746 
Methyl 2-furoate 
O
O
O
 
30 
37 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.003 
747 
Propyl 2-furoate O
O
O
 
0.061 
0.1 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.018 
450 
Furfural O O
 
440 
460 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.019 
451 
Furfuryl alcohol O OH
 
180 
24 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. Evaluated by 
JECFA before 2000 - No 
EFSA consideration 
required 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
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Table 12:  Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound(d or 
e)
 
EFSA conclusion on the 
named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion 
on the material 
of commerce 
13.057 
743 
Furfuryl isovalerate O
O
O
 
0.024 
1 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.062 
740 
Furfuryl propionate O
O
O
 
1.7 
5 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.068 
741 
Furfuryl valerate O
O
O
 
0.24 
14 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.128 
739 
Furfuryl acetate O
O
O
 
16 
21 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.005 
749 
Hexyl 2-furoate O
O
O
 
0.061 
0.1 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.025 
748 
Pentyl 2-furoate O
O
O
 
0.36 
0.1 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
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Table 12:  Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita per 
day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound(d or 
e)
 
EFSA conclusion on the 
named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion 
on the material 
of commerce 
13.038 
752 
2-Phenyl-3-
carbethoxyfuran O
O
O
 
0.012 
2 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.067 
742 
Furfuryl octanoate O
O
O
0.012 
6 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
13.073 
750 
Octyl 2-furoate O
O
O
2.2 
0.1 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
d No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern 
at the estimated 
level of intake 
based on the 
MSDI approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/capita per day, Class II = 540 µg/capita per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Appendix D.  Exposure 
Table 13:  Normal and Maximum Use Levels (mg/kg) Available for JECFA Evaluated Substances in FGE.67Rev2 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
13.031 - 
- 
- 
- 
2.5 
0 
- 
- 
- 
- 
5 
0 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
0 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
13.047 2 
0 
- 
- 
- 
- 
- 
- 
- 
- 
8.8 
18 
0.74 
9.9 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.0044 
0 
- 
- 
0.013 
0.11 
- 
- 
0.015 
0 
- 
- 
13.058 - 
- 
0.25 
1.8 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
13.066 - 
- 
0.0094 
0.019 
- 
- 
- 
- 
- 
- 
1.7 
2.8 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.085 
0.28 
- 
- 
- 
- 
- 
- 
13.070 0.04 
0.08 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
13.074 0.43 
0 
0.5 
1.4 
0.17 
0 
- 
- 
- 
- 
0.017 
0.043 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.43 
0 
- 
- 
0.23 
1.4 
0.54 
2.9 
- 
- 
- 
- 
13.101 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
- 
- 
10 
50 
15 
75 
5 
25 
13.103 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
13.105 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
- 
- 
10 
50 
20 
100 
5 
25 
13.106 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
13.123 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
13.138 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
13.148 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
13.163 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
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Table 14:  Estimated Intakes Based on the MSDI- and the mTAMDI Approach for Substances in FGE.67Rev2 
FL-no EU Register name MSDI – EU 
(µg/capita per day) 
MSDI – USA 
(µg/capita per day) 
mTAMDI 
(µg/person per day) 
Structural class Threshold of 
concern 
(µg/person per day) 
13.045 1-(2-Furyl)-propan-2-one 0.037 0.02  Class II 540 
13.052 Furfuryl methyl ether 0.024 0.09  Class II 540 
13.054 2-Acetylfuran 46 13  Class II 540 
13.059 2-Pentylfuran 0.18 0.03  Class II 540 
13.061 Difurfuryl ether 0.12 0.09  Class II 540 
13.069 2-Heptylfuran 0.012 0.9  Class II 540 
13.083 2-Acetyl-5-methylfuran 0.37 0.1  Class II 540 
13.101 2-Acetyl-3,5-dimethylfuran 0.0012 0.002 2200 Class II 540 
13.103 2-Butylfuran 0.24 0.5 1000 Class II 540 
13.105 2-Butyrylfuran 0.12 0.2 2300 Class II 540 
13.106 2-Decylfuran 0.0012 0.002 1000 Class II 540 
13.123 Ethyl furfuryl ether 0.0012 0.002 1000 Class II 540 
13.138 1-(2-Furyl)butan-3-one 2.2 3 1000 Class II 540 
13.148 3-Methyl-2(3-methylbut-2-enyl)furan 0.12 0.2 1000 Class II 540 
13.163 2-Pentanoylfuran 0.061 0.09 1000 Class II 540 
13.031 2-Benzofurancarboxaldehyde 0.012 0.01 670 Class III 90 
13.047 Propyl 3-(2-furyl)acrylate 2.2 1 690 Class III 90 
13.058 3-(5-Methyl-2-furyl) butanal 0.0012 0.5 33 Class III 90 
13.066 3-Acetyl-2,5-dimethylfuran ND 2 110 Class III 90 
13.070 2-Hexanoylfuran ND 0.9 5.3 Class III 90 
13.190 3-((2-Methyl3-furyl)thio)-2-butanone 0.012 0.02  Class III 90 
13.006 Phenethyl 2-furoate 0.012 0.2  Class III 90 
13.021 Isopentyl 4-(2-furan)butyrate 0.24 0.09  Class III 90 
13.022 Ethyl 3(2-furyl)propionate 0.012 0.07  Class III 90 
13.023 Isopentyl 3-(2-furan)propionate 0.24 0.09  Class III 90 
13.024 Isobutyl 3-(2-furyl)propionate 0.12 24  Class III 90 
13.074 2,3-Dimethylbenzofuran 0.52 0.01 160 Class III 90 
13.116 2,5-Dimethyl-3-thioacetoxyfuran 3.0 4  Class III 90 
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ABBREVIATIONS 
AFC  Food Additives, Flavourings, Processing Aids and Materials in contact with Food 
bw  body weight 
CAS  Chemical Abstract Service 
CEF  EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DPXL  DNA protein cross-link 
DSB  DNA strand breaks 
EFFA  European Flavour and Fragrance Association 
EPA  United States Environmental Protection Agency  
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
FR  Furan 
GLP  Good laboratory practice 
GSH  Gluthathione 
5HMF  5-Hydroxymethyl furfural 
HPRT  Hypoxanthine Phosphoribosyl transferase 
ID  Identity 
IP  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
MNBN  Micronucleated Binucleate cells 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
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NCE  Normochromatic erythrocyte 
NMR  Nuclear Magnetic Resonance 
No  Number 
NOAEL No Observed Adverse Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Cooperation and Development  
PAPS  3'-Phosphoadenosine-5'-phosphosulfate 
PCE  Polychromatic erythrocyte 
2-PF  2-Pentylfuran 
PK  Proteinase K 
RI  Replication Index 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
SMF  [(sulphoxy)methyl]furfural 
TK  Thymidine kinase 
UDS  Unscheduled DNA Synthesis 
VC  Vehicle controls 
WHO  World Health Organization 
